

**THE HIGH COURT OF SOUTH AFRICA
(GAUTENG PROVINCIAL DIVISION, PRETORIA)**

Case 24917/22

In the matter between:

LIBERTY FIGHTERS NETWORK

First Applicant

REYNO DAWID DE BEER

Second Applicant

and

MINISTER OF HEALTH

Respondent

and

Case 25363/22

In the matter between:

SOLIDARITY TRADE UNION

Applicant

and

MINISTER OF HEALTH

First Respondent

NATIONAL HEALTH COUNCIL

Second Respondent

DIRECTOR GENERAL, DEPARTMENT OF HEALTH

Third Respondent

NATIONAL DEPARTMENT OF HEALTH

Fourth Respondent

and

Case 25226/22

In the matter between:

AFRIFORUM NPC

First Applicant

DEAR SA

Second Applicant

and

MINISTER OF HEALTH

First Respondent

THE DIRECTOR GENERAL, DEPARTMENT OF HEALTH

Second Respondent

and

Case 27477/2022

In the matter between:

SAKELIGA NPC

First Applicant

and

MINISTER OF HEALTH

First Respondent

DIRECTOR GENERAL, DEPARTMENT OF HEALTH

Second Respondent

MINISTER OF COOPERATIVE AFFAIRS AND

GOVERNMENT

Third Respondent

PRESIDENT OF THE REPUBLIC OF

SOUTH AFRICA

Fourth Respondent

EXPERT AFFIDAVIT

I, the undersigned,

SALIM SAFURDEEN ABDOOL KARIM

do hereby make oath and state as follows:

INTRODUCTION

1. I am an adult male clinical epidemiologist who has been undertaking research and working in the field of infectious disease control for the past 35 years.
2. The facts deposed to in this affidavit fall within my personal knowledge (save where may be otherwise stated or the contrary appear from the context) and

are to the best of my knowledge and belief both true and correct. The views expressed in this affidavit are based on my professional expertise and experience, which are detailed below, and I am duly qualified to express these expert conclusions.

3. I am currently employed as the Director of the Centre for the Aids Programme of Research in South Africa ("CAPRISA") at the Nelson R Mandela School of Medicine, University of KwaZulu-Natal. I am also the Pro Vice-Chancellor (Research) at the University of KwaZulu-Natal.
4. In addition, I hold the following positions internationally:
 - a. CAPRISA Professor of Global Health in the Department of Epidemiology at Columbia University, New York, USA;
 - b. Adjunct Professor in Immunology and Infectious Diseases at Harvard University, USA; and
 - c. Adjunct Professor of Medicine at Cornell University, New York, USA.
5. I have dual medical specialties registered with the Colleges of Medicine in South Africa - a Fellowship in College of Public Health Medicine (FCPHM) and Fellowship in College of Pathology in Virology (FCPath (Virol)). The details of my credentials and expertise I have in the prevention, control, and treatment of infectious and communicable diseases are outlined in detail in my curriculum vitae, which is annexed hereto as "**SSAK 1**".

6. My international scientific leadership roles include:

- a. Serving on the 9-member Science Council of the World Health Organisation (WHO), advising the WHO Director-General;
- b. Vice-President of the International Science Council;
- c. Commissioner-Lancet Commission on Covid-19;
- d. Commissioner – African Commission on Covid-19
- e. Member – Africa Task Force on Coronavirus
- f. Member of the WHO TB-HIV Task Force.

7. On 23 March 2020, I was appointed as Chair of the Ministerial Advisory Committee ("MAC") on the Covid-19 epidemic in South Africa. After serving the first 6 months as chair, I then served as Co-Chair of the MAC and as a member of the Vaccine MAC up to 23 March 2021. In these capacities, I provided expert technical advice to the Department of Health on measures to control the spread and impact of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) including on prevention strategies and treatment protocols. The disease caused by SARS-CoV-2 is commonly referred to as "Covid-19".

8. As a trained Virologist and Public Health physician, I have extensive knowledge of viral infections, having previously chaired the South African National Advisory

Group on Immunisation and the Polio Expert Committee that oversaw the elimination of polio in South Africa. I have conducted research on several viruses, including measles, hepatitis A virus, hepatitis B virus, human papillomavirus and herpes simplex virus type 2. Further, I have been involved in developing vaccines and prevention technologies like microbicides for human immunodeficiency virus (HIV) over the past 30 years.

9. I depose to this affidavit to provide the scientific rationale to explain why:

- a. taking steps to reduce the spread of SARS-CoV-2 is essential, and
- b. implementing specific evidence-based public health prevention measures, including vaccines, is needed to achieve this goal.


THE COVID-19 PANDEMIC

10. SARS-CoV-2 was first identified in Wuhan City, China, towards the end of 2019 after hospitals had noticed an unusual incidence of pneumonia cases in which the underlying infection was not known. As its full name suggests, the virus has the potential to cause severe respiratory complications in a proportion of those who become infected.

11. The global spread of SARS-CoV-2 was declared a pandemic by the World Health Organization ("WHO") on 11 March 2020.

12. Although other viruses of the Coronaviridae family are known to infect humans - including SARS-CoV-1 and MERS-CoV, which have previously made international headlines for their severity and pandemic potential - SARS-CoV-2 is distinct from other known coronaviruses. As a result, the transmission dynamics of SARS-CoV-2 and the effective treatment of Covid-19 are developing areas of research.

13. I also emphasise the uniqueness of Covid-19. It is a disease that can affect almost every part of the body. It can be a silent asymptomatic infection or it can cause clinical illness. While older individuals and those with co-morbid conditions are at higher risk of severe acute disease, hospitalisation and death, anyone who has been infected, especially those who are unvaccinated, are at high risk of several medical conditions impacting the entire body from head to toe (see slide below – diagram from the journal, Nature).



nature

Every Covid-19 Symptom We Know About Right Now, From Head to Toe


The most perplexing things about a disease that has proved vexing, deadly, and 'unprecedented in many ways'

14. In the first two years since the first case in South Africa, ie. from March 2020 to March 2022, there were 99, 943 reported Covid-19 deaths in the country. Since these reports are an undercount, the number of excess deaths provide an estimate of more likely actual number of Covid-19 deaths. A caveat is that the cause of death is not known for the excess deaths. Since excess deaths have risen and fallen in concert with the increase and decline in the number of Covid-19 cases, it is likely that most, if not all, excess deaths are due to Covid-19. There were 303,969 excess deaths in the first 2 years of the pandemic in South Africa. Regardless of whether the reported Covid-19 deaths or the excess deaths estimates are used, Covid-19 is amongst the main causes of death in South Africa.

15. Covid-19 is not only an acute condition with severe illness and death. Besides the acute features of Covid-19, SARS-CoV-2 causes a chronic debilitating condition known as post-Covid-19 condition, post-acute sequelae of Covid-19 (PASC), or chronic Covid syndrome (CCS), which is a condition characterized by long-term sequelae appearing or persisting after the typical convalescence period of Covid-19. This condition, colloquially referred to as 'long Covid', occurs in 10 percent to 20 percent of people who acquire SARS-CoV-2 infection and the common features are: problems with memory and concentration ("brain fog"), shortness of breath, chest pain or tightness, heart palpitations, and depression. Current evidence suggests that long Covid occurs as commonly in people with asymptomatic or mildly symptomatic Covid-19 as it does in people with severe disease.

16. Separately from long Covid, anyone, young or old who has been infected, whether symptomatically or asymptotically, with SARS-CoV-2, is at higher risk of cardiovascular disease, diabetes and adverse neurological outcomes.
17. In a study in the United States of America of 153,760 adults who had Covid-19, it was found that they experienced more than a 50% increased risk of heart disease – from stroke to heart attacks to myocarditis – more than 1 year later.
18. This increase in heart disease is only becoming apparent now in the second year of the pandemic and is occurring in people across all ages and in those with asymptomatic, mild or severe Covid-19, regardless of cardiac risk factors such as age, smoking and weight.
19. The risk of new cases of cardiovascular disease in this study was concerning and spanned several heart conditions occurring even among those whose acute Covid-19 did not necessitate hospitalization (see slide below). (Reference: Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. *Nature Medicine*. 2022 Mar;28(3):583-90).

The Covid-19 illness burden long after infection



20. In another study by the same researchers in the United States, 181,280 adults were followed over the course of a year. The study found that people with Covid-19 had a 40% higher risk of new cases of diabetes (becoming diabetic without any pre-existing risks) and 85% increase in their needing to use medication for high blood sugar. (Reference: Xie Y, Al-Aly Z. *Risks and burdens of incident diabetes in long COVID: a cohort study. The Lancet Diabetes & Endocrinology. 2022 May 1;10(5):311-21*)
21. Much more concerning is a recent study in the United Kingdom, published in the journal, Nature, that found that even mild Covid-19 can cause brain-related abnormalities. This study investigated brain changes in 785 participants of the UK Biobank who had before-and-after magnetic resonance imaging ('MRI') of the brain, including 401 cases who tested positive for infection with SARS-CoV-2 between their two scans.
22. The study identified brain shrinkage (decrease in whole-brain volume) and greater loss of grey matter thickness in the brains of those who had Covid-19. The decline in brain size in those with Covid-19 infection was associated with a decline in the ability to perform complex tasks (see slide below). (Reference 1: Douaud G, Lee S, Alfaro-Almagro F, et al. *SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022 Mar 7; 604:697–707* and reference 2: Abbasi J. *Even Mild COVID-19 May Change the Brain. Journal of the American Medical Association 2022 Apr 12;327(14):1321-1322*).



- 401+ and 384- UK brain scans from Biobank

- Effects of SARS-CoV-2 infection:



- Smaller brain size
- ↓ in grey matter thickness – up to 2% loss
- Less able to complete complex tasks



23. The risk of acute illness combined with the long-term risks of Long Covid and the increased risk of heart disease, stroke, diabetes and neurological illness provide a compelling reason why preventing infection is essential. Even if only a fraction of infections is prevented, this could prevent debilitating long-term illnesses and premature death.

24. The pandemic is not over. It is important to note that globally, there has been an average of over 274,000 SARS-CoV-2 cases and about 1,000 Covid-19 deaths each day in June 2022. The world is still in the midst of the Covid-19 pandemic with the virus continuing to mutate, creating new variants as it spreads across the world.

25. Letting the virus spread unimpeded is not a justifiable option for 5 reasons.
Each new SARS-CoV-2 infection leads to:

- yet more new infections and reinfections

- b. increased risk of acute illness and death, especially when the virus spreads to a person at risk, such as someone above 60 years of age
- c. more people with long Covid
- d. more people with cardiovascular disease, stroke, diabetes and neurological conditions in the long term
- e. increased chances of new variants emerging as the virus can only mutate when replicating.

26. Early in 2020, before vaccines became available, a group of scientists proposed the Great Barrington Declaration, which recommended that the virus simply be allowed to spread within the community with steps to protect the elderly. This approach has been completely discredited and countries that tried versions of it, like Sweden, suffered substantial numbers of deaths.

TRANSMISSION AND PREVENTION OF SARS-COV-2

27. At present, SARS-CoV-2 is known to be transmitted directly through proximity or contact with an infected person, through breathing invisible airborne droplets teeming with infectious virus (aerosols), as well as, to a lesser extent, through contact with surfaces which have been contaminated with the virus by an infected person.

28. The risk of transmission from an infected person is greatest when she/he is exhaling the highest number of viruses in their expired droplets – this viral load is highest before a person becomes symptomatic (pre-symptomatic transmission). The virus also spreads from a person who is already showing symptoms of Covid-19 or when a person shows no symptoms (asymptomatic transmission).

29. If people do not know that they are infected with SARS-CoV-2, then they will be unaware of the risk of infection that they are posing to others in their midst. Due to this risk of pre-symptomatic and asymptomatic transmission, it is vitally important to adopt and implement wide-spread infection prevention measures that include as many people as possible.

30. The goal of prevention is accordingly to prevent as many people as possible from acquiring infection or re-infection. The most effective of these measures is vaccination. Vaccination has the following benefits:

- a. Vaccines markedly reduce the risk of severe Covid-19 and death - vaccine efficacy for preventing hospitalisations and severe infection was well retained at over 90 percent at 6 months post-vaccination for the Pfizer vaccine;
- b. Vaccines reduce the risk of acquiring asymptomatic and symptomatic SARS-CoV-2 infection when exposed; the extent of protection from infection depends on the interval since vaccination and the circulating variant;

- c. Vaccines reduce the viral load in the throat and nose - vaccinated individuals can have up to 1000-fold lower virus levels in their nose and throat, which in turn impacts infectiousness;
- d. Vaccines reduce the risk of transmitting SARS-CoV-2 infection to others. The risk of infection among individuals exposed to an infected vaccinated person is lower than the risk of infection from individuals exposed to an infected unvaccinated person. A UK study of 146,243 contacts of infected individuals showed a 68 percent lower infection rate for the Alpha variant and 50 percent lower infection rate for the Delta variant in contacts exposed to an individual with breakthrough infection following two doses of the Pfizer vaccine;
- e. Vaccines reduce the overall spread of the virus within the community by reducing both symptomatic and asymptomatic infections;
- f. Vaccines reduce the incidence or occurrence of long Covid.

31. Expanding on paragraph 30.d above, not only do vaccinations reduce the risk of asymptomatic infection, symptomatic infections, severe illness and death but they also have a marked impact on reducing the risk of transmission of the virus.

32. Vaccination reduces the chance that an infected parent will spread the virus to unvaccinated children. A study from Israel assessed 181,307 unvaccinated children from 76,621 distinct households. Where the parents were vaccinated

and had a breakthrough infection, the children had a 72% lower risk of getting infected compared to the children of unvaccinated parents. Unvaccinated parents are about 4 times more likely to spread their infection to their children. (Reference: *Hayek S, Shaham G, Ben-Shlomo Y, et al. Indirect protection of children from SARS-CoV-2 infection through parental vaccination. Science. 2022 Jan 27; 375(6585):1155–1159.*

33. In a study published in the New England Journal of Medicine, 146,243 contacts of 108,498 index patients were tested. When the infected patients had already received 2 Pfizer vaccine doses, they had a 68% lower chance of spreading the virus to people who they had come into contact with at home, events or work compared with infected patients who had not been vaccinated. (Reference: *Eyre DW, Taylor D, Purver M, et al. Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants. New England Journal of Medicine. 2022 Jan 5; 286:744-756.*

34. The two studies above make a critically important point that vaccinated people are less likely to get infected but when they do get infected (as vaccines are not 100% protective), they are much less likely to transmit the virus to others.

35. Vaccinated people protect everyone around them by reducing their risk of getting infected and thereby passing the virus to others. But even further, getting vaccinated reduces the chance of spreading the virus to others following breakthrough infection because an infected vaccinated person is much less infectious (lower viral load) and is infectious for a shorter period compared to unvaccinated infected individuals.

36. While vaccines have a marked prevention benefit, controlling the spread of SARS-CoV-2 requires combination prevention that goes beyond vaccination. SARS-CoV-2 is continuously mutating. In the process, new versions of the virus, referred to as variants, are created. Each variant is generated or created independently of other variants. A variant can also lead to sub-variants that have the same challenges as a completely new variant. There is accordingly no way to predict what the severity of the next variant or sub-variant will be, based on experience of past variants. Future waves may transpire to be more like the mild Omicron variant or more like the severe Delta variant, or significantly worse than any experienced before. New variants may also be able to escape immunity. For example, the Omicron variant readily escapes vaccine immunity causing clinical infections even in those individuals who have had 4 doses of the Pfizer vaccine.

37. Reducing transmission of the virus also reduces the risk of mutations forming.

38. A detailed exposition on why combination prevention of vaccines plus public health measures are essential is provided in the Lancet Covid-19 Commission report of March 2021 entitled, "*SARS-CoV-2 variants: the need for urgent public health action beyond vaccines*". Essentially, as SARS-CoV-2 vaccines are not 100 percent effective and as new variants that can escape immunity (at least partially) emerge, other prevention measures are needed over and above vaccination to achieve prevention of viral spread. These prevention measures include, amongst others, mask wearing, avoiding large gatherings and minimising the potential to spread in poorly ventilated indoor environments.

39. A study published in the scientific journal, *Proceedings of the National Academy of Science* in June 2022 provided compelling evidence that masks work and work in many different settings across all 6 continents. The authors summarise their study as, “We directly analyse the effect of mask wearing on SARS-CoV-2 transmission, drawing on several datasets covering 92 regions on six continents”. This included some large studies of mask wearing behaviour with up to 20 million study participants. They estimated, “the effect of mask wearing on transmission, by linking reported wearing levels to reported cases in each region, while adjusting for mobility and nonpharmaceutical interventions (NPIs), such as bans on large gatherings. Our estimates imply that the mean observed level of mask wearing corresponds to a 19% decrease in the reproduction number R .” In summary, masks have reduced the transmission of SARS-CoV-2 by about one fifth overall. While not as good as vaccines in preventing the spread of SARS-CoV-2, masks have the protective benefits of slowing viral transmission and reducing the number of people getting infected. (Reference: *Leech G, Rogers-Smith C, Teperowski Monrad J, et al. Mask wearing in community settings reduces SARS-CoV-2 transmission. Proceedings of the National Academy of Science 2022. 119:23: e2119266119.*)
40. There is also evidence that masks work in South Africa. The use of masks in 2020 and 2021 contributed to the lack of influenza transmission in the country's usual winter “flu” season in both years. South Africa experienced very few cases of influenza in both years. While lockdown in 2020 and social distancing in 2021 is thought to have contributed, masks have contributed to the prevention of

41. Indoor aerosols are a major source of viral transmission. A June 2022 article in the journal, *Clinical Infectious Diseases*, provides useful insights on transmission by aerosols. In this study (see slide below), the investigators made Covid-19 positive people breathe, speak and sing into a machine that collected the aerosol droplets. Some of the participants were asymptomatic or pre-symptomatic. The study showed:

- ## Fine aerosol droplets 85% more infectious than big droplets





-
- CAPRISA**
Safe sex & all pleasure products. No Condoms.

42. The risk of viral transmission is particularly difficult to mitigate in indoor settings where people (including those who do not know that they have Covid-19) are moving around and talking to others in close proximity without masks such as in restaurants, pubs and weddings. Good ventilation is key to reducing spread in these settings. These settings could potentially become super-spreading events. It also points to the importance of indoor settings where masks are not worn, like restaurants, needing to ensure that the windows are open and that outdoor serving should be prioritised.

43. There are several studies providing evidence showing that reducing gathering size impacts viral transmission. I will draw upon two of these studies to highlight the overall impact of reducing gatherings. In an analysis in the journal, Nature, over 1,000 government interventions were analysed. Haug et al ranked the effectiveness of interventions and showed that cancelling gatherings was among the most effective interventions that governments could implement to reduce the spread of SARS-CoV-2. In a separate analysis, Brauner et al, showed in the journal, Science, that gatherings have had a huge impact in facilitating spread of the virus and reducing gathering size reduces viral transmission. The findings of both studies are provided in the slides below:

Evidence-based selection of prevention measures



44. For these interventions, there is a benefit to the individuals who chose to use them. The community benefit is derived only when large numbers of people are implementing these measures simultaneously. Hence, these mass-based interventions need to be implemented at community level to prevent infections from those who are spreading the virus without even knowing it.
45. While it is estimated, based on seroprevalence surveys, that about 80 percent to 85 percent of South Africans have been naturally infected at some time since the

start of the pandemic. Somewhere between one in five and one in ten South Africans have been able to remain uninfected through South Africa's 5 waves of infection. While people with natural immunity have good protection against severe disease, these individuals will have only short-lived temporary protection against reinfection because immunity wanes over time. Within 3-4 months antibodies from natural infection are substantially lower than shortly after infection with a concomitant reduction in protection from future infection. Due to waning of immunity within a short period, population immunity (sometimes referred to as herd immunity) is at best transient and provides limited, if any, protection against reinfection in future.

The need for government regulation

46. Faced with the reality of the global spread of SARS-CoV-2, governments have been forced to decide how best to intervene to mitigate the effects of the pandemic on their populations. In addition to providing the public with reliable information and advice on infection prevention, most governments around the world have recognised the importance of actively regulating the public's behaviour by enforcing infection prevention practices. And, because the virus spreads rapidly, with a basic reproduction number often reaching above 3 (i.e., each infected person is likely to infect three other people), there is a need to act with urgency, especially as new waves start.


47. Globally and in South Africa, there is growing fatalism in dealing with the pandemic, where some of the Great Barrington Declaration (a discredited view that the virus should be allowed to spread while protecting the elderly) arguments are re-surfacing, such as “what is the point of trying to prevent infections as everyone is going to get infected anyway - let’s just let the virus spread and do little or nothing about it”. This is often accompanied by the argument that people’s personal freedom from the restrictions of public health measures is more important than saving a few lives. This position is defeatist and has no scientific rationale. In simple terms, this is a passive surrender to the virus – or worse, an active surrender when accompanied by a belief that any defensive action should deliberately NOT be taken in the belief that it has no prospect of success. Each new infection leads to more infections, illness, long Covid and new variants making prevention efforts critical while we continue to live in the midst of the pandemic. Public health measures need to prevent and/or slow the spread of infection as every person who does not get infected is saved from the risk of not only acute infection consequences but its many long-term consequences.

48. The concept of “living with the virus” has been proposed to capture the perspective that it is possible to continue close to normal activities while mitigating risk. However, this concept is sometimes used as a guise for “the pandemic threat is over (as omicron is mild) and so we can get back to living ‘normal’ lives without prevention measures”. To help counter this, I promote “living **smartly** with the virus” in order to differentiate it from the Great Barrington Declaration like approach of simply going about our business while

the virus spreads unchecked. The approach of “living smartly with the virus” means knowing when transmission is high/low and what the most risky activities are, so that each person can adjust his/her willingness to participate in riskier activities like attend indoor gatherings but not let it stop him/her from essential activities like going to work everyday. Living smartly with the virus is about adjusting the use of public health measures in response to the (changing) prevailing risk of infection. At a community level, living smartly with the virus is captured most simply in the “Vaccination Plus” maxim, which calls for the adoption of selected public health measures (selected as appropriate to the setting) in addition to being vaccinated.

49. Having researched the manner in which the virus is spread and the speed with which it spreads, I have concluded that a central aspect to slowing or stopping the spread of Covid-19 requires individuals to act jointly for both self-interest and for the common good.

50. At community level, mutual inter-dependence is a critical aspect of reducing risk. Each person’s risk of infection is dependent heavily on others, which is well captured in the phrase, “No-one is safe until everyone is safe”. But there are likely to be individuals who act in a manner that places not only themselves but several others at risk of infection. In these circumstances, individual behaviour can increase community risk, leading to harming others. For these individuals who fail to act for the common good, there is a need for government regulation to modify human behaviour in a manner that minimises risk for the whole population. This step becomes especially important for those at risk of severe acute illness and of long-term sequelae.



51. If South Africans lived the principles of Ubuntu – “I am because you are”, and hence “I am safe because you are safe” - the impact of the virus in our country would be dramatically reduced. To facilitate this, government needs to implement evidence-based regulations to achieve these goals of SARS-CoV-2 prevention and mitigating the impact of Covid-19.



SALIM SAFURDEEN ABDOOL KARIM

I hereby certify that the deponent knows and understands the contents of this affidavit and that it is to the best of the deponent's knowledge both true and correct. This affidavit was signed and sworn to before me at DURBAN on this the 23 day of JUNE 2022, and that the Regulations contained in Government Notice R.1258 of 21 July 1972, as amended by R1648 of 19 August 1977, and as further amended by R1428 of 11 July 1989, having been complied with.



COMMISSIONER OF OATHS
SUNITA PANDAY
CHARTERED ACCOUNTANT (SOUTH AFRICA)
APPOINTED IN TERMS OF SECTION 8
OF THE JUSTICE OF THE PEACE AND
COMMISSIONER OF OATHS ACT 16 OF 1963
CAPRISA
719 UMBILO ROAD, CONGELLA, 4013

COMMISSIONER OF OATHS

Full names: SUNITA PANDAY

Address: 719 UMBILO ROAD,
CONGELLA, 4013

Capacity: CA (SA)

Curriculum Vitae Professor Salim S Abdool Karim

1. DATE OF PREPARATION OF CV

1 February 2022

2. PERSONAL DATA

| | | |
|-----------------|-----------|---|
| Name | : | Salim S. Abdool Karim |
| Birthdate | : | July 29, 1960 |
| Birthplace | : | Durban, South Africa |
| Citizenship | : | South African |
| Residency | : | South Africa and USA |
| Work Addresses: | : | CAPRISA, Doris Duke Medical Research Institute (2nd Floor), Nelson R Mandela School of Medicine, University of KwaZulu- Natal, 719 Umbilo Road, Durban 4001, South Africa and Department of Epidemiology, Mailman School of Public Health, Columbia University, 722 West 168 th Street, New York, NY 10032 |
| Telephone | (work) : | +1 (646) 3178800 or +27-31-2604550 |
| | (home) : | +1 (917) 4633654 or +27-87-7025666 |
| | (mobile): | +27-82-7769705 |
| E-mail address | : | Salim.AbdoolKarim@caprisa.org or ssa16@columbia.edu |

3. ACADEMIC TRAINING

| | |
|------------------|---|
| 01/1992-12/1999: | PhD, University of Natal, South Africa |
| 01/1989-12/1992: | MMed (Community Health), University of Natal, South Africa. |
| 01/1989-12/1991: | FFCH (Community Medicine), College of Medicine, South Africa. |
| 01/1985-12/1989: | Diploma in Datametrics(Computer Science), University of South Africa. |
| 09/1987-08/1988: | MS(Epidemiology), School of Public Health, Columbia University, New York. |
| 01/1978-12/1983: | MBChB, University of Natal, South Africa. |

4. PROFESSIONAL ORGANIZATIONS AND SOCIETIES

| | | |
|--------------|---|--|
| 2021-Present | : | Vice President, International Science Council |
| 2019-Present | : | Fellow, Royal Society |
| 2018-Present | : | Member, US National Academy of Medicine |
| 2017-Present | : | Member, Association of American Physicians |
| 2016-Present | : | Fellow, University of KwaZulu-Natal |
| 2013-Present | : | Fellow, American Academy of Microbiology (AAM) |
| 2012-2017 | : | Foreign Associate Member, US National Academy of Medicine (previously Institute of Medicine (IOM) of the US National Academy of Sciences) |
| 2011-Present | : | Fellow, African Academy of Sciences (AAS) |
| 2009-Present | : | Fellow, The World Academy of Sciences (TWAS) |
| 2003-Present | : | Fellow, Royal Society of South Africa (RSSAf) |
| 2001-Present | : | Member, Academy of Science of South Africa (ASSAf) |
| 2000-Present | : | Member, International Society for Infectious Diseases |
| 1996-Present | : | Member, International AIDS Society |
| 1996-2000 | : | Member, Society for Epidemiological Research, USA |
| 1996-1999 | : | Councillor for Africa, International Epidemiological Association |
| 1996-1998 | : | Chairperson, Epidemiological Society of Southern Africa |
| 1995 | : | Member, New York Academy of Sciences |
| | : | Member, American Association for the Advancement of Science. |
| 1994-Present | : | Member, Sexually Transmitted Diseases Society of South Africa (now FIDSSA). |
| 1989-Present | : | Member, International Epidemiological Association. |

| | | |
|-----------|---|---|
| | : | Member, Epidemiological Society of Southern Africa (and subsequently FIDSSA). |
| 1989-1991 | : | Executive Committee Member, Epidemiological Society of Southern Africa. |
| | : | Member, Community Health Association of Southern Africa. |
| 1986-1987 | : | Chairperson, National Emergency Services Groups. |
| 1986-1987 | : | Assistant General Secretary, National Medical and Dental Association (NAMDA). |
| 1985-1986 | : | Member, South African Society for Occupational Medicine. |
| 1982-1986 | : | Member, Phoenix Child Welfare Society and David Landau Community Centre. |

5. PROFESSIONAL / BOARD QUALIFICATIONS:

| | | |
|--------------|---|--|
| 1992-Present | : | Registered with the South African Health Professions as a Community Health Specialist. |
| 1992-Present | : | Registered Fellow in the Faculty of Community Health of the South African College of Medicine. |
| 1985-Present | : | Registered as Medical Practitioner with Health Professions Council of South Africa (0271047MP) |

6. ACADEMIC APPOINTMENTS

Current appointments:

| | | |
|--------------|---|---|
| 2022-Present | : | (Honorary) Director: Global Virus Network Center of Excellence |
| 2019-Present | : | (Honorary) Adjunct Professor in Immunology and Infectious Diseases, Harvard University |
| 2016-Present | : | CAPRISA Professor of Global Health, Department of Epidemiology, Columbia University (Professor with tenure) |
| 2016-Present | : | (Honorary) Pro Vice-Chancellor (Research), University of KwaZulu-Natal |
| 2015-Present | : | (Honorary) Director: DST-NRF Centre of Excellence in HIV Prevention (hosted by CAPRISA) |
| 2014-Present | : | (Honorary) Director: MRC HIV-TB Pathogenesis and Treatment Research Unit (hosted by CAPRISA) |
| 2011-Present | : | (Honorary) Associate, Ragon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT) and Harvard University |
| 2005-Present | : | (Honorary) Adjunct Professor, Clinical Epidemiology and Health Services Research, Graduate School of Medical Sciences, Cornell University, New York |
| 2002-Present | : | Director: Centre for the AIDS Programme of Research in South Africa (CAPRISA) |
| 2000-Present | : | (Honorary) Adjunct Professor of Medicine, Weill Medical College, Cornell University, New York |

Previous positions held:

| | | |
|-----------|---|---|
| 2012-2014 | : | President, South African Medical Research Council |
| 2008-2011 | : | Honorary Professor in Public Health, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal |
| 2007-2008 | : | Interim Director, KwaZulu-Natal Research Institute for TB and HIV (K-RITH) of the Howard Hughes Medical Institute |
| 2005-2015 | : | Pro Vice-Chancellor (Research), University of KwaZulu-Natal (as an employee) |
| 2003-2006 | : | Honorary Professor in Community Health, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal |
| 2001-2004 | : | Deputy Vice-Chancellor (Research), University of Natal |
| 2000-2015 | : | Professor of Clinical Epidemiology, Mailman School of Public Health, Columbia University, New York |
| 2000-2001 | : | Director, HIV Prevention and Vaccine Research Unit, Medical Research Council. |

| | | |
|-----------|---|--|
| 1999-2001 | : | Honorary Associate Professor, School of Infectious Diseases, University of Natal, Durban. |
| 1998-2000 | : | Visiting Professor, Weill Medical College, Cornell University, New York. |
| 1997 | : | Interim Director, Africa Centre for Population Studies and Reproductive Health of the Wellcome Trust |
| 1996-2000 | : | Adjunct Associate Professor, Division of Epidemiology, Mailman School of Public Health, Columbia University, New York. |
| 1993-2000 | : | Director, CERSA: Centre for Epidemiological Research in South Africa, Medical Research Council (MRC). |
| 1992-1998 | : | Honorary Lecturer, Department of Paediatrics and Child Health, Faculty of Medicine, University of Natal. |
| 1992-1997 | : | Honorary Senior Lecturer, Department of Family Medicine, Medical University of South Africa. |
| 1994 | : | Accompanied Health Minister Dlamini-Zuma as her Technical Advisor for the Afro Region of World Health Organisation's Annual Ministers of Health Meeting in Brazzaville, Congo. |
| 1994 | : | Visiting Professor, Division of Epidemiology, School of Public Health, Columbia University. |
| 1992-1995 | : | Part-time Senior Lecturer, Department of Optometry, University of Durban-Westville. |
| 1992-1993 | : | Senior Epidemiologist, Medical Research Council (Natal). |
| 1989-1992 | : | Resident/Registrar, Department of Community Health, Faculty of Medicine, Natal University |
| 1989 | : | Part-time Researcher: Centre for Epidemiological Research in South Africa, Medical Research Council. |
| 1987-1988 | : | Post-doctoral Fellow, Gertrude H. Sergievsky Center, Columbia University, New York. Also studied health economics at London School of Hygiene and Tropical Medicine and methods of epidemic investigations at the Centers for Disease Control, USA during this Fellowship. |
| 1986-1987 | : | Resident/Registrar, Department of Virology, Faculty of Medicine, University of Natal. |
| 1985 | : | Post-Intern Research Fellow, Research Institute for Diseases in Tropical Environment of MRC. |
| 1984 | : | Internship, King Edward VIII Hospital Durban. Worked in the Departments of Obstetrics and Gynaecology, Medicine, Surgery & Orthopaedics. |

7. HONORS

7a Awards

| | | |
|------|---|--|
| 2022 | : | VinFuture Special Prize from the VinFuture Foundation in Vietnam |
| 2021 | : | UNISA Chancellor's Calabash Award from the University of South Africa |
| | : | Honorary Doctorate: DSc (honoris causa) from Rhodes University |
| | : | CPHIA 2021 Lifetime Achievement in Public Health Award from the African Union (AU) and Africa CDC |
| 2020 | : | John Dirks Canada Gairdner Global Health Award from the Gairdner Foundation |
| | : | John Maddox Prize for Standing up for Science from Sense about Science and Nature |
| | : | 500 years of the Straits of Magellan Award from the government of Chile |
| | : | The Sunday Times Top 100 Honorary Award for contributions to the South African Covid-19 response |

- 2018 : **Al-Sumait Prize** from the Amir of Kuwait and the Kuwait Foundation for the Advancement of Science
- 2017 : **Lifetime Achievement Award** from the Institute of Human Virology
- 2015 : African Union's **Kwame Nkrumah Continental Scientific Award**
- : **Platinum Lifetime Achievement Award** from the Medical Research Council
- : KwaZulu-Natal Department of Health "**MASEA Award**"
- 2014 : **DSc (Medicine) (Honoris causa)**, University of Cape Town
- : **US Science and Technology Pioneers Prize** (to the CAPRISA 004 trial team) from the United States Agency for International Development
- : **Mayor's Award**, eThekweni Metro, Durban.
- 2013 : **John F. W. Herschel Medal** in recognition of Highly Distinguished Multidisciplinary Contributions to the furtherance of Science from the Royal Society of South Africa
- : **Distinguished Scholar Award** from the Biomedical HIV Prevention Forum of Nigeria
- 2012 : **N'Galy-Mann Award** (to Quarraisha and Salim S. Abdool Karim) for global contributions in HIV clinical research and epidemiology of AIDS
- : **Minara recognition award for Academic Excellence** (to Quarraisha and Salim S. Abdool Karim)
- 2011 : **President's Award for Outstanding Achievement in World Health** (to the CAPRISA 004 Leadership Team) from DIA (Drug Information Association) for research on the tenofovir gel microbicide
- : **Research leading to Innovation Award** (to Quarraisha and Salim S Abdool Karim on behalf of the CAPRISA 004 Leadership Team) from the South African National Science & Technology Forum (NSTF) jointly with BHP Billiton in recognition of the contributions to HIV prevention through the CAPRISA 004 study
- : **Allan Rosenfield Alumni Award for Excellence** (to Quarraisha and Salim S. Abdool Karim) from Columbia University's Alumni Association in recognition for excellence in AIDS research
- : **Medicine Award - Fellowship in Art & Science of Medicine (Gold)** from the South African Medical Association in recognition for excellence in research on microbicides, vaccines and TB-HIV treatment
- : **Science-for-Society Gold Medal Award** from the Academy of Science in South Africa (ASSAf) in recognition of excellence in the application of outstanding scientific thinking in the service of society.
- : **Outstanding Senior African Scientist Award** from the European and Developing Countries Clinical Trials Partnership (EDCTP)
- : **Olusegun Obasanjo Prize for Scientific Discovery and Technological Innovation** from the African Academy of Sciences
- 2009 : **TWAS Prize in Medical Sciences** from The World Academy of Sciences (TWAS)
- : **Outstanding Leadership Award** from the Microbicide Trials Network (MTN) for the HPTN 035 trial

- 2008 : **Hero in Medicine Award** from the International Association of Physicians for AIDS Care (IAPAC)
- 2005 : **Best Man Award** in the Science & Technology category from Men's Health Magazine
- 1988 : **Reebok Human Rights Award** from the Reebok Foundation - the award was dedicated to the work of NAMDA (The National Medical and Dental Association) in the field of health and human rights.

7b Post-graduate Fellowships

- 1987 : Rockefeller Fellowship for special interests and explorations at Columbia University, New York, USA.
- 1986 : Post-doctoral Fellowship by the South African Medical Research Council.
- 1985 : Post-intern scholarship by the Medical Research Council to study the epidemiology of hepatitis B.
- 1981 : Denmark Clerkship by the Natal University Medical Students' Representative Council, Durban, South Africa. Hosted by the International Medical Co-operation Committee and spent two months in Denmark learning about the Danish Health Care System.

7c Committee and other professional activities

- 2021-present : Member, TWAS Advisory Committee on Covid-19
 : Member, Physicians for Human Rights (PHR) Advisory Council
 : Member of World Health Organization's Science Council
 : Member, Scientific Advisory Committee, Chulalongkorn University's School of Global Health, Thailand
- 2020-present : Member, Lancet Commission on COVID-19
 : Member of the Steering Committee, Africa Task Force for Coronavirus (AFCOR)
 : Member, International Science Council's (ISC) Oversight Committee on the Covid-19 endgame
- 2020-2021 : Chair, Ministerial Advisory Committee on Covid-19 (later Co-Chair)
- 2019-present : Member, Scientific Advisory Board of the Consortium for HIV/AIDS Vaccine Development (CHAVD)
- 2017-present : Chair, World Health Organisation (WHO) Strategic and Technical Advisory Committee for HIV and Viral Hepatitis (STAC-HIVHEP)
 : Member, Board of the Population Council, New York
 : Chair, Grant review committee for the US Department of Defense's Medical Research and Development Program
- 2016-2017 : Member, International Advisory Group (IAG) for the India TB research Consortium
- 2015-present : Member, WHO HIV/TB Task Force
- 2015 : Co-Chair, WHO Pre-exposure Prophylaxis (PrEP) Technical Advisory Group
- 2014-present : Member, International Society for Infectious Diseases (ISID)
 : Member, Scientific Advisory Committee of the South African National Institute for Communicable Diseases
 : Member, 2015 Gen-Probe Joseph Public Health Award Nominations Committee of the American Academy of Microbiology

| | | |
|--------------|---|---|
| 2014-2015 | : | Member, WHO Consolidated Antiretroviral Guidelines Steering Committee |
| 2014 | : | Member, WHO expert committee drafting 2014 WHO Consolidated Antiretroviral guidelines |
| 2013-2019 | : | Chair, UNAIDS Scientific Expert Panel |
| 2013-2015 | : | Member, UNAIDS - Lancet Commission on AIDS |
| 2012-present | : | Member, Scientific Advisory Board for Global Health, Bill and Melinda Gates Foundation |
| 2012 | : | Member, Scientific Program Committee (SPC) of the international symposium to celebrate the 30th anniversary of the discovery of HIV |
| 2011 | : | Member, The team writing South Africa's National Strategic Plan for HIV/AIDS, STIs and TB (2012-2016) |
| 2011-2013 | : | Member, Academy of Science in South Africa - Standing Committee on Health |
| 2010-2014 | : | Member, Scientific Advisory Board, US President's Emergency Plan for AIDS Relief (PEPFAR) |
| 2010 | : | Member, Scientific Committee, UNAIDS Declaration on HIV Prevention |
| | : | Member, Expert Review Panel, Fogarty International Research Scientist Career Development Grant |
| 2009 | : | Member, Institute of Medicine's Committee on "Envisioning a strategy to prepare for the long-term burden of HIV/AIDS" |
| | : | Member, Review Panel of the US Military Infectious Diseases Research Program |
| | : | Member, Strategic Advisory Board, Global HIV Vaccine Enterprise |
| | : | Member, Global Health Award Advisory Committee, Gairdner Foundation |
| | : | Member, WHO Expert Advisory Panel on Sexually Transmitted Infections and HIV |
| | : | Member, Population Council Microbicide Advisory Board |
| 2008 | : | Chair, WHO, Scientific and Technical Advisory Group for Reproductive Health |
| | : | Member Scientific Committee, AIDS 2008 Vaccine Conference |
| 2007 | : | Member, AIDS Accountability International Scientific Review Panel |
| | : | Co-Chair of the Planning Group for Research in International Settings, National Institutes of Health's Office of AIDS Research |
| | : | Review panel member, US Centers for Disease Control and Prevention intramural AIDS Research Program |
| | : | Member, International AIDS Vaccine Initiative (IAVI) Scientific Advisory Committee |
| 2006 | : | Member, International Scientific Advisory Committee for the 17 th International Society for STD Research (ISSTD) |
| | : | Member, The International Center for Indigenous Phytotherapy Studies (TICIPS) External Advisory Panel |
| | : | Member, Council of South African Association for Marine Biological Research (SAAMBR) |
| | : | Trustee of the South African Centre for Epidemiological Modelling of AIDS (SACEMA) trust |



- : Member, Scientific Advisory Committee, Aurum Health Research
- : Member, External Review Panel for NIAID funded activities of the U.S. Military HIV Research Program

- 2005 : Member, Scientific Advisory Board, International Partnership for Microbicides
- : Member, South African Higher Education AIDS Programme Scientific Advisory Committee
- : Vice-Chair, Scientific and Technical Advisory Group (STAG), Department of Reproductive Health and Research, World Health Organisation, Geneva, 2002.
- : Member, International Planning Committee, Office of AIDS Research, National Institutes of Health
- : Member, Advisory Council for the Harvard AIDS Initiative (HAI) Vaccine Think Tank Series

- 2004 : Member, Scientific Committee for the Prevention Science concentration, 3rd IAS Conference on HIV Pathogenesis and Treatment

- 2003 : Member, Board of the Oceanographic Research Institute, Durban.
- : Member, Scientific Committee, AIDS Vaccine 2004, Paris
- : Member, Scientific Committee, Microbicide Conference 2004, London
- : Member, Scientific Committee, 8th World STI/AIDS Congress, Uruguay, 2003

- 2002 : Member, Global HIV Prevention Working Group of the Gates Foundation.
- : Member, Program Committee, AIDS Vaccines 2003, New York
- : Member, Scientific and Technical Advisory Group (STAG), Department of Reproductive Health and Research, World Health Organisation, Geneva, 2002.
- : Drafting sub-committee, Council of International Organisations of Medical Societies (CIOMS) Conference on 1992 CIOMS Guidelines Revision, World Health Organisation, Geneva, 2002.
- : Chairman, Scientific Basis for Regulatory Decisions on Microbicides, UNDP/UNFPA/WHO/ WORLD BANK Special Programme of Research Development and Research Training in Human Reproduction, World Health Organisation, Villars-sur-Ollon, Switzerland, 2002.
- : Member, Scientific Committee, International Congress of Chemotherapy, Durban, 2003

- 2001 : Member, Program Committee, AIDS Vaccines 2001, Philadelphia 2001
- : Member of the Advisory Board, International Leadership Award program of the Elizabeth Glaser Pediatric AIDS Foundation
- : Member, International Scientific Advisory Board, XIV International AIDS Conference, Barcelona, 2002
- : Member, Board of Directors, Sugar Milling Research Institute, Durban.

- 2000 : Chairperson, Scientific Programme Committee, XIIIth International AIDS Conference, Durban, July 2000.
- : Member, KwaZulu-Natal Provincial AIDS Council.
- : Member, Scientific Steering Committee, HIV Vaccine Trials Network
- : Chairperson, International Working Group, HIV Vaccine Trials Network

- 1999 : Member of the International Advisory Committee of the Second International Conference on AIDS India 2000, India, December 1999.
- : Member of Review Panel Focus Group on the Centers for AIDS Research, Office of AIDS Research, National Institutes for Health.

- 1998 : Chairperson, Health Sector Working Group, National Research and Technology Foresight Project, Department of Arts, Culture, Science and Technology, South Africa.

- : Chairperson, Data, Safety and Monitoring Board, Vitamin A and vertical HIV transmission trial, University of Natal, Durban.
 - : Chairperson, Safety Monitoring Committee, Pneumococcal Vaccine Trial, University of Witwatersrand, Johannesburg.
- 1997
 - : Chairperson, National Advisory Group of Immunisation, South Africa.
 - : Member, International Scientific Committee of the 3rd International Conference on AIDS Impact: Biopsychosocial aspects of HIV infection, Melbourne, Australia, June 1997.
 - : Member, Organising Committee and Scientific Committee of the 18th African Health Sciences Congress, Cape Town, April 1997.
 - : Member, Scientific Programme Committee, 12th World AIDS Conference, Geneva, June 1998.
- 1996
 - : Chairperson of the South African Polio Expert Committee
 - : Adviser, Educational Programmes on Psychological Problems in General Health Care, WHO.
 - : Elected to Governing Council as Councillor for Africa, International Epidemiological Association.
 - : Board Member, Centre for Health Policy, University of Witwatersrand, South Africa.
 - : Board Member, Institute for Urban Primary Health care, Johannesburg.
 - : Board Member, Dental Research Institute, University of Witwatersrand, South Africa.
 - : Member, Selection Committee of Oxford Nuffield Medical fellowships in South Africa.
 - : Scientific Advisory Panel, Poliomyelitis Research Foundation, South Africa.
- 1995
 - : Technical team for the National Health Insurance Commission of the Department of Health.
 - : Board Member, Pneumococcal Research Unit, University of Witwatersrand, South Africa.
 - : International Review Panel for AIDS Research in the areas of natural history, epidemiology and prevention, National Institutes for Health, USA.
 - : Viral Hepatitis Advisory Board
 - : HIV/AIDS and STD Advisory Group, Department of Health, South Africa.
 - : International Scientific Committee, XI International Conference on AIDS, Vancouver, July 1996.
 - : Scientific Programme Committee, HELINA '96, Second International Working Conference on Health Informatics in Africa, Johannesburg.
- 1994
 - : Health Advisory Committee and Management Committee of the Valley Trust, a socio-medical project in the Valley of Thousand Hills.
 - : South African Department of Health Committee to develop a National Health Information System
- 1993
 - : Board of the National Centre for Occupational Health, South Africa.
 - : Expert Panel for a Sanitation Decision Support System for Umgeni Water.
 - : Steering Committee on Water supply and quality and health in developing communities of the Water Research Commission.
 - : National Advisory Group on Immunisation, the government's expert committee on vaccination.
 - : Strategy Drafting Committee of NACOSA (The National AIDS Co-ordinating Committee of South Africa).
- 1992
 - : Scientific Review Committee of the Human Sciences Research Council project to evaluate the government-initiated Food Aid Programme in Natal-KwaZulu.
 - : Evaluation Panel of the Progressive Primary Health Care Network's National AIDS Programme.

8. FELLOWSHIP AND GRANT SUPPORT

Received grants as Principal Investigator in excess of \$250million, including grants from the National Institutes for Health, Wellcome Trust, USAID, US Centers for Disease Control and Prevention, European Union, South African Department of Science and Technology and the Howard Hughes Medical Institute.

| Agency | Title | Type & # | Period | Total Direct Costs | Role |
|--|--|---|-------------------------|---|---------------------------|
| 2021 | | | | | |
| National Institutes of Health (NIH) | Role of Data Streams in Informing Infection Dynamics in Africa - INFORM Africa | 1U54TW012041 | 09/15/2021-08/31/2026 | \$158,373 To Date | Co-investigator |
| 2020 | | | | | |
| South African Medical Research Council (SAMRC) | MRC-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit (RENEWAL) | Cooperative Agreement | 04/01/2020-03/31/2025 | From R1,000,000 per annum. R8,335,757 To Date | Principal Investigator |
| National Research Foundation (NRF)/DST | DST-NRF Centre of Excellence in HIV Prevention (RENEWAL) | UID 96354 | 04/01/2020-03/31/2025 | R75,221,162 To Date | Principal Investigator |
| USAID/Right to Care | For the Accelerating Program Achievements to Control the Epidemic (APACE) Activity - (COVID-19) | Cooperative Agreement no. 72067418CA00029 | 03/30/2020 – 09/30/2020 | R3,547,168 | Principal Investigator |
| South African Medical Research Council (SAMRC) | COVID-19 Transmission and natural history in KwaZulu-Natal, South Africa: Epidemiological Investigation to Guide Prevention and Clinical Care | | 04/01/2020 – 03/31/2021 | R6,160,582 | Principal Investigator |
| The IQRAA Trust | Contribution towards research and development of the CAP256 bNAbs product testing | | | R250,000 | Principal Investigator |
| National Institutes of Health (NIH)/NIAID | KwaZulu-Natal Clinical Trials Unit (Cycle 3) | 2UM1AI069469 | 12/01/2020-30/11/2027 | From \$1,600,679 per annum | Co-Principal Investigator |
| 2019 | | | | | |
| EDCTP | CAPRISA 012 SAMBA TRIAL: Subcutaneous Administration of Monoclonal Broadly-neutralizing Antibodies | RIA2017S-2008 | 01/01/2019-12/31/2023 | £9,254,000 | Principal Investigator |
| South African Medical Research Council (SAMRC) | CAPRISA 012: Phase I/II trial of Subcutaneous Administration of Monoclonal Broadly-neutralizing Antibodies (SAMBA Trial) | | 02/01/2019 – 06/30/2023 | R31,337,316 | Principal Investigator |
| 2017 | | | | | |
| South African Medical Research Council (SAMRC) | NDoh-SAMRC Special Initiative on HIV Prevention Technology | 96151 | 04/01/2017 – 03/31/2021 | R50,000,000 | Principal Investigator |
| 2016 | | | | | |
| USAID/FHI 360 | DREAMS Initiative - Prep Demonstration Research Study- CAPRISA 084 | Prime Award No. AID-674-A-14-00009 FHI 360 - Project No. - 100312.001.001 | 06/01/2016 – 05/31/2018 | R64,669,114 | Co-Investigator |
| EDCTP | CAPRISA 018: A randomised controlled trial to assess the safety, acceptability and pharmacokinetics of sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women | SRIA2015-1061 | 02/01/2017-12/31/2023 | £9,869,514 | Principal Investigator |
| 2015 | | | | | |
| South African Medical Research | MRC-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit | Cooperative Agreement | 04/01/2015-03/31/2020 | R5,852,208 | Principal Investigator |

| | | | | | |
|---|---|---|--|---------------------------------|---------------------------|
| Council (SAMRC) | | | | | |
| National Research Foundation (NRF)/DST | DST-NRF Centre of Excellence in HIV Prevention | UID 96354 | 03/01/2015-12/31/2019 | R10,000,000 per annum | Principal Investigator |
| Crucell Holland B.V - Janssen Pharmaceutica (Pty) Ltd | A Phase 1/2a Trial to Evaluate the Safety/Tolerability and Immunogenicity of Homologous Ad26 Mosaic Vector Regimens or Ad26 Mosaic and MVA Mosaic Heterologous Vector Regimens, with High-Dose, Low-Dose or no Clade C gp140 Protein Plus Adjuvant for HIV Prevention | Crucell - HIV-V-A004 | 03/26/2015 – 05/31/2018 | R3,245,090 | Co-Investigator |
| Viiv | Collaboration for the development and testing of an injectable antiretroviral agent, cabotegravir long-acting (LA), for HIV prevention in women – CAPRISA 014 | | 04/16/2015-12/31/2018 Terminated – 08/18/2016 | \$3,000,000 | Principal Investigator |
| USAID | Collaboration for the development and testing of an injectable antiretroviral agent, cabotegravir long-acting (LA), for HIV prevention in women – CAPRISA 014 | AID-OAA-A-15-00040 | 07/24/2015-07/23/2019 Terminated -06/30/2017 | \$3,000,000 | Principal Investigator |
| Tides Foundation / MAC AIDS | Stopping new HIV infections in young women: A community-based program for ARV-based prevention | Grant # TFR15-01788 | 09/11/2015-09/10/2016 | \$1,000,000 | Principal Investigator |
| 2014 | | | | | |
| Centers for Disease Control and Prevention | The CAPRISA Regional Centers for Advanced Clinical Management of HIV/AIDS and TB | 5 U2GGH0011 42 | 04/01/2014 – 03/31/2019 | \$15,304,949 | Co-Investigator |
| National Institutes of Health (NIH)/NIAID | Inflammation and HIV risk: understanding partial Tenofovir efficacy in CAPRISA004 | 1R01AI11193 6 | 07/10/2014-06/30/2018 | \$2,102,402 | Co-Investigator |
| 2013 | | | | | |
| National Institutes of Health (NIH)/NIAID | CAPRISA Clinical Trials Unit for AIDS/Tuberculosis Prevention and Treatment | 2UM1AI0694 69 | 12/10/2013-30/11/2020 | \$36,703,972 | Co-Principal Investigator |
| UNAIDS | Chair of the UNAIDS Scientific Expert Panel at CAPRISA | 2015/587455 | 05/22/2013-08/31/2016 | \$271,028 | Principal Investigator |
| 2012 | | | | | |
| CONRAD /USAID | CAPRISA 008: Phase IIIb Open-Label Randomized Controlled Trial to Assess the Implementation Effectiveness and Safety of 1% Tenofovir Gel Provision through Family Planning Services in KwaZulu-Natal, South Africa | Subproject No.: PPA-12-143 / Cooperative Agreement GPO-A00-08-00005-00 Subproject No.: MAPS1-14-002 / Cooperative Agreement AID-OAA-A-14-00011 | 03/01/2012-11/30/2014 06/15/2014-08/31/2015 | \$5,787,387 \$2,905,438- | Co-Principal Investigator |
| Family Health International - FHI 360 | HPV Infection, Genital Inflammation and HIV Acquisition in Women in CAPRISA 004 | FHI 360 ID: 0437.0197/80 5288 | 12/01/2012-03/31/2014 | \$573,208 | Co-Principal Investigator |
| NIH | Mary E. Charlson training grant | AHRQ T32 | | | Co-Investigator |
| 2011 | | | | | |
| Technology Innovation Agency/DST | CAPRISA 008: Phase IIIb Open-Label Randomized Controlled Trial to Assess the Implementation Effectiveness and Safety of 1% Tenofovir Gel Provision through Family Planning Services in KwaZulu-Natal, SA | | 11/28/2011-11/27/2012 | R14,000.000 | Co-Principal Investigator |

| | | | | | |
|--|--|--|-------------------------|-----------------------|--|
| Department of Science and Technology (DST) | To Conduct CAPRISA 009 as an open label randomized controlled trial to assess the impact of prophylactic exposure to Tenofovir Gel | Project Funding: DST/CON 0216/2011 | | R9,808,758 | Principal Investigator |
| Technology Innovation Agency/DST | Post CAPRISA 004 Activities | | 03/01/2011-02/29/2012 | R12,500,000 | Co-Principal Investigator |
| Technology Innovation Agency | HIV Vaccine Immunogen Design: Identification of T Cell epitopes associated with control of viral replication in Indian and South African HIV-1 infected individuals | | 01/04/2011-31/03/2013 | R1,500,000 | Co-Investigator |
| Tides Foundation / MAC AIDS | Research preparing for the scale-up implementation of tenofovir gel for HIV prevention | Grant#TFR11 - 01545 | 12/07/2011-11/07/2013 | \$500,000 | Co-Principal Investigator |
| Technology Innovation Agency | Identification of neutralizing antibody epitopes on Indian and South African HIV-1 subtype C viruses for HIV vaccine design | | 01/04/2011-31/03/2013 | R1,500,000 | Co-investigator |
| 2008 | | | | | |
| Centers for Disease Control and Prevention | CAPRISA AIDS TREATMENT PROGRAMME (CAT) | 5U2 GPS001350 | 09/30/08 – 09/30/14 | \$26,922,692 | Principal Investigator |
| Howard Hughes Medical Institute (HHMI) | TB Recurrence upon Treatment with HAART (TRuTH) Study | HHMI 55007065 | 09/01/2008 – 08/31/2012 | \$1,348,731 | Principal Investigator |
| National Research Foundation | Acute HIV Infection | UID 67385 | 04/01/2008 -03/31/2011 | R7,500,000 | Principal Investigator |
| 2007 | | | | | |
| National Institutes of Health (NIH)/NIAID | UKZN-CAPRISA HIV/AIDS Clinical Trials Unit Description: To conduct clinical trials of HIV prevention and treatment | UI01 AI069469 | 01/01/2007-12/31/2013 | \$35,535,855 | Principal Investigator |
| 2006 | | | | | |
| NIH | Microbicide Trial Network Leadership – Executive Committee Member | U01 AI068633 | 01/07/2006-30/06/2013 | \$149,372 per annum | Co-investigator (PI: Sharon Hillier) |
| Family Health International | CAPRISA 004: Phase IIb trial to assess the safety and effectiveness of vaginal microbicide, 1% Tenofovir gel, for the prevention of HIV infection in women in South Africa | co operative agreement # GPO-A-00-05-00022-00, contract # 132119 | 01/07/2006-31/03/2011 | \$8,940,544 | Co-Principal Investigator (Co-PI: Quarraisha Abdool Karim) |
| NIH | Center for HIV/AIDS Vaccine Immunology (CHAVI) | U01 A1067854 | 01/10/2006-30/06/2009 | \$2,650,556 | Co-Investigator (PI: B Haynes) |
| NIH | Evaluation of HIV-specific immunological and virological responses of HIV-1 multiply-exposed seronegative individuals (HEPS) | R01 AI 047086 | 01/06/2006-31/05/2009 | \$373,329 | Co-investigator (PI: Juliana McElrath) |
| 2005 | | | | | |
| NIH, Fogarty International Center | International Training Program in Epidemiology of AIDS Description: The goal of the Program is to impact on the spread and control of AIDS and tuberculosis by developing a group of well-trained South African researchers in these fields | D43 TW00231 | 01/06/2005-31/05/2010 | \$816,000 per annum | Co-Investigator (PI: Quarraisha Abdool Karim) |
| LIFELab (EcoBio) | Training Programme for CAPRISA 004: Phase II trial to assess the safety and effectiveness of the vaginal microbicide 1% Tenofovir for the prevention of HIV infection in young women in South Africa | | 01/07/2005-30/06/2008 | R8,500,000 | Co-Investigator (PI: Quarraisha Abdool Karim) |
| 2004 | | | | | |
| NIH | CAPRISA AIDS Treatment (CAT) Programme: Supplement to | U19A105179 4-02S1 | 01/06/2004-31/05/2008 | \$2,000,000 per annum | Principal Investigator |

| | | | | | |
|------------------------------------|---|----------------|-----------------------|--------------|--|
| | Collaborative AIDS Programme of Research in South Africa | | | | |
| 2003 | | | | | |
| Medical Research Council | South African AIDS Vaccine Initiative (SAVI) HIV Vaccine Trials Unit | | 01/04/2003-31/03/2006 | | Co-Principal Investigator (PI: Gavin Churchyard) |
| 2002 | | | | | |
| NIH | Collaborative AIDS Programme of Research in South Africa (CAPRISA) | U19 A151794-01 | 01/07/2002-31/05/2007 | \$10,685,048 | Principal Investigator |
| NIH | Adult AIDS Clinical Trials Group (AACTG) | | 01/06/2002-31/05/2006 | \$250,000 | Co-investigator (PI: Scott Hammer) |
| Fogarty International Center, NIH | Natal-Columbia Clinical AIDS/TB Training Program: A collaborative programme in clinical, operational and health services research and training | PA-02-022 | 01/01/2002-30/08/2003 | \$75,000 | Principal Investigator |
| 2001 | | | | | |
| NIH | HIV Vaccine Trials Unit (HVTN) | | 01/06/2001-30/06/2004 | \$17,500 | Co-investigator (PI: Scott Hammer) |
| NIH | HIV Prevention Trials Unit | U01A146749-03 | 01/06/2001-31/05/2004 | \$35,000 | Co-investigator (PI: Wafaa El-Sadr) |
| 2000 | | | | | |
| NIH | South African MRC HIV Prevention Trials Unit | | 01/06/2000-31/05/2005 | \$6,216,050 | Principal Investigator (until 30 June 2001) |
| NIH | New York – Southern Africa HIV Vaccine Trials Unit | | 01/06/2000-31/05/2005 | \$9,996,270 | Principal Investigator (until 30 June 2001) |
| Fogarty International Center, NIH | AIDS International Training and Research Program | D43 TW00231 | 01/10/2000-30/09/2005 | \$3,153,399 | Principal Investigator |
| NIH | Studies on acceptability of vaginal microbicides | | 01/10/2000-30/09/2004 | \$700,000 | Co-investigator (until 30 June 2001) (PI: Gita Ramjee) |
| 1999 | | | | | |
| NIH | HIVNET 023: Phase I study to assess the safety and plasma concentrations of nevirapine given daily, twice per week or weekly as prophylaxis in breastfeeding infants from birth to six months | | 01/01/1999-31/12/2000 | \$439,955 | Co-Principal Investigator |
| NIH | Phase I multi-centre dose escalation safety and acceptability study of the investigational vaginal microbicide agent PRO2000 | | 01/01/1999-31/05/2000 | \$163,623 | Co-Principal Investigator |
| NIH | Virological and immunological studies of HIV infection in newly infected individuals in Southern Africa | | 01/01/1999-31/05/2000 | \$116,222 | Co-Investigator (PI: Haynes Sheppard) |
| 1998 | | | | | |
| NIH – Fogarty International Center | International training programme in medical informatics for African nationals | | 01/06/1998-31/05/2002 | \$664,228 | Co-Investigator (PI: Michael Bennis) |
| The Wellcome Trust | Migration and the spread of sexually transmitted diseases in southern Africa | | 01/01/1998-31/12/2001 | R2,389,540 | Co-Investigator (PI: Mark Lurie) |
| The Wellcome Trust | Syphilis in pregnancy: a health systems intervention trial | | 01/04/1998-30/09/2000 | R952,350 | Co-Principal Investigator (PI: David Wilkinson) |

| | | | | | |
|------------------------------------|---|--|-----------------------|------------|--|
| NIH | International training programme in the epidemiology of AIDS | | 01/06/1998-31/05/2000 | \$815,799 | Principal Investigator |
| NIH – Fogarty International Centre | Supplementary grant: International TB training programme | | 01/10/1998-31/05/2000 | \$250,854 | Principal Investigator |
| World Health Organisation | COL-1492 in the prevention of transmission of STDs and HIV: a multi-centre phase II/III study among commercial sex workers participating in a 100% condom programme | | 01/10/1998-30/04/2000 | \$409,338 | Co-Principal Investigator |
| 1997 | | | | | |
| The Wellcome Trust | Africa Centre for Population Studies and Reproductive Health | | 01/07/1997-30/06/2002 | £5,000,000 | Principal Investigator (until end of 1997) |
| NIH | Establishing a South African HIV vaccine trial site through intervention trials for HIV prevention among high risk rural women in Hlabisa (Core HIVNET grant) | | 30/10/1997-01/06/2000 | \$784,082 | Principal Investigator |
| Department of Health | Development of surveillance systems for the HIV/AIDS and STD Programme | | 01/02/1997-31/12/1999 | R1,500,000 | Principal Investigator |
| Department of Health | Development of monitoring tools and evaluation of the HIV/AIDS and STD Programme | | 01/02/1997-31/12/1999 | R1,000,000 | Principal Investigator |
| 1995 | | | | | |
| World Health Organisation | A multi-centre, randomized, double-blind, placebo-controlled clinical trial to evaluate efficacy, tolerance and effectiveness of three drug regimens using zidovudine in combination with lamivudine for the prevention of mother-to-child transmission of HIV (PETRA). | | 15/12/1995-30/06/1998 | \$90,234 | Co-Investigator (PI: Joseph Saba) |

9. TEACHING EXPERIENCE AND RESPONSIBILITIES

9a. Teaching

- 2002-Present : Teach a course on "Cluster randomized control trials" in the Department of Medicine, Weill Medical College, Cornell University
- 1996-Present : Teach a course entitled "Advanced epidemiology of infectious diseases" in the Division of Epidemiology, Columbia University.
- 1992-Present : Occasional lectures to post-graduate students in the University of KwaZulu-Natal, University of Witwatersrand, University of Cape Town, University of Western Cape and the Medical University of South Africa.
- 1995-2002 : External examiner, Masters in Epidemiology, University of Cape Town, South Africa.
: External examiner, Department of Community Health, University of Witwatersrand.
: Examiner for the South African College of Medicine, Faculty of Community Health.
- 1991 : External examiner for M.Med.Sc. (Social Work) degree at the University of Durban-Westville and M.Soc.Sc. Degree at University of Natal.
- 1989 : Post-graduate teaching in Biostatistics - Departments of Medicine and Paediatrics, Natal University
- 1988 : Lectured in epidemiology in the College of Physicians and Surgeons, and in comparative health systems in the School of Public Health, Columbia University.
- 1987-1988 : Teaching Assistant in MPH core epidemiology course, School of Public Health, Columbia University.
- 1986-1987 : Lectured in Virology and Microbiology at University of Natal Medical School.

9b. Post-graduate Supervision

Doctoral degrees:

- 2016 : Kogieleum Naidoo, Challenges in the integration of TB and HIV care: Evidence for improving patient management and health care policy, PhD, University of KwaZulu-Natal

- 2015 : Cheryl Baxter, Impact of intermittent tenofovir 1% gel on hepatitis B virus (HBV) infection, PhD, University of KwaZulu-Natal
- 2014 : Vivek Naranbhai, The role of natural killer cells in preventing HIV-1 acquisition and controlling disease progression, PhD, University of KwaZulu-Natal
- 2008 : Eleanor Gouws, Incidence of HIV infection in rural KwaZulu-Natal. PhD, University of KwaZulu-Natal
- 2001 : Cassandra Seethal. Evaluation of a teacher vision awareness programme for teachers to detect vision problems in preschool children. PhD, University of Durban-Westville
- 1999 : David Wilkinson. Epidemiology, treatment and control of tuberculosis in the HIV era in Hlabisa, South Africa. MD, University of Natal
- 1998 : Colin Pillai. Pharmacokinetic and pharmacodynamic characteristics of isoniazid and rifampicin in patients with multi drug-resistant tuberculosis. PhD, University of Durban-Westville

Masters degrees:

- 2015 : Nivashnee Naicker. Predictors of HIV Acquisition in High Risk Women in Durban, South Africa. MPH, University of KwaZulu-Natal
- 1998 : Nirupa Shah. The impact of dispensing restrictions, generic substitution, and professional fees on the cost of medicines to the patient. M.B.A., University of Wales.
- 1997 : Roxana Rustomjee. A randomised control trial of nonoxynol 9 among sex workers in South Africa. M.S.(Epi), Columbia University.
- 1995 : David McCoy. Assessment of the quality of sexually transmitted disease care in a rural health district. M.Phil., University of Cape Town.

Supervision of US K-awardees:

- Mark Lurie, Brown University (K-award)
- Donnie McGrath, Tufts University (K-award)
- Ingrid Bassett, Harvard University (K-award)
- William Carr, Harvard University (K-award)

9c. CU-SA Fogarty AITRP Trainee Supervision

As past Principal Investigator of the Columbia University – Southern African Fogarty AIDS International Training and Research program (CU-SA Fogarty AITRP) for several years, I have been involved in building capacity in South Africa to undertake AIDS research for more than a decade. Over 200 Fellows have been trained in this program.

10. OTHER PROFESSIONAL ACTIVITIES

10a. Editorial responsibilities

- 2017-present : Editorial Board Member: Journal of Acquired Immunodeficiency Syndrome
- 2016 - 2020 : Editorial Board Member: mBio
- 2015-present : Editorial Board Member: New England Journal of Medicine
- 2014-present : Editorial Board Member: Indian Journal of Medical Research
- 2013-present : Editorial Board Member: AIDS Research and Human Retroviruses
- 2012-2013 : Editorial Board Member: AIDS Reviews
- 2011 : International Advisory Board Member: Lancet HIV
- 2010 : International Advisory Board member, The Lancet Global Health
- 2009 : Board of Reviewing Editors, *eLife* Journal
- 2008 : Reviewer, Science
- 2007 : Reviewer, AIDS Research and Human Retroviruses
- 2006 : Editorial Board Member: HIV and Infectious Diseases
- 2005 : Reviewer, Indian Journal of Medical Research
- 2004 : Reviewer, BioMedCentral (BMC) International Health and Human Rights
- 2003 : Reviewer, New England Journal of Medicine
- 2002 : Reviewer, HIV Medicine
- 2001 : Reviewer, Drugs
- 2000 : Reviewer, Clinical Infectious Diseases

| | | |
|-----------|---|--|
| | : | Reviewer, Pan African Medical Journal |
| | : | Reviewer, Journal of the American Medical Association |
| | : | Reviewer, Journal of Infection in Developing Countries |
| 2009 | : | Reviewer, Lancet |
| | : | Reviewer, Science (Translational Medicine) |
| | : | Reviewer, Fertility and Sterility |
| | : | Reviewer, International Journal of Tuberculosis and Lung Diseases |
| | : | Reviewer, Global Public Health |
| | : | Reviewer, Journal of Infectious Diseases |
| 2008 | : | Reviewer, Expert Review of Vaccines |
| 2007-2013 | : | Editorial Board Member: The Open Journal of Virology |
| 2006 | : | Reviewer, PLoS Medicine |
| 2005 | : | Reviewer: Journal of Acquired Immunodeficiency Syndrome (JAIDS) |
| 2004 | : | Reviewer, Bulletin of the World Health Organization |
| | : | Reviewer, Journal of Health, Population and Nutrition |
| | : | Reviewer, Tropical Medicine and International Health |
| 2001-2014 | : | Associate Editor, AIDS Clinical Care |
| 2001-2003 | : | Member - Editorial Board, Sexually Transmitted Infections |
| 2001-2006 | : | Corresponding Editor, International Journal of Infectious Diseases |
| 2000-2010 | : | Member - Editorial Board, Southern African Journal of HIV Medicine |
| 1999 | : | Reviewer, Social Science and Medicine |
| 1998 | : | Reviewer, AIDS |
| 1998-2008 | : | Member - Editorial Board, Southern African Journal of Epidemiology and Infection |
| 1997 | : | Reviewer, Journal of Family and Community Medicine |
| 1996 | : | Reviewer, Southern African Journal of Food Science and Nutrition. |
| 1995-1998 | : | Editor, Southern African Journal of Public Health. |
| 1993 | : | Reviewer, South African Medical Journal. |
| 1992 | : | Reviewer, American Journal of Public Health. |
| 1989 | : | Reviewer, Southern African Journal of Epidemiology and Infection. |

11. PUBLICATIONS

11a. Peer-reviewed journal articles

2022

1. Sharana Mahomed, Nigel Garrett, Edmund V Capparelli, Farzana Osman, Ishana Harkoo, Nonhlanhla Yende-Zuma, Tanuja N Gengiah, Derseree Archary, Natasha Samsunder, Cheryl Baxter, Nonhlanhla N Mkhize, Tandile Modise, Kevin Carlton, Adrian McDermott, Penny L Moore, Quarraisha Abdool Karim, Dan H Barouch, Patricia E Fast, John R Mascola, Julie E Ledgerwood, Lynn Morris, Salim S Abdool Karim, Safety and pharmacokinetics of monoclonal antibodies VRC07-523LS and PGT121 administered subcutaneously for HIV prevention, *The Journal of Infectious Diseases*, 2022; jiac041, <https://doi.org/10.1093/infdis/jiac041>
2. Sandile Cele, Farina Karim, Gila Lustig, San Emmanuel James, Tandile Hermanus, Eduan Wilkinson, Jumari Snyman, Mallory Bernstein, Khadija Khan, Shi-Hsia Hwa, Houriiyah Tegally, Sasha W. Tilles, Jennifer Giandhari, Ntombifuthi Mthabela, Matilda Mazibuko, Yashica Ganga, Bernadett I. Gosnell, **Salim Abdool Karim**, Willem Hanekom, Wesley C. Van Voorhis, Thumbi Ndung'u, COMMIT-KZN Team, Richard J. Lessells, Penny L. Moore, Mahomed-Yunus S. Moosa, Tuilo de Oliveira, Alex Sigal. Divergence of delta and beta variants and SARS-CoV-2 evolved in prolonged infection into distinct serological phenotypes. doi: <https://doi.org/10.1101/2021.09.14.21263564>
3. Cele S, Karim F, Lustig G, San JE, Hermanus T, Tegally H, Snyman J, Moyo-Gwete T, Wilkinson E, Bernstein M, Khan K, Hwa S, Tilles SW, Singh L, Giandhari J, Mthabela N, Mazibuko M, Ganga Y, Gosnell BI, **Abdool Karim SS**, Hanekom W, van Voorhis WC, Ndung'u T, Lessells RJ, Moore PL, Moosa MS, de Oliveira T, Sigal A. SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. *Cell Host & Microbe* 2022, <https://doi.org/10.1016/j.chom.2022.01.005>.
4. Gengiah TN, Abdool Karim Q, Harkoo I, Mansoor L, Zuma NY, Radebe P, Samsunder N, Baxter C, Maharaj B, Baum MM, Moss JA, Pozzetto B, Hankins C, **Abdool Karim SS**. CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and

- pharmacokinetics of a sustained release tenofovir alafenamide subdermal implant for HIV prevention in women. *BMJ Open* 2022; 12(1):e052880. doi: 10.1136/bmjopen-2021-052880.
5. Khan K, Lustig G, Bernstein M, Archary D, Cele S, Karim F, Smith M, Ganga Y, Jule Z, Reedoy K, Miya Y, Mthabela N, Magula NP, Lessells R, de Oliveira T, Gosnell BI, **Abdool Karim SS**, Garrett N, Hanekom W, Gail-Bekker L, Gray G, Blackburn JM, Moosa MS, Sigal A; COMMIT-KZN Team. Immunogenicity of SARS-CoV-2 infection and Ad26.CoV2.S vaccination in people living with HIV. *Clinical Infectious Diseases* 2021 Dec. ciab1008. doi: 10.1093/cid/ciab1008. Epub ahead of print.
 6. **Abdool Karim SS**, Baxter C. Impact of SARS-CoV-2 variants of concern on Covid-19 epidemic in South Africa. *Transactions of the Royal Society of South Africa* 2021 Dec. Epub ahead of print.

2021

7. **Abdool Karim SS**, de Oliveira T. New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications. *New England Journal of Medicine* 2021; 384(19):1866-1868.
8. **Abdool Karim SS**. Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection. *Lancet* 2021; 397: 1263-1264.
9. **Abdool Karim SS**, de Oliveira T, Loots G. Appropriate names for COVID-19 variants. *Science* 2021 March; 371(6535): 1215. (Letter)
10. **Abdool Karim SS**, Baxter C. HIV incidence trends in Africa: young women at highest risk. *Lancet HIV* 2021; 8(7): e389-e390.
11. Fontanet A, Autran B, Lina B, Kieny MP, **Abdool Karim SS**, Sridhar D. SARS-CoV-2 variants and ending the COVID-19 pandemic. *Lancet* 2021; 397(10278):952-954.
12. IJsselmuiden C, Ntoumi F, Lavery JV, Montoya J, **Abdool Karim S**, Kaiser K. Should global financing be the main priority for pandemic preparedness? *Lancet* 2021; 398(10298):388. doi: 10.1016/S0140-6736(21)01387-8. (Letter)
13. Commissioners of the Lancet COVID-19 Commission (including Abdool Karim SS), Task Force Chairs and members of the Lancet COVID-19 Commission, Commission Secretariat and Staff of the Lancet COVID-19 Commission Priorities for the COVID-19 pandemic at the start of 2021: statement of the Lancet COVID-19 Commission. *Lancet* 2021; 397: 947-949.
14. Sachs JD, **Abdool Karim S**, Akinin L, Allen J, Brosbøl K, Barron GC, Daszak P, et al. Priorities for the COVID-19 pandemic at the start of 2021: statement of the Lancet COVID-19 Commission. *Lancet* 2021; 397(10278):947-950.
15. Skegg S, Gluckman P, Boulton G, Hackmann H, **Abdool Karim SS**, Piot P, Woopen C. Future scenarios for the COVID-19 pandemic. *Lancet* 397(10276):777-778.
16. Sachs J, **Abdool Karim S**, Akinin L, Boone L, Brosbøl K, Barron GC, Daszak P, Espinosa MF, Gaspar V, Gaviria A, Haines A, Hotez PJ, Koundouri P, Bascuñán PL, Lee J-K, Pate M, Frenk J, Polman P, Ramos G, Reddy KS, Serageldin I, Shah R, Thwaites J, Vike-Freiberga V, Wang C, Were MK, Xue L, Zhu M. Statement of The Lancet COVID-19 Commission: Enhancing Global Cooperation to End the COVID-19 Pandemic. 2021 February. <https://covid19commission.org/enhancing-global-cooperation>
17. Baxter C, Abdool Karim Q, **Abdool Karim SS**. Identifying SARS-CoV-2 infections in South Africa: Balancing public health imperatives with saving lives. *Biochemical and Biophysical Research Communications* 2021; 538:221-225.
18. Cromarty R, Sigal A, Liebenberg LJ, McKinnon LR, **Abdool Karim SS**, Passmore JS, Archary D. Betamethasone induces potent immunosuppression and reduces HIV infection in a PBMC in vitro model. *Journal of Investigative Medicine* 2021; 69(1):28-40.
19. Mahomed S, Garrett N, Baxter C, Abdool Karim Q, **Abdool Karim SS**. Clinical trials of broadly neutralizing monoclonal antibodies for HIV Prevention: A Review. *Journal of Infectious Diseases* 2021; 223(3):370-380.
20. Pillay K, Lewis L, Rambaran S, Yende-Zuma N, Archary D, Gengiah S, Govender D, Hassan-Moosa R, Samsunder N, **Abdool Karim SS**, McKinnon LR, Naidoo K, Siro A Plasma Biomarkers of Risk of Tuberculosis Recurrence in HIV Co-Infected Patients from South Africa. *Frontiers in Immunology* 2021; 12:631094. doi: 10.3389/fimmu.2021.631094.
21. Sharma M, Mudimu E, Simeon K, Bershteyn A, Dorward J, Violette LR, Akullian A, **Abdool Karim SS**, Celum C, Garrett N, Drain PK. Cost-effectiveness of point-of-care testing with task-shifting for HIV care in South Africa: a modelling study. *Lancet HIV* 2021; 8(4):e216-e224.
22. Lee J-K, Bullen C, Amor YB, Bush SR, Colombo F, Gaviria A, **Abdool Karim SS**, Kim B, Lavis JN, Lazarus JV, Lo Y-C, Michie SF, Norhei FP, Oha J, Reddy KS, Rostila M, Sáenz R, Smith LG, Thwaites JW, Were MK, Xue L, (The Lancet COVID-19 Commission Task Force for Public Health Measures to Suppress the Pandemic). Institutional and behaviour-change interventions

B 

- to support COVID-19 public health measures: a review by the Lancet Commission Task Force on public health measures to suppress the pandemic. *International Health* 2021;13(5):399-409.
23. Mngomezulu K, Mzobe GF, Mtshali A, Osman F, Liebenberg LJP, Garrett N, Singh R, Rompalo A, Mindel A, **Abdool Karim SS**, Abdool Karim Q, Baxter C, Ngcapu S. Recent Semen Exposure impacts the Cytokine Response and Bacterial Vaginosis in women. *Frontiers in Immunology* 2021; 12:695201. doi: 10.3389/fimmu.2021.695201.
 24. Singh R, Ramsuran V, Naranbhai V, Yende-Zuma N, Garrett N, Mlisana K, Dong KL, Walker BD, **Abdool Karim SS**, Carrington M, Ndung'u T. Epigenetic regulation of BST-2 expression levels and the effect on HIV-1 pathogenesis. *Frontiers in Immunology* 2021; 12:669241. doi: 10.3389/fimmu.2021.669241
 25. Jewanraj J, Ngcapu S, Osman F, Ramsuran V, Fish M, Mtshali A, Singh R, Mansoor LE, Abdool Karim SS, Abdool Karim Q, Passmore J-A S, Liebenberg LP. Transient association between semen exposure and biomarkers of genital inflammation in South African women at risk of HIV infection. *Journal of the International AIDS Society* 2021; 24:e25766. doi: 10.1002/jia2.25766
 26. Mtshali A, James SE, Osman F, Garrett N, Balle C, Giandhari J, Onywera H, Mngomezulu K, Mzobe G, De Oliveira T, Rompalo A, Mindel A, **Abdool Karim SS**, Ravel J, Passmore J-AS, Abdool Karim Q, Jaspan HB, Liebenberg LJP, Ngcapu S. Temporal changes in vaginal microbiota and genital tract cytokines among South African women treated for bacterial vaginosis. *Frontiers in Immunology* 2021, 12:730986. doi: 10.3389/fimmu.2021.730986
 27. Molatlhegi RP, Ngcobo S, Liebenberg LJP, Ngcapu S, Mabhula A, Leslie A, Mchunu N, Zondi MM, Adamson JH, Govender K, Samsunder N, **Abdool Karim SS**, Abdool Karim Q, Passmore JS, Sivo A, McKinnon LR. Genital and systemic immune effects of the injectable, contraceptive norethisterone enanthate (NET-EN), in South African women. *American Journal of Reproductive Immunology* 2021; 86(2):e13411. doi: 10.1111/aji.13411.
 28. Bardon AR, Dorward J, Sookrajh Y, Sayed F, Quame-Amaglo J, Pillay C, Feutz E, Ngobese H, Simoni JM, Sharma M, Cressey TR, Gandhi M, Lessells R, Moodley P, Naicker N, Naidoo K, Thomas K, Celum C, **Abdool Karim SS**, Garrett N, Drain PK. Simplifying TREATment and Monitoring for HIV (STREAM HIV): protocol for a randomised controlled trial of point-of-care urine tenofovir and viral load testing to improve HIV outcomes. *BMJ Open* 2021;11(10):e050116. doi: 10.1136/bmjopen-2021-050116.
 29. Gengiah S, Barker PM, Yende-Zuma N, Mbatha M, Naidoo S, Taylor M, Loveday M, Mhlongo M, Jackson C, Nunn AJ, Padayatchi N, **Abdool Karim SS**, Naidoo K. A cluster-randomized controlled trial to improve the quality of integrated HIV-tuberculosis services in primary healthcare clinics in South Africa. *Journal of the International AIDS Society* 2021;24(9):e25803. doi: 10.1002/jia2.25803.
 30. Ismail SD, Riou C, Joseph SB, Archin NM, Margolis DM, Perelson AS, Cassidy T, Abrahams M-R, Moeser M, Council OD, McKinnon LR8, Osman F, Abdool Karim Q, **Abdool Karim SS**, Swanstrom R, Williamson C, Garrett NJ, Burgers WA. Immunological correlates of the HIV-1 replication-competent reservoir size. *Clinical Infectious Diseases* 2021; 73(8):1528-1531.
 31. **Abdool Karim SS**, Baxter C. HIV pre-exposure prophylaxis implementation in Africa: some early lessons. *Lancet Global Health* 2021; 9(12):e1634-e1635.
 32. Garrett N, Mtshali A, Osman F, Masson L, McKinnon LR, Singh R, Mitchev N, Ngobese H, Kharsany ABM, Abdool Karim S, Mlisana K, Passmore JA, Rompalo A, Mindel A, Liebenberg L. Impact of point-of-care testing and treatment of sexually transmitted infections and bacterial vaginosis on genital tract inflammatory cytokines in a cohort of young South African women. *Sexually Transmitted Infections* 2021 97(8):555-565.
 33. Sobia P, Pillay T, Liebenberg LJ, Sivo A, Mansoor LE, Osman F, Passmore JA, Abdool Karim Q, **Abdool Karim SS**, Baxter C, McKinnon LR. Higher Mucosal Antibody Concentrations in Women with Genital Tract Inflammation. *Scientific Reports* 2021; 11(1):23514. doi: 10.1038/s41598-021-02954-0.
 34. Mielke D, Bandawe G, Zheng J, Jones J, Abrahams MR, Bekker V, Ochsenbauer C, Garrett N, **Abdool Karim SS**, Moore PL, Morris L, Montefiori D, Anthony C, Ferrari G, Williamson C. ADCC-mediating non-neutralizing antibodies can exert immune pressure in early HIV-1 infection. *PLoS Pathogens* 2021; 17(11):e1010046. doi: 10.1371/journal.ppat.1010046.
 35. **Abdool Karim SS** and Abdool Karim Q. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. *Lancet* 2021; 398(10317):2126-2128.
 36. **Abdool Karim SS**, Kelemu S, Baxter C. COVID-19 in Africa: Catalyzing change for sustainable development. *PLoS Medicine* 2021; 18(11):e1003869. doi: 10.1371/journal.pmed.1003869.

2020

37. **Abdool Karim SS.** The South African response to the pandemic. *New England Journal of Medicine* 2020; 382(24):e95. doi: 10.1056/NEJMc2014960
38. **Abdool Karim Q, Abdool Karim SS.** COVID-19 affects HIV and tuberculosis care. *Science* 2020; 369(6502):366-368
39. **Brault MA, Spiegelman D, Abdool Karim SS, Vermund SH.** Integrating and Interpreting Findings from the Latest Treatment as Prevention Trials. *Current HIV/AIDS Reports.* 2020; 17(3):249-258.
40. **Naidoo K, Hassan-Moosa R, Mlotshwa P, Yende-Zuma N, Govender D, Padayatchi N, Abdool Karim SS.** High rates of drug-induced liver injury in people living with HIV coinfecting with tuberculosis (TB) irrespective of antiretroviral therapy timing during antituberculosis treatment: results from the starting antiretroviral therapy at three points in TB trial. *Clinical Infectious Diseases* 2020; 70(12):2675-2682.
41. **Molatlhegi RP, Liebenberg LJ, Leslie A, Noel-Romas L, Mabhula A, Mchunu N, Perner M, Birse K, Ngcapu S, Adamson JH, Govender K, Garrett NJ, Samsunder N, Burgener AD, Abdool Karim SS, Abdool Karim Q, Passmore JS, McKinnon LR.** Plasma concentration of injectable contraceptive correlates with reduced cervicovaginal growth factor expression in South African women. *Mucosal Immunology* 2020; 13(3):449-459.
42. **Singh R, Ramsuran V, Mitchev N, Niehaus AJ, Han KSS, Osman F, Ngcapu S, Abdool Karim SS, Rompalo A, Garrett N, Mlisana K.** Assessing a diagnosis tool for bacterial vaginosis. *European Journal of Clinical Microbiology & Infectious Diseases.* 2020; 39(8):1481-1485
43. **Drain PK, Dorward J, Violette LR, Quame-Amaglo J, Thomas KK, Samsunder N, Ngobese H, Mlisana K, Moodley P, Donnell D, Barnabas RV, Naidoo K, Abdool Karim SS, Celum C, Garrett N.** Point-of-care HIV viral load testing combined with task shifting to improve treatment outcomes (STREAM): findings from an open-label, non-inferiority, randomised controlled trial. *Lancet HIV* 2020; 7(4):e229-e237.
44. **Fisher KL, Mabuka JM, Sivo A, Ngcapu S, Passmore J-AS, Osman F, Ndlovu B, Abdool Karim Q, Abdool Karim SS, Chung AW, Baxter C, Archary D.** Topical Tenofovir Pre-exposure Prophylaxis and Mucosal HIV-Specific Fc-Mediated Antibody Activities in Women. *Frontiers in Immunology* 2020; 11(1274).
45. **Msomi N, Naidoo K, Yende-Zuma N, Padayatchi N, Govender K, Singh JA, Abdool Karim SS, Abdool-Karim Q, Mlisana K.** High incidence and persistence of hepatitis B virus infection in individuals receiving HIV care in KwaZulu-Natal, South Africa. *BMC Infectious Diseases* 2020; 20(1):847. doi: 10.1186/s12879-020-05575-6.
46. **Mahomed S, Garrett N, Baxter C, Abdool Karim Q, Abdool Karim SS.** Clinical trials of broadly neutralizing monoclonal antibodies for HIV Prevention: A Review. *Journal of Infectious Diseases* 2020; 10(11): e042247. doi: 10.1136/bmjopen-2020-042247.
47. **Scheepers C, Bekker V, Anthony C, Richardson SI, Oosthuysen B, Moyo T, Kgagudi P, Kitchin D, Nonyane M, York T, Mielke D, Mabvakure BM, Sheng Z, Lambson BE, Ismail A, Garrett NJ, Abdool Karim SS, Shapiro L, Williamson C, Morris L, Moore PL.** Antibody Isotype Switching as a Mechanism to Counter HIV Neutralization Escape. *Cell Reports* 2020; 33(8):108430. doi: 10.1016/j.celrep.2020.108430.

2019

48. **Abdool Karim SS.** HIV-1 Epidemic Control — Insights from Test-and-Treat Trials. *New England Journal of Medicine* 2019; 381;3: 286-288.
49. **Abdool Karim SS, Baxter C, Passmore JS, McKinnon LR, Williams BL.** The genital tract and rectal microbiomes: their role in HIV susceptibility and prevention in women. *Journal of the International AIDS Society* 2019; 22(5):e25300. doi: 10.1002/jia2.25300
50. **Abdool Karim SS, Baxter C.** HIV incidence rates in adolescent girls and young women in sub-Saharan Africa. *Lancet Global Health* 2019; 7(11):e1470-e1471. doi: 10.1016/S2214-109X(19)30404-8.
51. **Abrahams MR, Joseph SB, Garrett N, Tyers L, Moeser M, Archin N, Council OD, Matten D, Zhou S, Doolabh D, Anthony C, Goonetilleke N, Abdool Karim SS, Margolis DM, Pond SK, Williamson C, Swanstrom R.** The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation. *Science Translational Medicine* 2019; 11(513): eaaw5589. doi: 10.1126/scitranslmed.aaw5589.
52. **Liebenberg L*, McKinnon L*, Yende-Zuma N*, Garrett N, Baxter C, Kharsany A, Archary D, Rositch A, Samsunder N, Mansoor L, Passmore J-A, Abdool Karim S, Abdool Karim Q.** HPV infection and the genital cytokine milieu in women at high risk of HIV acquisition. *Nature Communication* 2019; 10: 5227

53. Chimukangara B, Kharsany AB, Lessells RJ, Naidoo K, Rhee SY, Manasa J, Gräf T, Lewis L, Cawood C, Khanyile D, Diallo K, Ayalew KA, Shafer R, Hunt G, Pillay D, **Abdool Karim SS**, de Oliveira T. Moderate-to-High Levels of Pretreatment HIV Drug Resistance in KwaZulu-Natal Province, South Africa. *AIDS Research and Human Retroviruses*. 2019; 35(2):129-138.
54. Mabvakure BM, Scheepers C, Garrett N, **Abdool Karim SS**, Williamson C, Morris L, Moore PL. Positive selection at key residues in the HIV Envelope distinguishes broad and strain-specific plasma neutralizing antibodies. *Journal of Virology* 2019; 93(6): e01685-18.
55. Chimukangara B, Lessells RJ, Rhee S-Y, Giandhari J, Kharsany ABM, Naidoo K, Lewis L, Cawood C, Khanyile D, Ayalew KA, Diallo K, Samuel R, Hunt G, Vandormael A, Stray-Pedersen B, Gordon M, Makadzange T, Kiepiela P, Ramjee G, Ledwaba J, Kalimashe M, Morris L, Parikh UM, Mellors JW, Shafer RW, Katzenstein D, Moodley P, Gupta RK, Pillay D, **Abdool Karim SS**, de Oliveira T. Trends in pretreatment HIV-1 drug resistance in antiretroviral therapy-naïve adults in South Africa, 2000–2016: a pooled sequence analysis. *EClinicalMedicine* 2019; 9:26-34.
56. Mabvakure BM, Lambson BE, Ramdayal K, Masson L, Kitchin D, Allam M, **Abdool Karim SS**, Williamson C, Passmore J, Martin DP, Scheepers C, Moore PL, Harkins GW, Morris L. Evidence for both intermittent and persistent compartmentalization of HIV-1 in the female genital tract. *Journal of Virology* 2019; 93(10): e00311-19.
57. Mahomed S, Garrett N, Capparelli E, Baxter C, Yende Zuma N, Gengiah T, Archary D, Moore P, Samsunder N, Barouch DH, Mascola J, Ledgerwood J, Morris L, **Abdool Karim SS**. Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial. *BMJ Open* 2019; 9: e030283. doi:10.1136/bmjopen-2019-030283.
58. Baxter C, Ngcapu S, Blackard JT, Powell EA, Penton PK, **Abdool Karim SS**. Frequency of Hepatitis B Virus Resistance Mutations in Women Using Tenofovir Gel as Pre-Exposure Prophylaxis. *Viruses* 2019; 11(6): E569. doi: 10.3390/v11060569.
59. Darboe F, Mbandi SK, Naidoo K, Yende-Zuma N, Lewis L, Thompson E, Duffy F, Fisher M, Filander E, van Rooyen M, Bilek N, Mabwe S, McKinnon L, Chegou NN, Loxton AG, Walz G, Tromp G, Padayatchi N, Govender D, Hatherill M, **Abdool Karim SS**, Zak D, Penn-Nicholson A, Scriba T. Detection of tuberculosis recurrence, diagnosis and treatment response by a blood transcriptomic risk signature in HIV-infected persons on antiretroviral therapy. *Frontiers in Microbiology* 2019; 10:1441. doi: 10.3389/fmicb.2019.01441
60. Cromarty R, Sigal A, Liebenberg LJ, McKinnon LR, **Abdool Karim SS**, Passmore JS, Archary D. Diminished HIV infection of target CD4+ T cells in a Toll-Like Receptor 4 stimulated in vitro model. *Frontiers in Immunology* 2019; 10:1705. doi: 10.3389/fimmu.2019.01705
61. van den Berg FT, Makoah NA, Ali SA, Scott TA, Mapengo RE, Mutsunguma LZ, Mkhize NN, Lambson BE, Kgagudi PD, Crowther C, **Abdool Karim SS**, Balazs AB, Weinberg MS, Ely A, Arbuthnot PB, Morris L. AAV-Mediated Expression of Broadly Neutralizing and Vaccine-like Antibodies Targeting the HIV-1 Envelope V2 Region. *Molecular Therapy: Methods & Clinical Development* 2019; 14: 100-112. doi: 10.1016/j.omtm.2019.06.002
62. Mwatelah R, McKinnon LR, Baxter C, **Abdool Karim Q**, **Abdool Karim SS**. Mechanisms of sexually transmitted infection-induced inflammation in women: implications for HIV risk. *Journal of the International AIDS Society* 2019; 22 (Suppl 6): e25346. doi: 10.1002/jia2.25346.
63. Naidoo K, Rampersad S, **Abdool Karim SS**. Improving survival with tuberculosis & HIV treatment integration: a mini review. *Indian Journal of Medical Research* 2019; 150(2):131-138.
64. Kharsany ABM, Cawood C, Lewis L, Yende-Zuma N, Khanyile D, Puren A, Madurai S, Baxter C, George G, Govender K, Beckett S, Samsunder N, Toledo C, Ayalew KA, Diallo K, Glenshaw M, Herman-Roloff A, Wilkinson E, de Oliveira T, **Abdool Karim SS**, **Abdool Karim Q**. Trends in HIV Prevention, Treatment, and Incidence in a Hyperendemic Area of KwaZulu-Natal, South Africa. *JAMA Network Open* 2019; 2: e1914378-e1914378.
65. Naidoo K, Hassan-Moosa R, Mlotshwa P, Yende-Zuma N, Govender D, Padayatchi N, **Abdool Karim SS**. High rates of drug-induced liver injury in people living with HIV coinfecting with tuberculosis (TB) irrespective of antiretroviral therapy timing during antituberculosis treatment: results from the starting antiretroviral therapy at three points in TB trial. *Clinical Infectious Diseases* 2019; pii: ciz732. doi: 10.1093/cid/ciz732
66. Mielke D, Bandawe G, Pollara J, Abrahams M-R, Nyanhete T, Moore P, Thebus R, Yates NL, Kappes JC, Ochsenbauer C, Garrett N, **Abdool Karim SS**, Tomaras GD, Montefiori D, Morris L, Ferrari G, Williamson C. Antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies constrain neutralizing antibody escape pathway. *Frontiers in Immunology* 2019; 10: 2875. doi: 10.3389/fimmu.2019.02875.

2018

67. **Abdool Karim SS**. Optimising the accuracy of HIV drug resistance assays. *Lancet HIV* 2018; 5(11): e68-e69.
68. **Abdool Karim SS**, Jo-Ann Passmore, Cheryl Baxter. The Microbiome and HIV Prevention Strategies in Women. *Current Opinion in HIV and AIDS* 2018; 13(1):81–87.
69. Abdool Karim Q, **Abdool Karim SS**. HIV—no time for complacency. *Science* 2018; 360: 1153.
70. Sivo A, Schuetz A, Sheward D, Joag V, Yegorov S, Liebenberg LJ, Yende-Zuma N, Stalker A, Mwatelah RS, Selhorst P, Garrett N, Samsunder N, Balgobin A, Nawaz F, Cicala C, Arthos J, Fauci AS, Anzala AO, Kimani J, Bagaya BS, Kiwanuka N, Williamson C, Kaul R, Passmore JS, Phanuphak N, Ananworanich J, Ansari A, Abdool Karim Q, **Abdool Karim SS**, McKinnon LR; CAPRISA004 and RV254 study groups. Integrin $\alpha 4\beta 7$ expression on peripheral blood CD4+ T cells predicts HIV acquisition and disease progression outcomes. *Science Translational Medicine* 2018 24;10(425). pii: eaam6354.
71. McKinnon LR, Liebenberg LJ, Yende-Zuma N, Archary D, Ngcapu S, Sivo A, Nagelkerke N, Garcia Lerma JG, Kashuba AD, Masson L, Mansoor LE, Abdool Karim Q, **Abdool Karim SS**, Passmore JS. Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women. *Nature Medicine* 2018; 24(4):491-496. doi: 10.1038/nm.4506. doi: 10.1038/nm.4506.
72. Johnson EL, Doria-Rose NA, Gorman J, Bhiman JN, Schramm CA, Vu AQ, Law WH, Zhang B, Bekker V, **Abdool Karim SS**, Ippolito GC, Morris L, Moore PL, Kwong PD, Mascola JR, Georgiou G. Sequencing HIV-neutralizing antibody exons and introns reveals detailed aspects of lineage maturation. *Nature Communications* 2018; 9(1):4136.
73. Sheward DJ, Marais J, Bekker V, Murrell B, Eren K, Bhiman JN, Nonyane M, Garrett N, Woodman ZL, Abdool Karim Q, **Abdool Karim SS**, Morris L, Moore PL, Williamson C. HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth. *Cell Host & Microbe* 2018; 24(4): 593-599.
74. Setliff I, McDonnell WJ, Raju N, Bombardi RG, Murji AA, Scheepers C, Ziki R, Mynhardt C, Shepherd B, Mamchak AA, Garrett N, **Abdool Karim SS**, Mallal SA, Crowe JE, Morris L, Georgiev IS. Multi-Donor Longitudinal Antibody Repertoire Sequencing Reveals the Existence of Public Antibody Clonotypes in HIV-1 Infection. *Cell Host & Microbe* 2018; 23(6): 845-854.
75. van Eeden C, Wibmer CK, Scheepers C, Richardson SI, Nonyane M, Lambson B, Mkhize NN, Vijayakumar B, Sheng Z, Stanfield-Oakley S, Bhiman JN, Bekker V, Hermanus T, Mabvakure B, Ismail A, Moody MA, Wiehe K, Garrett N, **Abdool Karim SS**, Dirr H, Fernandes MA, Sayed Y, Shapiro L, Ferrari G, Haynes BF, Moore PL, Morris L. V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity. *Cell Reports* 2018; 25(11):3123-3135.
76. Dorward J, Lessells R, Drain PK, Naidoo K, de Oliveira T, Pillay Y, **Abdool Karim SS**, Garret N. Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research. *Lancet HIV* 2018; 5(7): e400-e404 .
77. Garrett N, Norman E, Leask K, Naicker N, Asari V, Majola N, Abdool Karim Q, and **Abdool Karim SS**. Acceptability of early antiretroviral therapy among South African women. *AIDS and Behavior* 2018; 22(3):1018-1024.
78. Moosa Y, Tanko RF, Ramsuran V, Singh R, Madzivhandila M, Yende-Zuma N, Abrahams MR, Selhorst P, Gounder K, Moore PL, Williamson C, **Abdool Karim SS**, Garrett NJ, Burgers WA. Case Report: Mechanisms of HIV Elite Control in two African Women. *BMC Infectious Diseases* 2018; 18(1): 54. doi: 10.1186/s12879-018-2961-8.
79. Richardson RI, Chung AW, Natarajan H, Mabvakure B, Mkhize NN, Garrett N, **Abdool Karim S**, Moore PL, Ackerman ME, Alter G, Morris L. HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies. *PLoS Pathogens* 2018; 14(4): e1006987.
80. Garrett NJ, Osman F, Maharaj B, Naicker N, Gibbs A, Norman E, Samsunder N, Ngobese H, Mitchev N, Singh R, **Abdool Karim SS**, Kharsany ABM, Mlisana K, Rompalo A, Mindel A. Beyond Syndromic Management: Opportunities for Diagnosis-based Treatment of Sexually Transmitted Infections in Low- and Middle-Income Countries . *PLoS One* 2018; 13(4): e0196209.
81. Barre-Sinoussi F, **Abdool Karim SS**, Albert J, Bekker LG, Beyrer C, Cahn P, Calmy A, Grinsztejn B, Grulich A, Kamarulzaman A, Kumarasamy N, Loutfy MR, El Filali KM, Mboup S, Montaner JS, Munderi P, Pokrovsky V, Vandamme AM, Young B, Godfrey-Faussett P. Expert consensus statement on the science of HIV in the context of criminal law. *Journal of the International AIDS Society* 2018; 21(7): e25161. doi: 10.1002/jia2.25161.

82. Tanko RF, Soares AP, Masson L, Garrett NJ, Samsunder N, Abdool Karim Q, **Abdool Karim SS**, Riou C, Burgers WA. Residual T cell activation and skewed CD8+ T cell memory differentiation despite antiretroviral therapy-induced HIV suppression. *Clinical Immunology* 2018; 195:127-138. doi: 10.1016/j.clim.2018.06.001.
83. Joag V, Siro A, Yende-Zuma N, Imam H, Samsunder N, Abdool Karim Q, **Abdool Karim S**, McKinnon L, Kaul R. Ex vivo HIV entry into blood CD4+ T cells does not predict heterosexual HIV acquisition in women. *PLoS One* 2018; 13(7): e0200359. doi: 10.1371/journal.pone.0200359.

2017

84. **Abdool Karim SS**. Assessing progress with HIV incidence in national cohorts. *Lancet HIV* 2017;4(2): e56-e58. doi: 10.1016/S2352-3018(16)30187-4.
85. **Abdool Karim SS**, Abdool Karim Q, Abimiku A, Linda-Gail Bekker L-G, Bukusi EA, Deschamps MMH, Derbew M, Garcia PJ, Gray G, Moses R Kanya, Swaminathan S, Wu Z. Closing the NIH Fogarty Center threatens US and global health. *The Lancet* 2017; 390(10093): 451. doi: 10.1016/S0140-6736(17)31912-8.
86. Singh JA, **Abdool Karim SS**. Trump's "global gag rule": implications for human rights and global health. *The Lancet Global Health* 2017; 5(4): e387-e389.
87. de Oliveira T, Kharsany ABM, Gräf T, Cawood C, Khanyile D, Grobler A, Puren A, Madurai S, Baxter C, Abdool Karim Q, **Abdool Karim SS**. Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: a community-wide phylogenetic study. *Lancet HIV* 2017; 4(1): e41-e50.
88. Klatt NR, Cheu R, Birse K, Zevin AS, Perner M, Noël-Romas L, Grobler A, Westmacott G, Xie IY, Butler J, Mansoor J, McKinnon LR, Passmore J-AS, Abdool Karim Q, **Abdool Karim S**, Burgener AD. Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women. *Science* 2017; 356(6341): 938-945.
89. Alam SM, Aussedat B, Vohra Y, Meyerhoff RR, Cale EM, Walkowicz WE, Radakovich NA, Anasti K, Armand L, Parks R, Sutherland L, Searce R, Joyce MG, Pancera M, Druz A, Georgiev IS, Von Holle T, Eaton A, Fox C, Reed SG, Louder M, Bailer RT, Morris L, **Abdool Karim SS**, Cohen M, Liao H-X, Montefiori DC, Park PK, Fernández-Tejada A, Wiehe K, Santra S, Kepler TB, Saunders KO, Sodroski J, Kwong PD, Mascola JR, Bonsignori M, Moody MA, Danishefsky S, and Haynes BF. Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. *Science Translational Medicine* 2017; 9(381): eaai7521. DOI: 10.1126/scitranslmed.aai7521.
90. Julg B, Tartaglia LJ, Keele B, Wagh K, Pegu A, Sok D, Abbink P, Schmidt SD, Wang K, Chen X, Joyce MG, Georgiev IS, Choe M, Kwong PD, Doria-Rose NA, Le K, Louder MK, Bailer RT, Moore PL, Korber B, Seaman MS, **Abdool Karim SS**, Morris L, Koup RA, Mascola JR, Burton DR, Barouch DH. Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer robust protection against a clade C SHIV challenge. *Science Translational Medicine* 2017; 9(406): eaal1321. DOI: 10.1126/scitranslmed.aal1321
91. Wibmer CK, Gorman J, Ozorowski G, Bhiman JN, Sheward DJ, Elliott DH, Rouelle J, Smira A, Joyce MG, Ndabambi N, Druz A, Asokan M, Burton DR, Connors M, **Abdool Karim SS**, Mascola JR, Robinson JE, Ward AB, Williamson C, Kwong PD, Morris L, Moore PL. Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. *PLOS Pathogens* 2017; 13(1): e1006074.
92. Tanko RF, Soares AP, Müller TL, Garrett NJ, Samsunder N, Abdool Karim Q, **Abdool Karim SS**, Riou C, Burgers WA. Effect of Antiretroviral Therapy on the Memory and Activation Profiles of B Cells in HIV-Infected African Women. *Journal of Immunology* 2017; 198(3):1220-1228.
93. Chopera DR, Ntale R, Ndabambi N, Garrett N, Gray CM, Matten D, Abdool Karim Q, **Abdool Karim SS**, Williamson C. Early evolution of human leucocyte antigen-Associated escape mutations in variable Gag proteins predicts CD4R decline in HIV-1 subtype C-infected women. *AIDS* 2017; 31(2):191-197.
94. Selhorst P, Masson L, Ismail SD, Samsunder N, Garrett N, Mansoor LE, Abdool Karim Q, **Abdool Karim SS**, Passmore Jo-AS, Williamson C. Cervicovaginal inflammation Facilitates Acquisition of less infectious HIV variants. *Clinical Infectious Diseases* 2017; 64(1):79-82.
95. Thobakgale C, Naidoo K, McKinnon LR, Werner L, Samsunder N, **Abdool Karim SS**, Ndung'u T, Altfeld M, Naidoo K. Interleukin 1-beta (IL-1 β) production by innate cells following TLR stimulation correlates with TB recurrence in ART-treated HIV infected patients *Journal of Acquired Immune Deficiency Syndrome* 2017; 74(2):213-220.

96. Doria-Rose NA, Altae-Tran HR, Roark RS, Schmidt SD, Sutton MS, Louder MK, Chuang GY, Bailer RT, Cortez V, Kong R, McKee K, O'Dell S, Wang F, **Abdool Karim SS**, Binley JM, Connors M, Haynes BF, Martin MA, Montefiori DC, Morris L, Overbaugh J, Kwong PD, Mascola JR, Georgiev IS. Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting. *PLoS Pathogens* 2017; 13(1):e1006148.
97. Liebenberg LJ, Masson L, Arnold KB, McKinnon LR, Werner L, Proctor E, Archary D, Mansoor LE, Lauffenburger DA, Abdool Karim Q, **Abdool Karim SS**, Passmore Jo-AS. Genital-systemic chemokine gradients and the risk of HIV acquisition in women. *Journal of Acquired Immune Deficiency Syndrome* 2017; 74(3):318-325.
98. Selhorst P, Combrinck C, Ndabambi N, Ismail SD, Abrahams M-R, Lacerda M, Samsunder N, Garrett N, Abdool Karim Q, **Abdool Karim SS**, Williamson C. Replication capacity of viruses from acute infection drives HIV-1 disease progression. *Journal of Virology* 2017; 91(8): e01806-16.
99. Naicker N, Naidoo A, Werner L, Garrett N, Majola N, Asari V, Baxter C, Grobler A, Abdool Karim Q, **Abdool Karim SS**. Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials. *Antiviral Therapy* 2017; 22(4):287-293.
100. Sivo A, Naidoo K, McKinnon L, Yende-Zuma N, **Abdool Karim SS**. Plasma cytokine predictors of TB recurrence in antiretroviral-treated HIV-infected individuals from Durban, South Africa. *Clinical Infectious Diseases* 2017; 65(5): 819-826.
101. Ngandu NK, Carlson JM, Chopera DR, Ndabambi N, Abdool Karim Q, **Abdool Karim S**, Williamson C. Brief Report: Selection of HIV-1 Variants with Higher Transmission Potential by 1% Tenofovir Gel Microbicide. *Journal of Acquired Immune Deficiency Syndrome* 2017; 76(1):43-47
102. Naidoo K, Hassan-Moosa R, Yende-Zuma N, Govender N, Padayatchi N, Dawood H, Adams RN, Govender A, Chinappa S, **Abdool Karim SS**, Abdool Karim Q. High mortality rates in men initiated on anti-retroviral treatment in KwaZulu-Natal, South Africa. *PLoS One* 2017; 12(9):e0184124
103. Anthony C, York T, Bekker V, Matten D, Selhorst P, Ferreria RC, Garrett NJ, **Abdool Karim SS**, Morris L, Wood NT, Moore PL, Williamson C. Cooperation between strain-specific and broadly neutralizing responses limited viral escape and prolonged exposure of the broadly neutralizing epitope. *Journal of Virology* 2017; 91(18): e00828-17. doi: 10.1128/JVI.00828-17.
104. Dorward J, Garrett N, Quame-Amaglo J, Samsunder N, Ngobese H, Ngomane N, Moodley P, Mlisana K, Schaafsma T, Donnell D, Barnabas R, Naidoo K, **Abdool Karim SS**, Celum C, Drain PK. Protocol for a randomised controlled implementation trial of point-of-care viral load testing and task shifting: the Simplifying HIV TREATment and Monitoring (STREAM) study. *BMJ Open* 2017; 7(9): e017507. doi:10.1136/bmjopen-2017-017507.
105. Scheepers C, Chowdhury S, Wright WS, Campbell CT, Garrett NJ, Abdool Karim Q, **Abdool Karim SS**, Moore PL, Gildersleeve JC, Morris L. Serum glycan-binding IgG antibodies in HIV-1 infection and during the development of broadly neutralizing responses. *AIDS* 2017; 31(16):2199-2209.

2016

106. **Abdool Karim SS**. Is the UNAIDS target sufficient for HIV control in Botswana? *Lancet HIV* 2016; 3(5):e195-6.
107. Doria-Rose NA, Bhiman JN, Roark RS, Schramm CS, Gorman J, Pancera M, Cale EM, Ernandes MJ, Louder MK, Asokan M, Bailer RT, Druz A, Frascilla IR, Garrett NJ, Jarosinski M, Lynch RM, McKee K, O'Dell S, Pegu A, Schmidt SD, Staupe RP, Sutton MS, Wang K, Wibmer CK, Haynes BF, **Abdool Karim S**, Shapiro L, Kwong PD, Moore PL, Morris L, Mascola JR. A new member of the V1V2-directed CAP256-VRC26 lineage that shows increased 2 breadth and exceptional potency. *Journal of Virology* 2016; 90(1): 76-91.
108. Arnold KB, Burgener A, Birse K, Romas L, Dunphy LJ, Shahabi K, Abou M, Westmacott GR, McCorrister S, Kwatampora J, Nyanga B, Kimani J, Masson L, Liebenberg LJ, **Abdool Karim SS**, Passmore J-AS, Lauffenburger DA, Kaul R, McKinnon LR. Increased levels of inflammatory cytokines in the female reproductive tract are associated with altered expression of proteases, mucosal barrier proteins, and an influx of HIV-susceptible target cells. *Mucosal Immunology* 2016; 9(1):194-205.
109. Rademeyer C, Korber B, Seaman M, Giorgi EE, Thebus R, Robles A, Sheward DJ, Wagh K, Garrity J, Carey BR, Gao H, Greene KM, Tang H, Bandawe GP, Marais JC, Diphoko TE, Hraber P, Tumba N, Moore PL, Gray GE, Kublin J, McElrath JM, Vermeulen J, Middelkoop K, Bekker L-

- G, Hoelscher M, Maboko L, Makhema J, Robb ML, **Abdool Karim S**, Abdool Karim Q, Kim JH, Hahn BH, Gao F, Swanstrom R, Morris L, Montefiori DC, Williamson C. Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. *PLoS Pathogens* 2016; 12(7): e1005742. doi:10.1371/journal.ppat.1005742
110. Bradley T, Fera D, Bhiman J, Eslamizar L, Lu X, Anasti K, Zhang R, Sutherland LL, Searce RM, Bowman CM, Stolarchuk C, Lloyd KE, Parks R5, Eaton A, Foulger A, Nie X, **Abdool Karim SS**, Barnett S, Kelsoe G, Kepler TB, Alam SM, Montefiori DC, Moody MA, Liao HX, Morris L, Santra S, Harrison SC, Haynes BF. Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. *Cell Reports* 2016; 14(1):43-54.
 111. Kløverpris HN, Kazer SW, Mjösberg J, Mabuka JM, Wellmann A, Ndhlovu Z, Yadon MC, Nhamoyebonde S, Muenchhoff M, Simoni Y, Andersson F, Kuhn W, Garrett N, Burgers WA, Kanya P, Pretorius K, Dong K, Moodley A, Newell EW, Kasprovicz V, Abdool Karim SS, Goulder P, Shalek AK, Walker BD, Ndung'u T, Leslie A. Innate Lymphoid Cells Are Depleted Irreversibly during Acute HIV-1 Infection in the Absence of Viral Suppression. *Immunity* 2016; 44(2):391-405.
 112. Balkus JE, Brown ER, Hillier SL, Coletti A, Ramjee G, Mgodini N, Mkanani B, Reid C, Martinson F, Soto-Torres L, **Abdool Karim SS**, Chirenje ZM. Oral and injectable contraceptive use and HIV acquisition risk among women in four African countries: a secondary analysis of data from a microbicide trial. *Contraception* 2016; 3(1): 25-31.
 113. Masson L, Arnold KB, Little F, Mlisana K, Lewis DA, Mkhize N, Gamielien H, Ngcapu S, Johnson L, Lauffenburger DA, Abdool Karim Q, **Abdool Karim SS**, Passmore JS. Inflammatory cytokine biomarkers to identify women with asymptomatic sexually transmitted infections and bacterial vaginosis who are at high risk of HIV infection. *Sexually Transmitted Infections* 2016; 92(3):186-93.
 114. Mkhize N, Durgiah R, Archary D, Garrett N, Moore P, Abdool Karim, Q, **Abdool Karim SS**, Passmore JS, Tomaras G, Ashley V, Yates N, Morris, L. Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women. *AIDS* 2016; 30(7): 1005-1014.
 115. Archary D, Seaton KE, Passmore JS, Werner L, Deal A, Dunphy LJ, Arnold KB, Yates NL, Lauffenburger DA, Bergin P, Liebenberg LJ, Samsunder N, Mureithi MW, Altfeld M, Garrett N, Abdool Karim Q, **Abdool Karim S**, Morris L, Tomaras GD. Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel. *Mucosal Immunology* 2016; 9(3):821-33.
 116. Naranbhai V, de Assis Rosa D, Werner L, Moodley R, Hong H, Kharsany A, Mlisana K, Sibeko S, Garrett N, Chopera D, Carr WH, Abdool Karim Q, Hill AV, **Abdool Karim SS**, Altfeld M, Gray CM, Ndung'u T. Killer-cell Immunoglobulin-like Receptor (KIR) gene profiles modify HIV disease course, not HIV acquisition in South African women. *BMC Infectious Diseases* 2016;16(1):27. doi: 10.1186/s12879-016-1361-1.
 117. Gray GE, Laher F, Doherty T, **Abdool Karim S**, Hammer S, Mascola J, Beyrer C, Corey L. Which new health technologies do we need to achieve an end to HIV/AIDS? *PLoS Biology* 2016; 14(3): e1002372. doi:10.1371/journal.pbio.1002372.
 118. Wagh K, Bhattacharya T, Williamson C, Robles A, Bayne M, Garrity J, Rist M, Rademeyer C, Yoon H, Lapedes A, Gao H, GreeneK Louder MK, KongR, **Abdool Karim SS**, Burton DR, Barouch DH, Nussenzweig MC, Mascola JR, Morris L, Montefiori DC, Korber B, Seaman MS. Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. *PLoS Pathogens* 12(3): e1005520. doi:10.1371/journal.ppat.1005520.
 119. MacQueen KM, Dlamini S, Perry B, Okumu E, Sortijas S, Singh C, Pillay D, Majors A, Jerome S, Watson S, **Abdool Karim SS**, Abdool Karim Q, Mansoor LE. Social Context of Adherence in an Open-Label 1 % Tenofovir Gel Trial: Gender Dynamics and Disclosure in KwaZulu-Natal, South Africa. *AIDS & Behavior* 2016; 20(11): 2682-2691.
 120. Shey MS, Maharaj N, Archary D, Ngcapu S, Garrett N, **Abdool Karim SS**, Jo-Ann S. Passmore J-AS. Modulation of Female Genital Tract-Derived Dendritic Cell Migration and Activation in Response to Inflammatory Cytokines and Toll-Like Receptor Agonists. *PLoS ONE* 2016 May; 11(5): e0155668. doi:10.1371/journal.pone.0155668.
 121. Madlala P, Singh R, An P, Werner L, Mlisana K, **Abdool Karim SS**, Winkler CA, Ndung'u T. Association of polymorphisms in the regulatory region of the cyclophilin A gene (PPIA) with gene expression and HIV/AIDS disease progression. *Journal of Acquired Immune Deficiency Syndrome* 2016; 72(5):465-473
 122. Garrett NJ, Drain PK, Werner L, Samsunder N, **Abdool Karim SS**. Diagnostic accuracy of the point-of-care xpert HIV-1 viral load assay in a South African HIV Clinic. *Journal of Acquired Immune Deficiency Syndrome* 2016; 72(2): e45-e4.

123. Baxter C, **Abdool Karim SS**. Combination HIV prevention options for young women in Africa. *African Journal of AIDS Research* 2016; 15:2, 109-121.
124. Sobieszczyk ME, Werner L, Mlisana K, Naicker N, Feinstein A, Gray CM, Masson L, Passmore J-AS, Williamson C, Abdool Karim Q, **Abdool Karim SS**, Garrett NG. Metabolic syndrome after HIV acquisition in South African women. *Journal of Acquired Immune Deficiency Syndrome* 2016; 73(4): 438-445.
125. Wibmer K, Gorman J, Anthony C, Mkhize N, Druz A, York T, Schmidt S, Labuschagne P, Louder M, Bailer R, **Abdool Karim S**, Mascola J, Williamson C, Moore P, Kwong P, Morris L. Structure of an N276-dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole adjacent to the CD4 Binding Site. *Journal of Virology* 2016; 90(22): 10220-10235.
126. Bradley T, Trama A, Tumba N, Gray E, Lu X, Madani N, Jahanbakhsh F, Eaton A, Xia S-M, Parks R, Lloyd KE, Sutherland LL, Searce RM, Bowman CM, Barnett S, **Abdool-Karim SS**, Boyd SD, Melillo B, Smith III AB, Sodroski J, Kepler TB, Alam SM, Gao F, Bonsignori M, Liao H-X, Moody MA, Montefiori D, Santra S, Morris L, Haynes BF. Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. *EBioMedicine* 2016; 12: 196-207.

2015

127. **Abdool Karim SS**. Overcoming Impediments to Global Implementation of Early Antiretroviral Therapy. *New England Journal of Medicine* 2015; 373: 875-876.
128. **Abdool Karim SS**, Abdool Karim Q, Kharsany ABM, Baxter C, Grobler AC, Werner L, Kashuba A, Mansoor LE, Samsunder N, Mindel A, Gengiah TN, for the CAPRISA 004 Trial Group. Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection. *New England Journal of Medicine* 2015; 373: 530-9.
129. Piot P, **Abdool Karim SS**, Hecht R, Legido-Quigley H, Buse K, Stover J, Ryckman T, Resch S, Mogedal S, Dybul M, Goosby E, Watts C, Kilongo N, McManus J, Sidibe M on behalf of the Lancet- Unaid Commission on HIV/AIDS. The UNAIDS-Lancet Commission: Defeating AIDS—advancing global health. *Lancet* 2015; 386: 171–218.
130. Bhiman JN, Anthony C, Doria-Rose NA, Karimanzira O, Schramm CA, Khoza T, Kitchin D, Botha G, Gorman J, Garrett NJ, **Abdool Karim SS**, Shapiro L, Williamson C, Kwong PD, Mascola JR, Morris L, Moore PL. Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. *Nature Medicine* 2015; 21(11): 1332-6.
131. Gornalusse G, Mummidi S, Gaitan AA, Jimenez F, Ramsuran V, Picton ACP, Rogers K, Manoharan M, Avadhanam N, Murthy KK, Martinez H, Murillo AM, Chykarenko ZA, Hutt R, Daskalakis D, Shostakovitch-Koretskaya L, **Abdool Karim SS**, Martin JN, Deeks SG, Hecht F, Sinclair E, Clark RA, Okulicz J, Valentine FT, Martinson N, Tiemessen CT, Ndung'u T, Hunt PW, He W, Ahuja SK. Epigenetic mechanisms, T-cell activation, and CCR5 genetics interact to regulate T-cell expression of CCR5, the major HIV-1 coreceptor. *Proceedings of the National Academy of Sciences* 2015; 112(34): E4762-71.
132. van Loggerenberg F, Grant AD, Naidoo K, Murrman M, Gengiah S, Gengiah TN, Fielding K, **Abdool Karim SS**. Individualised Motivational Counselling to Enhance Adherence to Antiretroviral Therapy is not Superior to Didactic Counselling in South African Patients: Findings of the CAPRISA 058 Randomised Controlled Trial. *AIDS & Behavior* 2015; 19: 145–156
133. Garrett N, Werner L, Naicker N, Naranbhai V, Sibeko S, Samsunder N, Gray C, Williamson C, Morris L, Abdool Karim Q, **Abdool Karim SS**. HIV Disease Progression in Seroconvertors from the CAPRISA 004 Tenofovir Gel Pre-exposure Prophylaxis Trial. *Journal of Acquired Immune Deficiency Syndrome* 2015; 68(1): 55-61
134. Bandawe G, Moore PL, Werner L, Gray ES, Sheward DJ, Madiga M, Nofemela A, Thebus R, Marais JC, Maboko L, **Abdool Karim SS**, Hoelscher M, Morris L, Williamson C. Differences in HIV type 1 neutralization breadth in 2 geographically distinct cohorts in Africa. *Journal of Infectious Diseases* 2015; 211: 1461-1466
135. Abdool Karim Q, Dellar RC, Bearnot B, Werner L, Frohlich JA, Kharsany AB, **Abdool Karim SS**. HIV-Positive Status Disclosure in Patients in Care in Rural South Africa: Implications for Scaling up Treatment and Prevention Interventions. *AIDS & Behavior* 2015; 19(2): 322-9
136. Gengiah TN, Botha JH, Yende-Zuma N, Naidoo K, **Abdool Karim SS**. Efavirenz dosing: influence of drug metabolizing enzyme polymorphisms and concurrent tuberculosis treatment. *Antiviral Therapy* 2015; 20(3): 297-306.
137. Laeyendecker O, Redd AD, Nason M, Longosz AF, Abdool Karim Q, Naranbhai V, Garrett N, Eshleman SH, **Abdool Karim SS**, Quinn TC. Antibody Maturation in Women who Acquire HIV

- Infection While Using Antiretroviral Pre-Exposure Prophylaxis. *Journal of Infectious Diseases* 2015; 212: 754–759
138. **Abdool Karim SS** Abdool Karim Q, Baxter C. Antibodies for HIV prevention in young women. *Current Opinion in HIV & AIDS* 2015; 10(3): 183-189.
 139. Naicker N, Kharsany ABM, Werner L, van Loggerenberg F, Mlisana K, Garrett N, **Abdool Karim SS**. Risk factors for HIV acquisition in high risk women in a generalised epidemic setting. *AIDS & Behavior* 2015; 19 (7): 1305-1316
 140. Sheward DJ, Ntale R, Garrett NJ, Woodman ZL, **Abdool Karim SS**, Williamson C. HIV-1 superinfection resembles primary infection. *Journal of Infectious Diseases* 2015; 212: 904-908.
 141. *Masson L, Passmore JA, Liebenberg LJ, Werner L, Baxter C, Arnold KB, Williamson C, Little F, Mansoor LE, Naranbhai V, Lauffenburger DA, Ronacher K, Walzl G, Garrett NJ, Williams BL, Couto-Rodriguez M, Hornig M, Lipkin WI, Grobler A, Abdool Karim Q, **Abdool Karim SS**. Genital inflammation and the risk of HIV acquisition in women. *Clinical Infectious Diseases* 2015; 61(2): 260-269.
 142. Ngcapu S, Masson L, Sibeko S, Werner L, McKinnon LR, Mlisana K, Shey M, Samsunder N, **Abdool Karim SS**, Abdool Karim Q, Passmore J-AS. Lower concentrations of chemotactic cytokines and soluble innate factors in the lower female genital tract associated with the use of injectable hormonal contraceptive. *Journal of Reproductive Immunology* 2015; 110 (2015) 14–21.
 143. Kashuba ADM, Gengiah T, Werner L, Yang K-H, White N, Karim Q, **Abdool Karim SS**. Genital tenofovir concentrations correlate with protection against HIV infection in the CAPRISA 004 trial: Importance of adherence for microbicide effectiveness. *Journal of Acquired Immune Deficiency Syndrome* 2015, 69(3): 264–269.
 144. Naidoo K, Grobler AC, Deghaye N, Reddy T, Gengiah S, Gray A, **Abdool Karim SS**. Cost-effectiveness of initiating antiretroviral therapy at different points in TB treatment in HIV-TB co-infected ambulatory patients in South Africa. *Journal of Acquired Immune Deficiency Syndrome* 2015; 69(5): 576–584.
 145. Madan RP, Masson L, Tugetman J, Werner L, Grobler A, Mlisana K, Lo Y, Che D, Arnold KB, **Karim Abdool S**, Passmore JA-S, Herold B. Innate antibacterial activity in female genital tract secretions is associated with increased risk of HIV acquisition. *AIDS Research and Human Retroviruses* 2015; 31(11): 1153-1159.
 146. Richardson SI, Gray ES, Mkhize NN, Sheward DJ, Lambson BE, Wibmer CK, Masson L, Werner L, Garrett N, Passmore J-AS, Abdool Karim Q, **Abdool Karim SS**, Williamson C, Moore PL, Morris L. South African HIV-1 subtype C transmitted variants with a specific 1 V2 motif show higher dependence on $\alpha 4\beta 7$ for replication. *Retrovirology* 2015; 12:54. doi: 10.1186/s12977-015-0183-
 147. Scheepers C, Shrestha RK, Lambson BE, Jackson KJ, Wright IA, Naicker D, Goosen M, Berrie L, Ismail A, Garrett N, Abdool Karim Q, **Abdool Karim SS**, Moore PL, Travers SA, Morris L. Ability To Develop Broadly Neutralizing HIV-1 Antibodies Is Not Restricted by the Germline Ig Gene Repertoire. *Journal of Immunology* 2015; 194(9): 4371-8.
 148. Archary D, Liebenberg LJ, Werner L, Tulsi S, Majola N, Naicker N, Dlamini S, Hope TJ, Samsunder N, **Abdool Karim SS**, Morris L, Passmore J-AS, Garrett NJ. Randomized Cross-Sectional Study to Compare HIV-1 Specific Antibody and Cytokine Concentrations in Female Genital Secretions Obtained by Menstrual Cup and Cervicovaginal Lavage. *PLoS One* 2015; 10(7): e0131906.
 149. Kharsany AB, Frohlich JA, Yende-Zuma N, Mahlase G, Samsunder N, Dellar RC, Zuma-Mkhonza M, **Abdool Karim SS**, Abdool Karim Q. Trends in HIV prevalence in pregnant women in rural South Africa. *Journal of Acquired Immune Deficiency Syndrome* 2015; 70(3): 289–295.
 150. Riou C, Tanko RF, Soares AP, Masson L, Werner L, Garrett NJ, Samsunder N, Abdool Karim Q, **Abdool Karim SS**, Burgers WA. Restoration of CD4+ responses to co-pathogens in HIV-infected individuals on antiretroviral therapy is dependent on T cell memory phenotype. *Journal of Immunology* 2015; 195(5): 2273-2281.
 151. Masson L, Salkinder AL, Olivier AJ, McKinnon LR, Gamielien H, Mlisana K, Scriba TJ, Lewis DA, Little F, Jaspan HB, Ronacher K, Denny L, **Abdool Karim SS**, Passmore JS. Relationship between female genital tract infections, mucosal IL-17 production and local Th17 cells. *Immunology*. 2015; 146(4): 557-567.

2014

152. **Abdool Karim SS**. Retrospective: Nelson R. Mandela (1918–2013). *Science* 2014; 343: 150.

153. **Abdool Karim SS**, Baxter C. Microbicides for Prevention of HIV Infection: Clinical Efficacy Trials. *Current Topics in Microbiology and Immunology* 2014; 383: 97-116.
154. **Abdool Karim S**, Mervyn W. Susser – His Contributions to the Acquired Immune Deficiency Syndrome Response in South Africa. *Paediatric and Perinatal Epidemiology*, 2014; 28(6): 473-5.
155. *Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, DeKosky BJ, Ernandes MJ, Georgiev IS, Kim HJ, Pancera M, Staupe RP, Altae-Tran HR, Bailer RT, Crooks ET, Cupo A, Druz A, Garrett NJ, Hoi KH, Kong R, Louder MK, Longo NS, McKee K, Nonyane M, O'Dell S, Roark RS, Rudicell RS, Schmidt SD, Sheward DJ, Soto C, Wibmer CK, Yang Y, Zhang Z, NISC Comparative Sequencing Program, Mullikin JC, Binley JM, Sanders RW, Wilson IA, Moore JP, Ward AB, Georgiou G, Williamson C, **Abdool Karim SS**, Morris L, Kwong PD, Shapiro L, Mascola JR. Developmental pathway for potent V1V2-directed HIV-1-neutralizing antibodies. *Nature* 2014; 509(7498): 55-62.
156. Piot P, Barré-Sinoussi F, Abdool Karim Q, **Abdool Karim SS**, Beyrer C. Appeal to global donors to save the Treatment Action Campaign. *Lancet* 2014; 384: e62. DOI: 10.1016/S0140-6736(14)62045-6
157. Wei X, Hunt G, **Abdool Karim SS**, Naranbhai V, Sibeko S, Abdool Karim Q, Li J-F, Kashuba ADM, Werner L, Passmore J-AS, Morris L, Heneine W, Johnson JA. Sensitive Tenofovir Resistance Screening of HIV-1 from the Genital and Blood Compartments of Women with Breakthrough Infections in the CAPRISA 004 Tenofovir Gel Trial. *Journal of Infectious Diseases* 2014; 209: 1916-1920.
158. Masson L, Mlisana K, Little F, Werner L, Mkhize NN, Ronacher K, Gamielien H, Williamson C, Mckinnon LR, Walzl G, Abdool Karim Q, **Abdool Karim SS**, Passmore JA-S. Defining genital tract cytokine signatures of sexually transmitted infections and bacterial vaginosis in women at high risk of HIV infection: a cross-sectional study. *Sexually Transmitted Infections* 2014; 90:580–587.
159. Padayatchi N, **Abdool Karim SS**, Naidoo K, Grobler A, Friedland G. Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPIt Trial. *International Journal of Tuberculosis and Lung Disease* 2014; 18(2):147–154.
160. Naranbhai V, Hill AVS, **Abdool Karim SS**, Naidoo K, Abdool Karim Q, Warimwe GM, Mc Shane H, Fletcher H. Ratio of monocytes to lymphocytes in peripheral blood identifies adults at risk of incident tuberculosis among HIV-infected adults initiating antiretroviral therapy. *Journal of Infectious Diseases* 2014; 209(4): 500-509.
161. Balkus JE, Richardson BA, Rabe LK, Taha TE, Mgodi N, Kasaro MP, Ramjee G, Hoffman IF, **Abdool Karim S.S.** Bacterial Vaginosis and the Risk of Trichomonas vaginalis Acquisition Among HIV-1 Negative Women. *Sexually Transmitted Diseases* 2014; 41(2): 123-128.
162. Riou C, Burgers W, Mlisana K, Koup R, Roederer M, **Abdool Karim S**, Williamson C, Gray C. Differential impact of magnitude, polyfunctional capacity and specificity of HIV-specific CD8+ T cell responses on HIV viral set point. *Journal of Virology* 2014; 88:3: 1819-1824.
163. Singh R, Patel V, Mureithi M, Naranbhai V, Ramsuran D, Tulsii S, Hiramien K, Werner L, Mlisana K, Altfield M, Luban J, Kasproicz V, Dheda K, **Abdool Karim S**, Ndung'u T. TRIM5α and TRIM22 are differentially regulated according to HIV-1 infection phase and compartment. *Journal of Virology* 2014; 88(8): 4291-303.
164. Naidoo K, Abdool Karim Q, Bhushan A, Naidoo K, Yende-Zuma N, McHunu PK, Frohlich J, Karim F, Upfold M, Kocheleff P, **Abdool Karim SS**. High rates of Tuberculosis in patients accessing HAART in rural South Africa. *Journal of Acquired Immune Deficiency Syndrome* 2014; 65: 438–446.
165. Maman S, van Rooyen H, Stankard P, Chingono A, Muravha T, Ntongwisangu J, Phakathi Z, Srirak N, Morin SF, the NIMH Project Accept (HPTN 043) study team*. NIMH Project Accept (HPTN 043): Results from In-Depth Interviews with a Longitudinal Cohort of Community Members. *PLoS ONE* 2014; 9(1): e87091. doi:10.1371/journal.pone.0087091 (*study team includes Salim S. Abdool Karim)
166. Naidoo A, Naidoo K, Yende-Zuma N, Gengiah TN, Padayatchi N, Gray AL, Bamber S, Nair G, **Abdool Karim SS**. Changes to antiretroviral drug regimens during integrated TB-HIV treatment: Results of the SAPIt trial. *Antiviral Therapy* 2014; 19(2): 161-169.
167. Tomita A, Garrett N, Werner L, Burns J, Mpanza L, Mlisana K, van Loggerenberg F, **Abdool Karim SS**. Health-related Quality of Life Dynamics of HIV-positive ART-naïve South African Women: Evidence from the CAPRISA 002 Acute Infection Cohort Study. *AIDS & Behaviour* 2014; 18(6): 1114-23.

168. Mansoor LE, Abdool Karim Q, Yende-Zuma N, MacQueen KM, Baxter C, Madlala B, Grobler A, **Abdool Karim SS**. Adherence in the CAPRISA 004 tenofovir gel microbicide trial. *AIDS & Behavior* 2014; 18(5): 811-819.
169. Mansoor LE, Abdool Karim Q, Werner L, Madlala B, Ngcobo N, Cornman DH, Amico KR, Fisher J, Fisher WA, MacQueen KM, **Abdool Karim SS**. Impact of an Adherence Intervention on the Effectiveness of Tenofovir Gel in the CAPRISA 004 Trial. *AIDS & Behavior* 2014; 18: 841-848.
170. Gengiah TN, Mansoor LE, Upfold M, Naidoo A, Yende-Zuma N, Kashuba ADM, Abdool Karim Q, **Abdool Karim SS**. Measuring Adherence by Visual Inspection of Returned Empty Gel Applicators in the CAPRISA 004 Microbicide Trial. *AIDS & Behavior* 2014; 18: 820-825.
171. Gengiah TN, Upfold M, Naidoo A, Mansoor LE, Feldblum PJ, Abdool Karim Q, **Abdool Karim SS**. Monitoring microbicide gel use with real-time notification of the container's opening events: results of the CAPRISA Wisebag study. *AIDS & Behavior* 2014; 18: 833-840.
172. Mngadi KT, Maarschalk S, Grobler AC, Mansoor LE, Frohlich JA, Madlala B, Ngcobo N, **Abdool Karim SS**, Abdool Karim Q. Disclosure of microbicide gel use to sexual partners: influence on adherence in the CAPRISA 004 Trial. *AIDS & Behavior* 2014; 18: 849-854.
173. MacQueen KM, Weaver MA, van Loggerenberg F, Succop S, Majola N, Taylor D, Abdool Karim Q, **Abdool Karim S**. Assessing adherence in the CAPRISA 004 tenofovir gel HIV prevention trial: Results of a nested case-control study. *AIDS & Behavior* 2014; 18: 826-832.
174. Dellar RC, Abdool Karim Q, Mansoor LE, Grobler A, Humphries H, Werner L, Ntombela F, Luthuli L, **Abdool Karim SS**. The Preventive Misconception: Experiences from CAPRISA 004. *AIDS & Behavior* 2014; 18:1746-1752.
175. Guffey MB, Richardson B, Husnik M, Makanani B, Chilongozi D, Yu E, Ramjee G, Mgodini N, Gomez K, Hillier SL, **Abdool Karim S**, on behalf of the HIV Prevention Trials Network (HPTN) 035 Study Team. HPTN 035 phase II/IIb randomised safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women. *Sexually Transmitted Infections* 2014; 90:363-369.
176. Redd AD, Mullis CE, Wendel SK, Sheward D, Martens C, Bruno D, Werner L, Garrett NJ, Abdool Karim Q, Williamson C, Porcella SF, Quinn TC, **Abdool Karim SS**. Limited HIV-1 superinfection in seroconverters from the CAPRISA 004 microbicide trial. *Journal of Clinical Microbiology* 2014; 52(3): 844-8.
177. Tomita A, Garrett N, Werner L, Burns JK, Ngcobo N, Zuma N, Mlisana K, van Loggerenberg F, **Abdool Karim SS**. Impact of Antiretroviral Therapy on Health-Related Quality of Life among South African Women in the CAPRISA 002 Acute Infection Study. *AIDS & Behavior* 2014; 18(9): 1801-1807.
178. Mlisana K, Werner L, Garrett NJ, McKinnon LR, van Loggerenberg F, Passmore J-AS, Gray CM, Morris L, Williamson C, **Abdool Karim SS** and the CAPRISA 002 Study Team. Rapid disease progression in HIV-1 subtype C infected South African women. *Clinical Infectious Diseases* 2014; 5(9): 1322-1331.
179. Abdool Karim Q, Kharsany ABM, Leask K, Ntombela F, Humphries H, Frohlich JA, Samsunder N, Grobler A, Dellar R, **Abdool Karim SS**. Prevalence of HIV, HSV-2 and pregnancy amongst high school students in rural KwaZulu-Natal: a bio-behavioral cross-sectional survey. *Sexually Transmitted Infections* 2014; 90: 620-626.
180. Penrose KJ, Richardson B, Besson G, Dezzutti CS, Herold B, Abdool Karim S, Levy L, Marrazzo J, Mellors JW, Hillier SL, Urvi PM. Y chromosome and HIV DNA Detection in Vaginal Swabs as Biomarkers of Semen and HIV Exposure in Women. *Sexually Transmitted Diseases* 2014; 41(11): 674-679.
181. Abdool Karim Q, Baxter C, **Abdool Karim S**. Microbicides and their potential as a catalyst for multipurpose sexual reproductive health technologies. *British Journal of Obstetrics and Gynecology* 2014; 121(Suppl 5): 53-61.
182. **Abdool Karim SS**, Baxter C, Frohlich J, Abdool Karim Q. The need for multipurpose prevention technologies in sub-Saharan Africa. *British Journal of Obstetrics and Gynecology* 2014; 121 (Suppl 5): 27-34.
183. Succop SM, MacQueen KM, van Loggerenberg F, Majola N, Abdool Karim Q, **Abdool Karim SS**. Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial. *AIDS Care* 2014; 26(12):1521-5.
184. Kharsany ABM, Buthelezi TJ, Frohlich JA, Yende-Zuma N, Samsunder N, Mahlase G, Williamson C, Travers S, Marais JC, Dellar RC, Abdool Karim Q, **Abdool Karim SS**. HIV infection in rural South African high schools: Role of transmissions among students. *AIDS Research and Human Retroviruses* 2014; 30(10):956-65.

185. Gengiah T, Botha J, Soowamber D, Naidoo K, **Abdool Karim SS**. Low rifampicin concentrations in tuberculosis patients with HIV infection. *Journal of Infection in Developing Countries* 2014; 8(8):987-993.
186. Kepler TB, Liao HX, Alam SM, Bhaskarabhatla R, Zhang R, Yandava C, Stewart S, Anasti K, Kelsoe G, Parks R, Lloyd KE, Stolarchuk C, Pritchett J, Solomon E, Friberg E, Morris L, **Abdool Karim SS**, Cohen MS, Walter E, Moody MA, Wu X, Altae-Tran HR, Georgiev IS, Kwong PD, Boyd SD, Fire AZ, Mascola JR, Haynes BF. Immunoglobulin Gene Insertions and Deletions in the Affinity Maturation of HIV-1 Broadly Reactive Neutralizing Antibodies. *Cell Host & Microbe* 2014; 16(3):304-313
187. Seaton KE, Ballweber L, Lan A, Donathan M, Hughes, Vojtech L, Moody MA, Liao H-X, Haynes BF, Galloway CG, Richardson BA, **Abdool Karim S**, Dezzutti CS, McElrath J, Tomaras GD, Hladik F. HIV-1-specific IgA detected in vaginal 1 secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities. *PLoS One* 2014; 9(7): e101863. doi:10.1371/journal.pone.0101863.
188. Mansoor LE, Abdool Karim Q, Mngadi KT, Dlamini S, Montague C, Nkomonde N, Mvandaba N, Baxter C, Gengiah TN, Samsunder N, Dawood H, Grobler A, Frohlich JA, **Abdool Karim SS**. Assessing the Implementation Effectiveness and Safety of 1% Tenofovir Gel Provision through Family Planning Services in KwaZulu-Natal, South Africa: Study Protocol for an Open-Label Randomized Controlled Trial. *Trials* 2014; 15:496.
189. Mann JK, Chopera D, Omarjee S, Kuang XT, Le AQ, Anmole G, Danroth R, Mwimanzi P, Reddy T, Carlson J, Radebe M, Goulder P, Walker BD, **Abdool Karim S**, Novitsky V, Williamson C, Brockman MA, Brumme ZL, Ndung'u T. Nef-mediated down-regulation of CD4 and HLA class I in HIV-1 subtype C infection: association with disease progression and influence of immune pressure. *Virology* 2014; 468-470C:214-225.
190. Ritchie AJ, Cai F, Smith NMG, Chen S, Song H, Brackenridge S, **Abdool Karim SS**, Korber BT, McMichael AJ, Gao F, Goonetilleke N. Recombination-mediated escape from primary CD8+ T cells in acute HIV-1 infection. *Retrovirology* 2014 11:69. DOI: 10.1186/s12977-014-0069-9

2013

191. **Abdool Karim SS**. HIV pre-exposure prophylaxis in injecting drug users. *Lancet* 2013; 381(9883): 2060-2062
192. Abdool Karim Q, Baxter C, **Abdool Karim S**. Topical Microbicides—What's New? *Journal of AIDS* 2013; 63: S144-S149.
193. Naidoo K, Baxter C, **Abdool Karim SS**. When to start antiretroviral therapy during tuberculosis treatment? *Current Opinion in Infectious Diseases* 2013; (26)1: 35-42.
194. Naranbhai V, Altfeld M, **Abdool Karim SS**, Ndung'u T, Abdool Karim Q, Carr W. Changes in Natural Killer Cell Activation and Function during Primary HIV-1 Infection. *PLoS ONE* 2013 8(1): e53251. doi:10.1371/ journal.pone.0053251
195. Abrahams MR, Treurnicht FK, Ngandu NK, Goodier SA, Marais JC, Bredell H, Thebus R, de Assis Rosa D, Mlisana K, Seoighe C, **Abdool Karim S**, Gray CM, Williamson C. Rapid, complex adaptation of transmitted HIV-1 full-length genomes in subtype C-infected individuals with differing disease progression. *AIDS*; 2013; 27: 507-518.
196. Richardson BA, Kelly C, Ramjee G, Fleming T, Makanani B, Roberts S, Musara P, Mkandawire N, Moench T, Coletti A, Soto-Torres L, **Abdool Karim SS** for the HPTN 035 Study Team. Appropriateness of hydroxyethylcellulose gel as a placebo control in vaginal microbicide trials: A comparison of the two control arms of HPTN 035. *Journal of AIDS* 2013; 63(1): 120-125.
197. Moore PL, Sheward D, Nonyane M, Ranchobe N, Hermanus T, Gray ES, **Abdool Karim SS**, Williamson C, Morris L. Multiple Pathways of Escape from HIV Broadly Cross-Neutralizing V2-Dependent Antibodies. *Journal of Virology* 2013; 87(9): 4882-4894.
198. Naranbhai V, Samsunder N, Sandler NG, Roque A, Abdool Karim Q, Ndung'u T, Carr WH, Altfeld M, Douek DC, **Abdool Karim SS**; and The CAPRISA004 Trial Team. Neither microbial translocation nor TLR responsiveness are likely explanations for pre-existing immune activation in women who subsequently acquired HIV in CAPRISA004. *Journal of AIDS* 2013; 63(3): 294-298.
199. Koff WC, Russell ND, Walport M, Feinberg MF, Shiver JW, **Abdool Karim S**, Walker BD, McGlynn MG, Nweneka CV, Nabel GJ. Accelerating the Development of a Safe and Effective HIV Vaccine: HIV Vaccine Case Study for the Decade of Vaccines. *Vaccine* 2013; 31(supplement 2): B204-B208.
200. Ping L-H, Joseph SB, Anderson JA, Abrahams M-R, Salazar-Gonzalez JF, Kincer LP, Treurnicht FK, Arney L, Ojeda S, Zhang M, Keys J, Potter EL, Chu H, Moore P, Salazar-Gonzalez M, Iyer

- S, Jabara C, Kirchherr J, Mapanje C, Ngandu N, Seoighe C, Hoffman I, Gao F, Tang Y, Labranche C, Lee B, Saville A, Vermeulen M, Fiscus S, Morris L, **Abdool Karim S**, Haynes BF, Shaw GM, Korber BT, Hahn BH, Cohen MS, Montefiori D, Williamson C, Swanstrom R, for the CAPRISA Acute Infection Study and the Center for HIV-AIDS Vaccine Immunology Consortium. Comparison of Viral Env Proteins from Acute and Chronic Infections of Subtype C Human Immunodeficiency Virus Type 1 Identifies Differences In Glycosylation and CCR5 Utilization and Suggests A New Strategy For Immunogen Design. *Journal of Virology* 2013; 87(13): 7218-7223.
201. Baxter C, Yende-Zuma N, Tshabalala P, Abdool Karim Q, **Abdool Karim SS**. Safety of coitally administered tenofovir 1% gel, a vaginal microbicide, in chronic hepatitis B virus carriers: Results from the CAPRISA 004 trial. *Antiviral Research* 2013; 99(3): 405-408.
 202. Sokal D, Abdool Karim Q, Sibeko S, Yende-Zuma N, Mansoor LE, Baxter C, Grobler A, Frohlich J, Kharsany A, Mlisana K, Maarshalk S, **Abdool Karim SS**. Safety of Tenofovir Gel, a Vaginal Microbicide, in South African Women: Results of the CAPRISA 004 Trial. *Antiviral Therapy* 2013; 18(3): 301-310.
 203. Liu MKP, Hawkins N, Ritchie AJ, Ganusov VV, Whale V, Brackenridge S, Li H, Pavlicek JW, Cai F, Rose-Abrahams M, Treurnicht F, Hraber P, Riou C, Gray C, Ferrari G, Tanner R, Ping LH, Anderson JA, Swanstrom R, Cohen M, **Abdool Karim SS**, Haynes B, Borrow P, Perelson AS, Shaw GM, Hahn BH, Williamson C, Korber BT, Gao F, Self S, McMichael A, Goonetilleke N. Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. *Journal of Clinical Investigation* 2013; 123(1): 380-393.
 204. Chopera DR, Mann JK, Mqimanzi P, Omarjee S, Kuang XT, Ndabambi N, Goodier S, Martin E, Naranbhai V, **Abdool Karim SS**, Abdool Karim Q, Brumme ZL, Ndung'u T, Williamson C, Brochman MA. No evidence for selection of HIV-1 with enhanced Gag-Protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial. *PLoS One* 2013; e71758. doi:10.1371/journal.pone.0071758.
 205. Wibmer CK, Bhiman JN, Gray ES, Tumba N, **Abdool Karim SS**, Williamson C, Morris L, Moore PL. Viral Escape from HIV-1 Neutralizing 1 Antibodies 2 Drives Increased Plasma Neutralization Breadth through Sequential recognition of Multiple Epitopes and Immunotypes. *PLoS Pathogens* 2013; 9(10): e1003738. doi:10.1371/journal.ppat.1003738
 206. Lacerda M, Moore PL, Ngandu NK, Seaman M, Gray ES, Murrell B, Krishnamoorthy M, Nonyane M, Madiga M, Wibmer CK, Sheward D, Bailer RT, Gao H, Greene KM, **Abdool Karim SS**, Mascola JR, Korber BTM, Montefiori DC, Morris L, Williamson C, Seoighe C, the CAVD-NSDP Consortium. Identification of Broadly Neutralizing Antibody Epitopes in 1 the HIV-1 Envelope Glycoprotein using Evolutionary Models. *Virology Journal* 2013; 10(1): 347.
- 2012**
207. **Abdool Karim SS**. An AIDS-Free Generation? *Science* 2012; 337: 133.
 208. **Abdool Karim SS** Gray GE, Martinson N. Clinical decisions - Preexposure prophylaxis for HIV prevention Recommend initiating PrEP. *New England Journal of Medicine* 2012; 397: 1-2.
 209. **Abdool Karim SS**, Abdool Karim Q. Antiretroviral prophylaxis for HIV prevention reaches a key milestone. *Lancet* 2012; 379(9831): 2047-2048.
 210. **Abdool Karim SS**, Baxter C. Overview of microbicides. *Best Practice & Research Clinical Obstetrics & Gynaecology* 2012; 26: 427-439.
 211. Moore PL, Gray ES, Wibmer CK, Bhiman JN, Nonyane M, Sheward DJ, Hermanus T, Bajimaya S, Tumba NL, Abrahams M-R, Lambson BE, Ranchobe N, Ping L, Ngandu N, Abdool Karim Q, **Abdool Karim SS**, Swanstrom RH, Seaman MS, Williamson C, Morris L. Evolution of an HIV glycan-dependent broadly 1 neutralizing antibody 2 epitope through immune escape. *Nature Medicine* 2012 18(11): 1688-92.
 212. Naranbhai V, Abdool Karim Q, Naidoo K, Yende-Zuma N, **Abdool Karim SS**. Sustainability of task-shifting for antiretroviral treatment. *Lancet* 2012; 380(9857): 1907-1908.
 213. Naidoo K, Yende-Zuma N, Padayatchi N, Naidoo K, Nair G, Bamber S, Gengiah S, El-Sadr WM, Friedland G, **Abdool Karim SS**. The Immune Reconstitution Inflammatory Syndrome After Antiretroviral Therapy Initiation in Patients With Tuberculosis: Findings From the SAPIt Trial. *Annals in Internal Medicine* 2012; 157: 313-324.
 214. Mayosi BM, Lawn JE, van Niekerk A, Bradshaw D, **Abdool Karim SS**, Coovadia HM. Health in South Africa: changes and challenges since 2009. *Lancet* 2012; 380(9858): 2029-2043.
 215. Naranbhai V, **Abdool Karim SS**, Altfeld M, Samsunder N, Durgiah R, Sibeko S, Abdool Karim Q, Carr WH. Innate Immune activation enhances HIV acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. *Journal of Infectious Diseases* 2012; 206(7): 993-1001.

216. Roberts L, Passmore J-A S, Mlisana K, Williamson C, Little F, Bebell LM, Walzl G, Abrahams M-R, Woodman Z, Abdool Karim Q, **Abdool Karim SS**. Genital Tract Inflammation During Early HIV-1 Infection Predicts Higher Plasma Viral Load Set Point in Women. *Journal of Infectious Diseases* 2012; 205(2): 194-203.
217. Grobler AC, **Abdool Karim SS**. Design challenges facing clinical trials of the effectiveness of new HIV prevention technologies. *AIDS* 2012; 26(5): 529-532.
218. Mureithi MW, Poole D, Naranbhai V, Reddy S, Mkhwanazia NP, Sibeko S, Werner L, Abdool Karim Q, **Abdool Karim S**, Ndung'u T, Altfeld M and the CAPRISA004 Trial Group. Preservation HIV-1-specific IFN γ + CD4+ T cell responses in breakthrough infections following exposure to Tenofovir Gel in the CAPRISA 004 microbicide trial. *Journal of AIDS* 2012; 60(2): 124-127.
219. Gengiah TN, Holford NH, Botha JH, Gray AL, Naidoo K, **Abdool Karim SS**. The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. *European Journal of Clinical Pharmacology* 2012; 68: 689-695.
220. Gengiah TN, Baxter C, Mansoor LE, Kharsany ABM, **Abdool Karim SS**. A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection. *Expert Opinion on Investigational Drugs* 2012; 21(5): 695-715
221. Kharsany AMB, Mlotshwa M, Frohlich JA, Yende Zuma N, Samsunder N, **Abdool Karim SS**, Abdool Karim Q. HIV prevalence among high school learners - Opportunities for schools-based HIV testing programmes and sexual reproductive health services. *World Health Population* 2012; 13(4):43-50.
222. Lynch R, Tran L, Louder M, Cohen M, DerSimonian R, Euler Z, Gray E, **Abdool Karim S**, Kirchherr J, Montefiori D, Sibeko S, Soderberg K, Tomaras G, Yang Z-Y, Nabel G, Schuitemaker H, Morris L, Haynes B, Mascola J. The Development of CD4 Binding Site Antibodies During HIV-1 Infection. *Journal of Virology* 2012; 86 (14): 7588-7595.
223. Mlisana K, Naicker N, Werner L, Roberts L, van Loggerenberg F, Baxter C, Passmore J-AS, Grobler AC, Sturm W, Williamson C, Ronacher K, Walzl G, **Abdool Karim SS**. Symptomatic Vaginal Discharge Is a Poor Predictor of Sexually Transmitted Infections and Genital Tract Inflammation in High-Risk Women in South Africa. *Journal of Infectious Diseases*; 2012; 206: 6-14
224. Abdool Karim Q, Kharsany ABM, Frohlich JA, Werner L, Mlotshwa M, Madlala BT, **Abdool Karim SS**. HIV Incidence in Young Girls in KwaZulu-Natal, South Africa-Public Health Imperative for Their inclusion in HIV Biomedical Intervention Trials. *AIDS & Behaviour* 2012; 16(7): 1870-1876.
225. Valley-Omar Z, Sibeko S, Anderson J, Goodier S, Werner L, Arney L, Naranbhai V, Treurnicht F, Abrahams M-R, Bandawe G, Swanstrom R, Abdool Karim Q, **Abdool Karim SS**, Williamson C. CAPRISA 004 Tenofovir Microbicide Trial: No Impact of Tenofovir Gel on the HIV Transmission Bottleneck. *Journal of Infectious Diseases* 2012; 206(1): 35-40.
226. Dezzutti CS, Richardson BA, Marrazzo JM, Tugetman J, Ramjee G, Taha T, Chirenje ZM, **Abdool Karim SS**, Hillier SL, Herold BC, on behalf of the MTN Biomedical Sciences Working Group and the HPTN 035 Protocol Team. Mucosal E. coli bactericidal activity and immune mediators are associated with HIV-1 seroconversion in women participating in the HPTN 035 trial. *Journal of Infectious Disease* 2012; 206(12): 1931-1935.
227. Grobler A, **Abdool Karim S**. Declining adherence is a more likely explanation than frailty of the apparent decline in efficacy in the CAPRISA 004 trial: response to O'Hagan et al. *AIDS* 2012; 26(17): 2261.
228. Naranbhai V, Altfeld M, Abdool Karim Q, Ndung'u T, **Abdool Karim SS**, Carr WH; on behalf of the Centre for the AIDS Programme of Research in South Africa (CAPRISA) Tenofovir gel Research for AIDS Prevention Science (TRAPS) Team. Natural killer cell function in women at high risk for HIV acquisition: insights from a microbicide trial. *AIDS* 2012; 26(14): 1745-1753.
229. Wecker M, Gilbert P, Russell N, Hural J, Allen M, Pensiero M, Chulay J, Chiu Y-L, **Abdool Karim S**, Burke D. Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine (AVX101) in healthy HIV-1 uninfected adults. *Clinical and Vaccine Immunology* 2012; 19(10): 1651-60.
230. Chirenje ZM, Masse BR, Maslankowski LA, Ramjee G, Coletti AS, Tembo TN, Magure TM, Soto-Torres L, Kelly C, Hillier S, **Abdool Karim S**. Utility of colposcopy in a phase 2 portion of a microbicide clinical trial of BufferGel and 0.5% PRO 2000 Gel. *Journal of the International AIDS Society* 2012, 15: 17376.
231. Chopera DR, Cotton LA, Zawaira A, Mann JK, Ngandu NK, Ntale R, Carlson JM, Mlisana K, Woodman Z, Assis Rosa DD, Martin E, Miura T, Pereyra F, Walker BD, Gray CM, Martin DP, Ndung'u T, Brockman MA, **Abdool Karim S**, Brumme ZL, Williamson C, the CAPRISA 002 Study

- Team. Intersubtype 1 differences in the effect of a rare p24 Gag mutation on HIV-replicative fitness. *Journal of Virology* 2012; 86(24): 13423-13433.
232. Riou C, Abrahams M-R, Mlisana K, Liu M, Goonetilleke N, Treurnicht F, Koup R, Roederer M, **Abdool Karim S**, De Bruyn G, Williamson C, Gray C. Increased memory differentiation is associated with decreased polyfunctionality for HIV but not for CMV-specific CD8⁺ T cells. *Journal of Immunology* 2012; 189(8): 3838-3847.
 233. Ntale R, Chopera D, Ngandu N, Assis de Rosa D, Mlotshwa M, Werner L, Woodman Z, Mlisana K, **Abdool Karim S**, Gray C, Williamson C, and the CAPRISA 002 Study Team. Temporal association of HLA-B*81:01 and B*39:10 mediated HIV-1 p24 sequence evolution with disease progression. *Journal of Virology* 2012; 86(22): 12013-12024
 234. Taylor DJ, Grobler A., **Abdool Karim SS**. An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure. *Clinical Trials* 2012; 9 (4): 377-384
- 2011**
235. **Abdool Karim SS**, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL, Gengiah T, Gengiah S, Naidoo A, Jithoo N, Nair G, El-Sadr WM, Friedland G, Abdool Karim Q. Integration of Antiretroviral Therapy with Tuberculosis Treatment. *New England Journal of Medicine* 2011; 365(16): 1492-1501.
 236. **Abdool Karim SS**, Kashuba A, Werner L, Abdool Karim Q. Drug concentrations following topical and oral antiretroviral pre-exposure prophylaxis: Implications for HIV prevention in women. *Lancet* 2011; 378: 279-281.
 237. **Abdool Karim SS**, Richardson BA, Ramjee G, Hoffman IF, Chirenje ZM, Taha T, Kapina M, Maslankowski L, Coletti A, Profy A, Moench TR, Piwowar-Manning E, Mâsse B, Hillier SL, Soto-Torres L on behalf of the HPTN 035 Study Team. Safety and Effectiveness of BufferGel and 0.5% PRO2000 Gel for the Prevention of HIV Infection in high-risk Women. *AIDS* 2011; 25(7): 957-966.
 238. **Abdool Karim SS**. Stigma impedes AIDS prevention. *Nature* 2011; 474: 29-31.
 239. **Abdool Karim SS**, Abdool Karim Q. Antiretroviral prophylaxis: a defining moment in HIV control. *Lancet* 2011; 378(9809):e23-5
 240. Abdool Karim Q, Kharsany ABM, Naidoo K, Yende N, Gengiah T, Omar Z, Arulappan N, Mlisana KP, **Abdool Karim SS**. Co-enrollment in multiple HIV prevention trials — Experiences from the CAPRISA 004 Tenofovir gel trial. *Contemporary Clinical Trials* 2011; 32(3): 333-338.
 241. Padian NS, McCoy SI, **Abdool Karim S**, Hasen N, Kim J, Bartos M, Katabira E, Bertozzi S, Schwartländer B, Cohen MS. HIV prevention transformed: the new prevention research agenda. *Lancet* 2011; 378: 269-278.
 242. Singh R, Gaiha G, Werner L, McKim K, Mlisana K, Luban J, Walker BD, **Abdool Karim SS**, Brass AL, Ndung'u T, and the CAPRISA 002 Study Team. Association of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infection. *Journal of Virology* 2011; 85(1): 208-216.
 243. Abdool Karim Q, Kharsany ABM, Frohlich JA, Baxter C, Yende N, Mansoor LE, Mlisana KP, Maarschalk S, Arulappan N, Grobler A, Sibeko S, Omar Z, Gengiah TN, Mlotshwa M, Samsunder N, **Abdool Karim SS**. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. *Trials* 2011; 12: 67.
 244. Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba NL, Werner L, Mlisana K, Sibeko S, Williamson C, **Abdool Karim SS**, Morris L and the CAPRISA 002 Study Team. The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4 T Cell Decline and High Viral Load during Acute Infection. *Journal of Virology* 2011; 85(10): 4828-4840.
 245. Ramsuran V, Kulkarni H; He W; Mlisana K; Wright E, Werner L, Castiblanco-Quinche J, Dhanda R, Le T, Dolan M, Guan W, Weiss R, Clark R, **Abdool Karim S**, Ahuja SK, Ndung'u T. Duffy-Null-Associated Low Neutrophil Counts Influence HIV-1 Susceptibility in High-Risk South African Black Women. *Clinical Infectious Diseases* 2011; 52(10): 1248-1256.
 246. Gray ES, Moody MA, Wibmer CK, Chen X, Marshall D, Amos J, Moore PL, Foulger A, Yu J, Lambson B, **Abdool Karim SS**, Whitesides J, Tomaras GD, Haynes BF, Morris L, and Liao H. Isolation of a monoclonal antibody targeting the alpha-2 helix of gp120 representing the initial autologous neutralizing antibody response in an HIV-1 subtype C infected individual. *Journal of Virology* 2011; 85: 7719-7729.
 247. Williams BG, **Abdool Karim SS**, Gouws E, Abdool Karim Q. Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa. *Journal of AIDS* 2011; 58: 207-210

248. **Abdool Karim, SS.** Microbicides: New Hope for HIV Prevention. *UN Chronicle*, 2011 XLVIII(1):14-15. Available from http://www.un.org/wcm/content/site/chronicle/cache/bypass/home/archive/issues2011/hivaidsth efourthdecade/microbicides?ctnscroll_articleContainerList=1_0&ctnlistpagination_articleContainerList=true
 249. Moore PL, Gray ES, Sheward D, Madiga M, Ranchobe N, Lai Z, Honnen WJ, Nonyane M, Tumba N, Hermanus T, Sibeko S, Mlisana K, **Abdool Karim SS**, Williamson C, Pinter A, Morris L; and the CAPRISA 002 study. Potent and broad neutralization of HIV-1 subtype C viruses by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. *Journal of Virology* 2011; 85(7): 3128-3141
 250. Chopera DR, Mlotshwa M, Woodman Z, Mlisana K, de Assis Rosa D, Martin DP, **Abdool Karim S**, Gray CM, Williamson C; the CAPRISA 002 Study Team. Virological and Immunological Factors Associated with HIV-1 Differential Disease Progression in HLA-B*58:01 Positive Individuals. *Journal of Virology* 2011; 85(14): 7070-7080.
 251. Sibeko S, Baxter C, Yende N, Abdool Karim Q, **Abdool Karim SS**, on behalf of the Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004 Trial Group. Contraceptive Choices, Pregnancy Rates, and Outcomes in a Microbicide Trial. *Obstetrics & Gynecology* 2011; 118(4): 895-904
 252. Morris L, Chen X, Alam M, Tomaras G, Zhang R, Marshall D, Chen B, Parks B, Foulger A, Jaeger F, Donathan M, Bilska M, Gray ES, **Abdool Karim SS**, Kepler TB, Whitesides J, Montefiori D, Moody AM; Liao H-X, Haynes BF. Isolation of a Human Anti-HIV gp41 Membrane Proximal Region Neutralizing Antibody by Antigen-Specific Single B Cell Sorting. *PLoS One* 2011; 6(9): e23532 doi:10.1371/journal.pone.0023532.
 253. Abdool Karim Q, Kharsany ABM, Frohlich JA, Werner L, Mashego M, Mlotshwa M, Madlala BT, Ntombela F, **Abdool Karim SS**. Stabilizing HIV prevalence masks high HIV incidence rates amongst rural and urban women in KwaZulu-Natal, South Africa. *International Journal of Epidemiology* 2011, 40: 922-930.
 254. Tomaras GD, Binley JM, Gray ES, Crooks ET, Osawa K, Moore PL, Tumba N, Tong T, Shen X, Yates NL, Decker J, Wibmer CK, Gao F, Alam SM, Easterbrook P, **Abdool Karim S**, Kamanga G, Crump JA, Cohen M, Shaw GM, Mascola JR, Haynes BF, Montefiori DC, Morris L. Polyclonal B Cell Responses to Conserved Neutralization Epitopes in a Subset of HIV-1-Infected Individuals. *Journal of Virology*, 2011; 85(21): 11502-11519.
 255. Madlala P, Gijssbers R, Christ F, Hombrouck A, Werner L, Mlisana K, An P, **Abdool Karim SS**, Winkler CA, Debyser Z, Ndung'u T. Association of Polymorphisms in the LEDGF/p75 Gene (PSIP1) with Susceptibility to HIV-1 Infection and Disease Progression. *AIDS* 2011; 25(14):1711-9.
 256. Boily MC, Dimitrov D, **Abdool Karim SS**, Mâsse B. The future role of rectal and vaginal microbicides to prevent HIV infection in heterosexual populations: implications for product development and prevention. *Sexually Transmitted Diseases* 2011; 87(7):646-53.
 257. Woodman Z, Mlisana K, Treurnicht F, Abrahams M-R, Thebus R, **Abdool Karim S**, Williamson C for the CAPRISA Acute Infection Study Team. Decreased Incidence of Dual Infections in South African Subtype C-Infected Women Compared to a Cohort Ten Years Earlier. *AIDS Research and Human Retroviruses* 2011; 27(11): 1167-1172.
- 2010
258. **Abdool Karim SS**, Abdool Karim Q. AIDS research must link to local policy. *Nature* 2010; 463: 733-734.
 259. **Abdool Karim SS**, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, Gengiah T, Nair G, Bamber S, Singh A, Khan M, Pienaar J, El-Sadr W, Friedland G, Abdool Karim Q. Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy. *New England Journal of Medicine* 2010; 362: 697-706.
 260. Abdool Karim Q[†], **Abdool Karim SS[†]**, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany ABM, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D, on behalf of the CAPRISA 004 Trial Group. Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. *Science* 2010; 329: 1168-1174 (†joint first authors).
 261. **Abdool Karim SS.** Results of effectiveness trials of PRO 2000: Lessons for future microbicide trials. *Future Microbiology* 2010; 5(4): 527-529. <http://www.futuremedicine.com/doi/full/10.2217/fmb.10.29>

262. Reddy K, Winkler CA, Werner L, Mlisana K, **Abdool Karim SS**, Ndung'u T; CAPRISA Acute Infection Study Team; APOBEC3G expression is dysregulated in primary HIV-1 infection and polymorphic variants influence CD4+ T-cell counts and plasma viral load. *AIDS* 2010; 24(2): 195-204.
 263. Treurnicht FK, Seoighe C, Martin DP, Wood N, Abrahams MR, de Assis Rosa D, Bredell H, Woodman Z, Hide W, Mlisana K, **Abdool Karim S**, Gray CM and Williamson C, Adaptive changes in HIV-1 subtype C proteins during early infection are driven by changes in HLA-associated immune pressure. *Virology* 2010; 396(2): 213-225.
 264. Khurana S, Norris PJ, Busch mp, Haynes BF, Park S, Sasono P, Mlisana K, **Abdool Karim S**, Hecht FM, Mulenga J, Chomba E, Hunter E, Allen S, Nemo G, Rodriguez-Chavez IR, Women's Interagency HIV Study, The Multicenter AIDS Cohort Study, and Golding H. HIV-selectest EIA and rapid test: ability to detect seroconversion following HIV-1 infection. *Journal of Clinical Microbiology* 2010; 48(1): 281-285.
 265. Roberts L, Passmore J-AS, Williamson C, Little F, Bebell LM, Mlisana K, Burgers WA, van Loggerenberg F, Walzlf G, Djoba Siaway JF, Abdool Karim Q, **Abdool Karim SS**. Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression. *AIDS* 2010; 24(6): 819-31.
 266. Alexandre KB, Gray ES, Lambson BE, Moore PL, Choge IA, Mlisana K, **Abdool Karim SS**, McMahon J, O'Keefe B, Chikwamba R, Morris L. Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin. *Virology* 2010; 402: 187-196.
 267. Kharsany ABM; Abdool Karim Q; **Abdool Karim SS**. Uptake of Provider Initiated HIV Testing and Counseling among women attending an urban Sexually Transmitted Disease Clinic in South Africa- missed opportunities for early diagnosis of HIV infection. *AIDS Care* 2010; 22(5): 533-537.
 268. Kharsany AB, Hancock N, Frohlich JA, Humphries HR, **Abdool Karim SS**, Abdool Karim Q. Screening for 'window-period' acute HIV infection among pregnant women in rural South Africa. *HIV Medicine* 2010; 11:661-665
 269. Abdool Karim Q, **Abdool Karim SS**, Baxter C, Friedland G, Gengiah T, Gray A, Grobler A, Naidoo K, Padayatchi N, El-Sadr W. The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis. *South African Medical Journal* 2010; 100(12): 808-809.
 270. **Abdool Karim SS**, Baxter C. Microbicides and their implications in HIV prevention. *Indian Journal of Medical Research* 2010; 132: 656-659.
 271. Mlotshwa M, Riou C, Chopera D, De Assis Rosa D, Ntale R, Treunicht F, Woodman Z, Werner L, Van Loggerenberg, Mlisana K, **Abdool Karim S**, Williamson C, Gray CM. Fluidity of HIV-1-specific T-cell responses during acute and early subtype C HIV-1 infection and associations with early disease progression. *Journal of Virology* 2010; 84(22): 12018-12029.
- 2009**
272. **Abdool Karim SS**, Churchyard GJ, Abdool Karim Q, Lawn SD. HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. *Lancet* 2009; 374 (9693): 921-933.
 273. **Abdool Karim SS**, Coovadia HM, Makgoba MW. Scientists stand by decision to join Mbeki's AIDS panel. *Nature* 2009; 457: 379.
 274. **Abdool Karim SS**. South Africa needs an HIV/AIDS truth commission. <http://www.scidev.net/en/opinions/south-africa-needs-an-hiv-aids-truth-commission.html> 15 October 2009.
 275. **Abdool Karim SS**, Baxter C. Antiretroviral prophylaxis for the prevention of HIV infection: Future implementation challenges. *HIV Therapy* 2009; 3(1): 3-6.
 276. **Abdool Karim SS**. Spatial clustering of HIV infection: providing clues for effective HIV prevention. *International Journal of Epidemiology* 2009; 38: 1016-1017.
 277. Gray CM, Mlotshwa M, Riou C, Mathebula T, de Assis Rosa D, Mashishi T, Seoighe C, Ngandu N, van Loggerenberg F, Morris L, Mlisana K, Williamson C, **Abdool Karim S** on behalf of the CAPRISA 002 Acute Infection Study Team. Human Immunodeficiency Virus-Specific Gamma Interferon Enzyme-Linked Immunospot Assay Responses Targeting Specific Regions of the Proteome during Primary Subtype C Infection Are Poor Predictors of the Course of Viremia and Set Point. *Journal of Virology* 2009; 83(1): 470-478.
 278. Sewram S, Singh R, Kormuth E, Werner L, Mlisana K, **Abdool Karim SS**, Ndung'u T and the CAPRISA Acute Infection Study. Human TRIM5alpha Expression and Reduced Susceptibility to

- Human Immunodeficiency Virus Type 1 Infection. *Journal of Infectious Diseases* 2009; 199(11): 1657-1663.
279. Naicker DD, Werner L, Kormuth E, Passmore J-A, Mlisana K, **Abdool Karim S**, Ndung'u T. Interleukin-10 Promoter Polymorphisms Influence HIV-1 Susceptibility and Primary HIV-1 Pathogenesis. *Journal of Infectious Diseases* 2009; 200(3): 448-452.
 280. Abrahams M-R, Anderson JA, Giorgi EE, Seoighe C, Mlisana K, Ping L-H, Athreya GS, Treurnicht FK, Keele BF, Wood N, Salazar-Gonzalez JF, Bhattacharya T, Chu H, Hoffman I, Galvin S, Mapanje C, Kazembe P, Thebus R, Fiscus S, Hide W, Cohen MS, **Abdool Karim S**, Haynes BF, Shaw GM, Hahn BH, Korber BT, Swanstrom R, Williamson C. Quantitating the multiplicity of infection with HIV subtype C reveals a non-Poisson distribution of variants. *Journal of Virology* 2009; 83(13): 69-74.
 281. Burgers WA, Riou C, Mlotswa M, de Assis Rosa D, Mlisana K, Koup R, Roederer M, **Abdool Karim S**, Williamson C, Gray CM, and the CAPRISA 002 Acute Infection Study Team. Association of HIV-specific and total CD8+ T memory phenotypes in subtype C HIV-1 infection with viral set point. *Journal of Immunology* 2009; 182(8): 4751-61.
 282. Chopra M, Lawn JE, Sanders D, Barron P, **Abdool Karim SS**, Bradshaw D, Jewkes R, Abdool Karim Q, Flisher AJ, Mayosi BM, Tollman SM, Churchyard GJ, Coovadia H. Achieving the health Millennium Development Goals for South Africa: challenges and priorities. *Lancet* 2009; 374(9694): 1023-31.
 283. Moore PL, Ranchobe N, Lambson B, Gray ES, Cave E, Abrahams M, Bandawe G, Mlisana K, **Abdool Karim SS**, Williamson C and Morris L, the CAPRISA 002 study and the CHAVI. Limited Neutralizing Antibody Specificities Drive Neutralization Escape in Early HIV-1 Subtype C Infection. *PLoS Pathogens* 2009; 5(9): e1000598. doi:10.1371/journal.ppat.1000598
 284. Gray ES, Madiga MC, Moore PL, Mlisana K, **Abdool Karim SS**, Binley JM, Shaw GM, Mascola JR, Morris L. Broad Neutralization of Human Immunodeficiency Virus Type 1 Mediated by Plasma Antibodies against the gp41 Membrane Proximal External Region. *Journal of Virology* 2009; 83: 11265-11274.
 285. McCormack S, Taylor D, Richardson B, Darbyshire J, Sattentau Q, Abdool Karim Q, **Abdool Karim S**, Kharsany A, Lacey C, Nunn A, Weber J, In Reply: Enhancement of HIV infection by cellulose sulfate. *AIDS Research and Human Retroviruses* 2009; 25(3): 373.
 286. **Abdool Karim SS**, Baxter C. PRO 2000: next steps for microbicide development. *Future Virology* 2009; 4(4): 317-320.
 287. Naidoo S, Chikte U, Gouws E, **Abdool-Karim S**. Oral mucosal lesions and HIV status in a rural household survey in South Africa. *Journal of the South African Dental Association* 2009; 64(10): 466-469.
- 2008**
288. Bebell LM, Passmore J, Williamson C, Mlisana K, Iriogbe I, van Loggerenberg F, Abdool Karim Q, **Abdool Karim SS**. Relationship Between Levels of Inflammatory Cytokines in the Genital Tract and CD4 Cell Counts in Women with Acute HIV-1 Infection. *Journal of Infectious Diseases* 2008; 198: 710-714.
 289. Chopera DR, Woodman Z, Mlisana K, Mlotswa M, Martin DP, Seoighe C, Treurnicht F, de Rosa DA, Hide W, **Abdool Karim S**, Gray CM, Williamson C and the CAPRISA 002 Study Team. Transmission of HIV-1 CTL Escape Variants Provides HLA-Mismatched Recipients with a Survival Advantage. *PLoS Pathogens* 2008; 4(3): e1000033. doi:10.1371/journal.ppat.1000033.
 290. Alam SM, Searce RM, Parks RJ, Plonk K, Plonk SG, Sutherland LL, Gorny MK, Zolla-Pazner S, VanLeeuwen S, Moody M.A, Xia SM, Montefiori DC, Tomaras GD, Weinhold KJ, **Abdool Karim SS**, Hicks CB, Liao HX, Robinson J, Shaw GM and Haynes BF. 2008. Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: Antibody binding kinetics, induction, and potential for regulation in acute infection. *Journal of Virology* 2008; 82: 115-125.
 291. Abdool Karim Q, Meyer-Weitz A, Mboyi L, Carrara H, Mahlase G, Frohlich J, **Abdool Karim SS**. The influence of AIDS stigma and discrimination and social cohesion on HIV testing and willingness to disclose HIV in rural KwaZulu-Natal, South Africa. *Global Public Health* 2008; 3(4): 351-365.
 292. van Loggerenberg F, Mlisana K, Williamson C, Auld S.C., Morris L, Gray C.M., Abdool Karim Q, Grobler A, Barnabas N, Iriogbe I, **Abdool Karim SS**. for the CAPRISA 002 Acute Infection Study Team. Establishing a Cohort at High Risk of HIV Infection in South Africa: Challenges and Experiences of the CAPRISA 002 Acute Infection Study. *Plos One* 2008; 3(4): e1954.

293. Moore PL, Gray ES, Choge IA, Ranchobe N, Mlisana K, **Abdool Karim SS**, Williamson C, Morris L. The C3-V4 region is a major target of autologous neutralizing antibodies in HIV-1 subtype C infection. *Journal of Virology* 2008; 82(4): 1860–1869.
294. Mlisana K, Auld SC, Grobler A, van Loggerenberg F, Williamson C, Iriogbe I, Sobieszczyk ME, **Abdool Karim SS**, and the CAPRISA Acute Infection Study Team. Anaemia in acute HIV-1 subtype C infection. *PLoS One* 2008; 3(2): e1626.
295. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, Chavez LL, Decamp AC, Parks RJ, Ashley VC, Lucas JT, Cohen M, Eron J, Hicks CB, Liao HX, Self SG, Landucci G, Forthal DN, Weinhold KJ, Keele BF, Hahn BH, Greenberg ML, Morris L, **Abdool Karim S**, Blattner WA, Montefiori DC, Shaw GM, Perelson AS, Haynes BF. Initial B cell responses to transmitted HIV-1: Virion binding IgM and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. *Journal of Virology* 2008; 82(24): 12449-63.
296. Bandawe GP, Martin DP, Treurnicht F, Mlisana K, **Abdool Karim SS**, Williamson C and The CAPRISA 002 Acute Infection Study Team. Conserved positive selection signals in HIV-1 gp41 across multiple subtypes and difference in selection signals detectable in gp41 sequences sampled during acute and chronic HIV-1 subtype C infection. *Virology Journal* 2008; 5: 141.
297. Cooper PA, Madhi SA, Hubner RE, Mbelle N, **Abdool Karim SS**, Kleinschmidt I, Forrest BD, Klugman KP. Apnea and its possible relationship to immunization in ex-premature infants. *Vaccine* 2008; 26(27-28): 3410-3413.
298. Harrison P, Mellors JW, Richardson B, Masse BR, Abdool Karim Q, **Abdool Karim SS**, Cates W, Coletti AS, Darbyshire J, Dorflinger LJ, Feldblum P, Gabelnick H, Halpern VG, Hillier SL, Jespers V, Kharsany ABM, McCormack S, Nunn A, McGowan I, Omar RF, Padian NS, Pedneault L, Robbiani MP, Sailer J, Taylor D, Tolley EE, Van Damme L, Vermund SH, van de Wijgert J. Challenges in HIV-Prevention Microbicide Research. Published E letter 17 December 2008 in response to: Grant RM, et al. Whither or Wither Microbicides? *Science* 2008; 321: 532-534.
299. Khumalo-Sakutukwa G, Morin SF, Fritz K, Charlebois ED, van Rooyen H, Chingono A, Modiba P, Mrumbi K, Visrutaratna S, Singh B, Sweat M, Celentano DD, Coates TJ; NIMH Project Accept Study Team Project Accept (HPTN 043): a community-based intervention to reduce HIV incidence in populations at risk for HIV in sub-Saharan Africa and Thailand. *Journal of Acquired Immune Deficiency Syndrome* 2008; 49(4): 422-31 (contributor of group publication)

2007

300. **Abdool Karim SS**, Abdool Karim Q. Diverse approaches useful for microbicide trials. *Nature* 2007; 449: 24
301. **Abdool Karim SS**, Mlisana K, Kharsany ABM, Williamson C, Baxter C, Abdool Karim Q. Utilising nucleic acid amplification to identify acute HIV infection. *AIDS* 2007; 21(5): 653-655.
302. **Abdool Karim SS**, Abdool Karim Q, Gouws E, Baxter C. Global Epidemiology of HIV. *Infectious Disease Clinics of North America* 2007; 21(1): 1-18.
303. **Abdool Karim SS**. HIV incidence estimates are key to understanding the changing HIV epidemic in South Africa. *South African Medical Journal* 2007; 97: 190.
304. Dilraj A, **Abdool Karim SS**, Pillay S. Challenging racial stereotyping of AIDS in South Africa with prevalence of HIV in pregnant women. *South African Medical Journal* 2007; 97(1): 42.
305. Gray ES, Moore PL, Choge IA, Decker JM, Bibollet-Ruche F, Li H, Leseka N, Treurnicht F, Mlisana K, Shaw GM, **Abdool Karim SS**, Williamson C, Morris L. and the CAPRISA 002 study team. Neutralizing antibody responses in acute HIV-1 subtype C infection. *Journal of Virology* 2007; 81(12): 6187–6196.
306. Coetzer M, Cilliers T, Papathanasopoulos M, Ramjee G, **Abdool Karim S**, Williamson C, Morris L. Longitudinal analysis of HIV-1 subtype C envelope sequences from South African patients. *AIDS Research and Human Retroviruses* 2007; 23(2): 316-321.
307. Williams BG; Gouws E; Ramjee G; **Abdool Karim S**. Response to Brown et al., Incident and prevalent herpes simplex virus type 2 infection increases risk of HIV acquisition among women in Uganda and Zimbabwe. *AIDS* 2007; 21(17): 2356-7.
308. Frohlich J, Abdool Karim Q, Mashego MM, **Abdool Karim S**. Opportunities for treating sexually transmitted infections and reducing HIV risk in Primary Health Care Settings in rural South Africa. *Journal of Advanced Nursing* 2007; 60(4): 377-383.

2006

309. Gray A, **Abdool Karim SS**, Gengiah TN. Ritonavir/Saquinavir safety concerns curtail ART options for TB-HIV co-infected patients in resource-constrained settings. *AIDS* 2006; 20(2): 302-303.

310. Kharsany ABM, Connolly C, Olowalogba A, **Abdool Karim SS**, Abdool Karim Q. Tuberculosis treatment outcomes following Directly Observed Treatment at a South African Primary Health Care Facility: Opportunities for strengthening Tuberculosis case management. *Tropical Doctor* 2006; 36: 23-25.
311. Singh JA, **Abdool Karim SS**, Abdool Karim Q, Mlisana K, Williamson C, Gray C, Govender M, Gray A. Enrolling Adolescents in Research on HIV and Other Sensitive Issues: Lessons from South Africa. *PLoS Medicine* 2006; 3(7): e180 DOI: 10.1371/journal.pmed.0030180.
312. Kharsany ABM, Connolly C, Olowalogba A, **Abdool Karim SS**, Abdool Karim Q. Increasing burden of pulmonary TB in young women. *South African Medical Journal* 2006; 96: 524-525.
313. Amirfar S, Hollenberg JP, **Abdool Karim SS**. Modeling the impact of a partially effective HIV vaccine on HIV infection and death among women and infants in South Africa. *Journal of AIDS* 2006; 43(2): 219-225.
314. **Abdool Karim SS**. Durban 2000 to Toronto 2006: The evolving challenges in implementing AIDS treatment in Africa. *AIDS* 2006; 20: N7-N9.
315. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, Robinson J, Decker JM, Li Y, Salazar M, Mlisana K, **Abdool Karim S**, Hong K, Greene KM, Bilska M, Zhou J, Allen S, Chomba E, Mulenga J, Vwalika C, Gao F, Zhang M, Korber B, Hunter E, Hahn BH, Montefiori DC. Neutralization Properties of Acute and Early Subtype C Human Immunodeficiency Virus Type 1 *env* Clones from Heterosexually Acquired Infections in Southern Africa. *Journal of Virology* 2006; 80(23): 11776-11790.
316. Gray A, **Abdool Karim SS**. In reply: Saquinavir and rifampicin for tuberculosis and AIDS: new considerations. *International Journal of Tuberculosis and Lung Disease* 2006; 10(11): 1302-1303.

2005

317. Gray CM, Williamson C, Puren A, Xia X, Filter R, Zijenah L, Cao H, Morris L, Vardas E, Colvin M, Gray G, McIntyre J, Musonda R, Allen S, Katzenstein D, Mbizo M, Kumwemba N, Taha T, **Abdool Karim S**, Flores J and Sheppard HW. Viral dynamics and CD4(+) T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa. *AIDS Res. Hum. Retro.* 2005; 21: 285-291
318. Ramjee G, Williams B, Gouws E, Van Dyck E, De Deken B, **Abdool Karim S**. The impact of incident and prevalent HSV-2 infection on the incidence of HIV-1 infection among commercial sex workers in South Africa. *Journal of AIDS* 2005; 39(3): 333-339.
319. **Abdool Karim SS**. Microbicides for the Prevention of HIV Infection. In: HIV Sequence Compendium 2005, Leitner T, Foley B, Hahn B, Marx P, McCutchan F, Mellors J, Wolinsky S, and Korber B, editors. 2005. Published by Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, LA-UR number 06-0680. pp30-40. Available at <http://hiv.lanl.gov/content/hiv-db/COMPENDIUM/2005/partI/karim.pdf>

2004

320. **Abdool Karim SS**, Abdool Karim Q, Friedland G, Lalloo U and El Sadr WM on behalf of the START project. Implementing Antiretroviral Therapy in Resource Constrained Settings: opportunities and challenges in integrating HIV and TB care. *AIDS* 2004; 18: 1-5.
321. **Abdool Karim S**. Medical Education after the first decade of democracy in South Africa. *Lancet* 2004; 363:1395.
322. Gottlieb GS, Nickle DC, Jensen MA, Wong KG, Grobler J, Li F, Liu S-L, Rademeyer C, Learn GH, **Abdool Karim SS**, Williamson C, Corey L, Margolick JB, Mullins JI. Dual HIV-1 infection associated with rapid disease progression. *Lancet* 2004; 363: 619-22.
323. Friedland G, **Abdool Karim SS**, Abdool Karim Q, Lalloo U, Jack C and El Sadr W. The Utility of Tuberculosis Directly Observed Therapy (DOT) programs as sites for access and provision of antiretroviral therapy in resource limited settings. *Clinical Infectious Diseases* 2004; 38(suppl5): S421-428.
324. Jack C, Lalloo U, Abdool Karim Q, **Abdool Karim S**, El-Sadr W, Cassol S, Friedland G. A Pilot Study of once daily antiretroviral therapy with tuberculosis directly observed therapy (TBDOT) in a resource limited setting. *Journal of AIDS* 2004; 36(4): 929-934.
325. Rademeyer C, van Harmelen JH, Ramjee G, **Abdool Karim SS**, Williamson C. Heretrosexual transmission of multiple highly conserved variants in HIV-1 subtype C-infected seronegative women. *AIDS* 2004; 18(15): 10-12.
326. Masemola A, Mashishi T, Khoury G, Mohube P, Mokgotho P, Vardas E, Colvin M, Zijenah L, Katzenstein D, Musonda R, Allen S, Kumwenda N, Taha T, Gray G, McIntyre J, **Abdool Karim**

- S, Sheppard HW, Gray CM and the HIVNET 028 Study team. Hierarchical targeting of subtype C HIV-1 proteins by CD8+ T cells: Correlation with viral load. *Journal of Virology* 2004; 78(7): 3233–3243.
327. Masemola AM, Mashishi TN, Khoury G, Bredell H, Paximadas M, Mathebula T, Barkhan D, Puren A, Vardas E, Colvin M, Zijenah L, Katzenstein D, Musonda R, Allen S, Kumwenda N, Taha T, Gray G, McIntyre J, **Abdool Karim S**, Sheppard HW, Gray CM, and the HIVNET 028 Study team. Novel and Promiscuous Cytotoxic T Lymphocyte Epitopes in Conserved Regions of Gag Targeted by Individuals with Early Subtype C Human Immunodeficiency Virus Type-1 Infection from Southern Africa. CTL epitopes in conserved regions of subtype C Gag. *Journal of Immunology* 2004; 173: 4607–4617.
 328. Grobler J, Gray CM, Rademeyer C, Seoighe C, Ramjee G, **Abdool-Karim SS**, Morris L, Williamson C. The incidence of HIV-1 dual infection and its association with increased viral load set point in a cohort of subtype C infected female sex-workers. *Journal of Infectious Diseases* 2004; 190(7): 1355-9.
 329. Myer L, **Abdool Karim SS**, Lombard C, Wilkinson D. Treatment of maternal syphilis in rural South Africa: effect of multiple doses of benzathine penicillin on pregnancy loss. *Tropical Medicine and International Health* 2004; 9(11): 1216–1221.
- 2003:**
330. Lurie MN, Williams BG, Zuma K, Mkaya-Mwamburi D, Garnett GP, Sturm AW, Sweat MD, Gitteksohn J, **Abdool Karim SS**. The impact of migration on HIV-1 transmission in South Africa: A study of migrant and nonmigrant men and their partners. *Sexually Transmitted Diseases* 2003; 30: 149- 156.
 331. Williamson C, Morris L, Maughan MF, Ping L, Dryga SA, Thomas R, Reap EA, Cilliers T, van Harmelen J, Pascual A, Ramjee G, Gray G, Johnston R, **Abdool Karim SS**, Swanstrom R. Characterisation and selection of HIV-1 subtype C isolates for use in vaccine development. *AIDS Research and Human Retroviruses* 2003; 19: 133-144.
 332. **Abdool Karim SS**, Baxter C. HIV vaccines and immunity. *Current Opinion in Allergy & Clinical Immunology* 2003; 16(2): 67-69.
 333. Myer L, Wilkinson D, Lombard C, Zuma K, Rotchford K, **Abdool Karim SS**. Impact of on-site testing for maternal syphilis on treatment delays, treatment rates, and perinatal mortality in rural South Africa: a randomized controlled trial. *Sexually Transmitted Infection* 2003; 79: 208–213.
 334. **Abdool Karim SS**, Abdool Karim Q, Baxter C. Antiretroviral therapy: challenges and options for South Africa. *Lancet* 2003; 362: 1499.
 335. Frohlich JA, Abdool Karim Q, Biyela D, **Abdool Karim SS**. Developing partnerships in preparing communities for HIV prevention and vaccine efficacy trials: experiences from rural South Africa. *Retroviruses of Human AIDS and Related Animal Diseases* 2003; 191-197.
 336. Morrow K, Rosen R, Richter L, Emans A, Forbes A, Day J, Morar N, Maslankowski L, Profy AT, Kelly C, **Abdool Karim SS**, Mayer KH. The acceptability of an investigational vaginal microbicide, PRO 2000 gel, among women in a Phase I clinical trial. *Journal of Women's Health* 2003; 12(7): 655-666.
 337. Mayer KH, **Abdool Karim S**, Kelly C, Maslankowski L, Rees H, Profy A, Day J, Welch J, Rosenberg Z, for the HPTN 020 Protocol team. Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV infected women. *AIDS* 2003; 17: 221-229.
 338. *Lurie MN, Williams BG, Khangelani Z, Mkaya-Mwamburi D, Garnett GP, Sweat MD, Gittelsohn J, **Abdool Karim SS**. Who infects who? HIV-1 concordance and discordance among migrant and non-migrant couples in South Africa. *AIDS* 2003; 17: 2245-2252.
 339. Shetty AK, Coovadia HM, Mirochnick MM, Maldonado Y, Mofenson LM, Eshleman SH, Fleming T, Emel L, George K, Katzenstein DA, Wells J, Maponga CC, Mwatha A, Adeniyi Jones S, **Abdool Karim SS**, Bassett MT, HIVNET 023 Study Team. Safety and Trough Concentrations of Nevirapine Prophylaxis Given Daily, Twice Weekly, or Weekly in Breast-Feeding Infants From Birth to 6 Months. *Journal of AIDS* 2003; 34(5): 482-490.
- 2002:**
340. **Abdool Karim SS**, Abdool Karim Q, Adhikari M, et al. Vertical HIV transmission in South Africa: translating research into policy and practice. *Lancet* 2002; 359: 992-993.
 341. Bures R, Morris L, Williamson C, Ramjee G, Deers M, Fiscus SA, **Abdool Karim S**, Montefiori DC. Regional clustering of shared neutralization determinants of primary isolates of clade C human immunodeficiency virus type 1 from South Africa. *Journal of Virology* 2002; 76: 2233-2244.

342. Abdool Karim Q, **Abdool Karim SS**. The evolving HIV epidemic in South Africa. *International Journal of Epidemiology* 2002; 31: 37-40.
343. Gouws E, Williams BG, Sheppard HW, Enge B, **Abdool Karim SS**. High incidence of HIV-1 in South Africa using a standardized algorithm for recent HIV seroconversion. *Journal of AIDS* 2002; 29: 531-535.
344. Rustumjee R, Kharsany AB, Connolly C, **Abdool Karim SS**. A randomized controlled trial of azithromycin versus doxycycline/ciprofloxacin for the syndromic management of sexually transmitted infections in a resource-poor setting. *Journal of Antimicrobial Chemotherapy* 2002; 49: 875-878.
345. **Abdool Karim SS**. Conducting HIV vaccine trials in South Africa. *Continuing Medical Education* 2002; 20: 588-592.
346. Connolly C, Ramjee G, Sturm W, **Abdool Karim SS**. Incidence of sexually transmitted infections among HIV positive sex workers in KwaZulu-Natal, South Africa. *Sexually Transmitted Diseases* 2002; 29: 721-724.
347. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, Sirivongrangson P, Mukenge-Tshibaka L, Ettiegne-Traore V, Uaheowitchai C, **Abdool Karim SS**, Masse B, Perriens J, Laga M, on behalf of the COL-1492 study group. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomized controlled trial. *Lancet* 2002; 360: 971-977.

2001:

348. **Abdool Karim SS**. Clinical testing of microbicides: a global research priority. *AIDS* 2001; 15: 929-930.
349. Myer L, Mathews C, Little F, **Abdool Karim SS**. The fate of male condoms distributed to the public in South Africa. *AIDS* 2001; 15: 789-793.
350. Williams B, Gouws E, Wilkinson D, **Abdool Karim SS**. Estimating HIV incidence rates from age prevalence data in epidemic situations. *Statistics in Medicine* 2001; 20: 2003-2016.
351. Wilkinson D, Gouws E, Sach M, **Abdool Karim SS**. Effect of removing user fees on attendance for curative and preventive primary health care services in rural South Africa. *Bulletin of the World Health Organisation* 2001; 79: 665-671.
352. Wilkinson D, **Abdool Karim SS**, Lurie M, Harrison A. Public-private health sector partnerships for STD control in South Africa: perspectives from the Hlabisa experience. *South African Medical Journal* 2001; 91: 517-520.
353. van Harmelen J, Williamson C, Kim B, Morris L, Carr J, **Abdool Karim SS**, McCutchan F. Characterization of full-length HIV type 1 subtype C sequences from South Africa. *AIDS Research and Human Retroviruses* 2001; 17: 1527-1531.
354. Mashishi T, Loubser S, Hide W, Hunt G, Morris L, Ramjee G, **Abdool Karim SS**, Williamson C, Gray CM. Conserved domains of subtype C nef from South African HIV-1 infected individuals include cytotoxic T lymphocyte epitope-rich regions. *AIDS Research and Human Retroviruses* 2001; 17: 1681-7.
355. Coutoudis A, Pillay K, Kuhn L, Spooner E, Tsai W, Coovadia HM, for the South African Vitamin A Study Group (group publication including **Abdool Karim SS**). Method of feeding and transmission of HIV-1 from mothers to children by 15 months of age: prospective cohort study from Durban, South Africa. *AIDS* 2001; 15: 379-387.

2000:

356. **Abdool Karim SS**. Globalization, ethics and AIDS vaccines. *Science* 2000; 288: 2129.
357. Williams BG, Gouws E, Colvin M, Sitas F, Ramjee G, **Abdool Karim SS**. Patterns of Infection: using age prevalence data to understand the epidemic of HIV in South Africa. *South African Journal of Science* 2000; 96: 305-312.
358. Williams BG, Gouws E, **Abdool Karim SS**. Where are we now? Where are we going? The demographic impact of HIV/AIDS in South Africa. *South African Journal of Science* 2000; 96: 297-300.
359. Dorrington R, Bradshaw D, Bourne D, **Abdool Karim SS**. HIV surveillance results – little grounds for optimism yet. *South African Medical Journal* 2000; 90: 452-453.
360. **Abdool Karim SS**. Rising to the challenge of the AIDS epidemic. *South African Journal of Science* 2000; 96: 262.
361. Gilmour E, **Abdool Karim SS**, Fourie HJ. Availability of condoms in urban and rural areas of KwaZulu-Natal, South Africa. *Sexually Transmitted Diseases* 2000; 27: 353-357.

362. Wilkinson D, **Abdool Karim SS**, Williams B, Gouws E. High HIV incidence and prevalence among young women in rural South Africa: developing a cohort for Intervention Trials. *Journal of AIDS* 2000; 23: 405-409.
363. Morris L, Bredell H, van Harmelen J, Ping L-H, Pasqual A, Ramjee G, **Abdool Karim SS**, Gray G, McIntyre J, Maartens G, Swanstrom R, Williamson C. No evidence for naturally occurring mutations resistant to HIV-1 reverse transcriptase inhibitors among South African HIV-1 subtype C isolates. *South African Journal of Science* 2000; 96: 369-370.
364. Harrison A, **Abdool Karim SS**, Floyd K, Lombard C, Lurie M, Ntuli N, Wilkinson D. Syndrome packets and health worker training improve quality of sexually transmitted disease management in rural South Africa: results of a randomised controlled trial. *AIDS* 2000; 14: 2769-2779.
365. Van Damme L, Chandeying V, Ramjee G, Rees H, Sirivongrangson P, Laga M, Perriens J, on behalf of COL-1492 Phase II Study Group (group publication including **Abdool Karim SS**). Safety of multiple daily applications of COL-1492, a nonoxynol-9 vaginal gel, among female sex workers. *AIDS* 2000; 14: 85-88.
366. Ramjee G, Morar N, Alary M, Tshibaka LM, Vuylsteke B, Traore VE, Chandeying V, **Abdool Karim SS**, Van Damme L. on behalf of the COL 1492 study group. Challenges in the conduct of vaginal microbicide effectiveness trials in the developing world. *AIDS* 2000; 14: 2553-2557.

1999:

367. Wilkinson D, **Abdool Karim SS**, Coovadia HM. Short course antiretroviral regimens to reduce maternal transmission of HIV: May be effective but shouldn't be allowed to strangle research that might help Africans. *British Medical Journal* 1999; 318: 479-480.
368. **Abdool Karim SS**, **Abdool Karim SS**. Epidemiology of HIV infection in South Africa. *AIDS* 1999; 13: S4-S7.
369. **Abdool Karim SS**. Making AIDS a notifiable disease - is it an appropriate policy for South Africa. *South African Medical Journal* 1999; 89: 609-611.
370. Wilkinson D, Harrison A, Lurie M, **Abdool Karim SS**. STD syndrome packets: Improving syndromic management of sexually transmitted diseases in developing countries. *Sexually Transmitted Diseases* 1999; 26: 152-156.
371. **Abdool Karim SS**, **Abdool Karim SS**. South Africa: host to a new and emerging HIV epidemic. *Sexually Transmitted Infections* 1999; 75: 139-140.
372. Ramjee G, **Abdool Karim SS**, Morar NS, Gwamanda Z, Xulu G, Ximba T, Gouws E. Acceptability of a vaginal microbicide among female sex workers. *South African Medical Journal* 1999; 89: 673-676.
373. Rotchford K, **Abdool Karim SS**, Rollins N. Prevention of vertical transmission of HIV in South Africa. *British Medical Journal* 1999; 319: 1431-1432.
374. Wilkinson D, **Abdool Karim SS**, Harrison A, Lurie M, Colvin M, Connolly C, Sturm AW. Unrecognised sexually transmitted infections in rural South African women: a hidden epidemic. *Bulletin of the World Health Organisation* 1999; 77: 22-28.
375. Rustonjee R, **Abdool Karim SS**, **Abdool Karim SS**, Laga M, Stein ZA. Phase 1 trial of nonoxynol-9 film among sex workers in South Africa. *AIDS* 1999; 13: 1511-1515.
376. Connolly AM, Wilkinson D, Harrison A, Lurie M, **Abdool Karim SS**. Inadequate treatment of sexually transmitted diseases in the South African private sector. *International Journal of STD & AIDS* 1999; 10: 324-327.
377. Perinatal HIV intervention research in developing countries workshop participants (group publication including **Abdool Karim SS**). Science, ethics, and the future of research into maternal infant transmission of HIV-1. *Lancet* 1999; 353: 832-835.
378. Coutoudis A, Pillay K, Spooner E, Kuhn L and Coovadia HM for the South African Vitamin A Study Group (group publication including **Abdool Karim SS**). Randomized trial testing the effect of vitamin A supplementation on pregnancy outcomes and early mother-to-child HIV-1 transmission in Durban, South Africa. *AIDS* 1999; 13: 1517-1524.
379. Coutoudis A, Pillay K, Spooner E, Kuhn L and Coovadia HM for the South African Vitamin A Study Group (group publication including **Abdool Karim SS**). Influence of infant-feeding patterns on early mother-to-child transmission of HIV-1 in Durban, South Africa: a prospective cohort study. *Lancet* 1999; 354: 471-476.

1998:

380. **Abdool Karim SS**. Placebo controls in HIV perinatal transmission trials: A South African's viewpoint. *American Journal of Public Health* 1998; 88: 564-566.

381. Abdool Karim Q, **Abdool Karim SS**, Coovadia HM, Susser M. Informed consent for HIV testing in a South African hospital: Is it truly informed and truly voluntary? *American Journal of Public Health* 1998; 88: 637-640.
 382. Wilkinson D, Connolly A, Harrison A, Lurie M, **Abdool Karim SS**. Sexually transmitted disease syndromes in rural South Africa: Results from health facility surveillance. *Sexually Transmitted Diseases* 1998; 25: 20-23.
 383. Morar NS, Ramjee G, **Abdool Karim SS**. Vaginal insertion and douching practices among sex workers at truck stops in KwaZulu-Natal. *South African Medical Journal* 1998; 88: 470.
 384. Colvin M, **Abdool Karim SS**. HIV infection among patients with tuberculosis in KwaZulu/Natal, South Africa. *International Journal of Tuberculosis and Lung Disease* 1998; 2: 172.
 385. **Abdool Karim SS**. Hospital inpatient audit - information for action. *South African Medical Journal* 1998; 88: 781.
 386. **Abdool Karim SS**. What is the best hepatitis B vaccination strategy for South Africa? *South African Medical Journal* 1998; 88: 693-694.
 387. **Abdool Karim SS**, Ramjee G. Anal sex and HIV transmission in women. *American Journal of Public Health* 1998; 88: 1265-1266.
 388. Ramjee G, **Abdool Karim SS**, Sturm AW. Sexually transmitted infections among sex workers in KwaZulu-Natal, South Africa. *Sexually Transmitted Diseases* 1998; 25: 346-349.
 389. Colvin M, **Abdool Karim SS**, Connolly C, Hoosen AA, Ntuli N. HIV infection and asymptomatic sexually transmitted infections in a rural South African community. *International Journal of STD & AIDS* 1998; 9: 548-550.
 390. Harrison A, Wilkinson D, Lurie M, Connolly AM, **Abdool Karim SS**. Improving quality of sexually transmitted disease case management in rural South Africa. *AIDS* 1998; 12: 2329-2335.
- 1997:**
391. **Abdool Karim SS**. South Africa: HIV and tuberculosis. *Lancet* 1997; 349: 1542-1543.
 392. Rustomjee R, **Abdool Karim SS**. Underreporting and overreporting of hepatitis B at a tertiary hospital. *South African Medical Journal* 1997; 87: 249-251.
 393. Kay BJ, Katzenellenbogen J, Fawcus S, **Abdool Karim SS**. An analysis of the cost of incomplete abortion to the public health sector in South Africa - 1994. *South African Medical Journal* 1997; 87: 442-447.
 394. Wilkinson D, Cutts F, Ntuli N, **Abdool Karim SS**. Maternal and child health indicators in a rural South African health district. *South African Medical Journal* 1997; 87: 456-460.
 395. Lurie M, Wilkinson D, Harrison A, **Abdool Karim SS**. Migrancy and HIV/STDs in South Africa - a rural perspective. *South African Medical Journal* 1997; 87: 908-909.
 396. **Abdool Karim SS**. Measuring effectiveness of tuberculosis control programmes. *South African Medical Journal* 1997; 87: 1040-1041.
 397. Wilkinson D, Sach ME, **Abdool Karim SS**. Examination of attendance patterns before and after introduction of South Africa's policy of free health care for children aged under 6 years and pregnant women. *British Medical Journal* 1997; 314: 940-941.
 398. **Abdool Karim SS**. Promoting health and human rights in South Africa. *South African Medical Journal* 1997; 87: 240.
 399. Anastasis D, Pillai G, Rambiritch V, **Abdool Karim SS**. A retrospective study of human immunodeficiency virus infection and drug-resistant tuberculosis in Durban, South Africa. *International Journal of Tuberculosis and Lung Disease* 1997; 1: 220-224.
 400. Lurie M, Harrison A, Wilkinson D, **Abdool Karim SS**. Circular migration and sexual networking in rural KwaZulu/Natal: implications for the spread of HIV and other sexually transmitted diseases. *Health Transition Review* 1997; 7(Suppl 3): 15-24
- 1996:**
401. **Abdool Karim SS**, Pillai G, Ziqubu-Page TT, Cassimjee MH, Morar NS. Potential savings from generic prescribing and generic substitution in South Africa. *Health Policy and Planning* 1996; 11: 198-205.
 402. **Abdool Karim SS**, Dilraj A. Reasons for under-reporting of notifiable conditions. *South African Medical Journal* 1996; 86: 834-836.
 403. Fawcus S, Moodley J, Bradshaw D, Theron GB, **Abdool Karim SS**. Measuring maternal mortality in South Africa. *South African Medical Journal* 1996; 86: 403-406.
 404. **Abdool Karim SS**, Chapman A, Shapiro JB. Rationalisation of data collection for a child health service. *South African Medical Journal* 1996; 86: 837.

405. Anastasis D, Pillai G, Rambiritch V, **Abdool Karim SS**. Multidrug-resistant tuberculosis in patients without HIV infection. *South African Medical Journal* 1996; 86: 1294-1296.
406. **Abdool Karim SS**. A new voice for public health. *South African Medical Journal* 1996; 86: 1474.
407. **Abdool Karim SS**, Abdool Karim Q. Is there a cure for AIDS? *South African Medical Journal* 1996; 86(9): 1058, 1063

1995:

408. Abdool Karim Q, **Abdool Karim SS**, Soldan K, Zondi M. Reducing the risk of HIV infection among South African sex workers: socio-economic and gender barriers. *American Journal of Public Health* 1995; 85: 1521-1525.
409. Colvin M, **Abdool Karim SS**, Wilkinson D. Migration and AIDS. *Lancet* 1995; 346: 1303-1304.
410. Katzenellenbogen JM, **Abdool Karim SS**, Fawcus S. Putting the records straight - a plea for improved abortion data. *South African Medical Journal* 1995; 85: 135-136.

1994:

411. Kirsch RE, **Abdool Karim SS**, Prozesky W. Why viral hepatitis? *South African Medical Journal* 1994; 84: 523-524.
412. Robson SC, Schoub B, **Abdool Karim SS**. Viral hepatitis B - an overview. *South African Medical Journal* 1994; 84: 530-535.
413. Buchel E, Hift RH, Wilson T, **Abdool Karim SS**. The prevention of hepatitis. *South African Medical Journal* 1994; 84: 578-583.
414. **Abdool Karim SS**, Ziqubu-Page TT, Arendse R. Bridging the Gap: Potential for a health care partnership between African traditional healers and biomedical personnel in South Africa. *South African Medical Journal* 1994; 84: s1-s16.
415. Dilraj A, **Abdool Karim SS**. Sex difference in measles fatality after introduction of new measles vaccine. *Lancet* 1994; 343: 1366-1367.
416. **Abdool Karim SS**. Challenges to the control of sexually transmitted diseases in Africa. *American Journal of Public Health* 1994; 84: 1891-1893.

1993:

417. **Abdool Karim SS**, Tait DR. Hepatitis C virus in urban and rural Natal/KwaZulu. *South African Medical Journal* 1993; 83: 191-193.
418. **Abdool Karim SS**, Abdool Karim Q, Dilraj A, Chamane M. Unsustainability of a measles immunization campaign - Rise in measles incidence within 2 years of the campaign. *South African Medical Journal* 1993; 83: 322-323.
419. **Abdool Karim SS**. Traditional healers and AIDS prevention. *South African Medical Journal* 1993; 83: 423-425.
420. Soni PN, **Abdool Karim SS**, Coovadia HM, Hurribunce AC, Jinabhai CC, Mokoena T, Moodley J, Seedat MA. Academic health complexes - Ivory towers or national resources? *South African Medical Journal* 1993; 83: 464-465.
421. **Abdool Karim SS**. Traditional healers and AIDS prevention. *South African Medical Journal* 1993; 83: 691.
422. Colvin MSE, **Abdool Karim SS**, Gouws E. Occupational disease in a chormate producing factory. *South African Medical Journal* 1993; 83: 857-858.
423. Soni PN, **Abdool Karim SS**, Coovadia HM, Hurribunce AC, Jinabhai CC, Mokoena T, Moodley J, Seedat MA. Academic health complexes. *South African Medical Journal* 1993; 83: 860.
424. **Abdool Karim SS**, Coutsooudis A. Sero-epidemiology of hepatitis A in black South African children. *South African Medical Journal* 1993; 83: 748-750.

1992:

425. **Abdool Karim SS**, Abdool Karim Q, Preston-Whyte E, Sankar N. Reasons for lack of condom use among high school students. *South African Medical Journal* 1992; 82: 107-110.
426. **Abdool Karim SS**. Measles control: A public health challenge. *Southern African Journal of Epidemiology & Infection* 1992; 7: 63-64.
427. **Abdool Karim SS**, Abdool Karim Q. Changes in HIV seroprevalence in a rural black community in KwaZulu. *South African Medical Journal* 1992; 82: 484.
428. Abdool Karim Q, Preston-Whyte E, **Abdool Karim SS**. Teenagers seeking condoms at family planning services: Part I. A user's perspective. *South African Medical Journal* 1992; 82: 356-359.

429. Abdool Karim Q, **Abdool Karim SS**, Preston-Whyte E. Teenagers seeking condoms at family planning services: Part II. A provider's perspective. *South African Medical Journal* 1992; 82: 360-362.
430. Seedat YK, **Abdool Karim SS**. Primary health care in South Africa. *Advances in Medical Science* 1992; 20: 362-373.
431. Abdool Karim Q, **Abdool Karim SS**, Singh B, Short R, Ngxongo S. Seroprevalence of HIV infection in rural South Africa. *AIDS* 1992; 6: 1535-1539.

1991:

432. **Abdool Karim SS**. Should AIDS be made notifiable? *South African Medical Journal* 1991; 79: 179-181.
433. Kiepiela P, Coovadia HM, Loening WEK, Coward P, **Abdool Karim SS**. Loss of maternal measles antibody in black South African infants in the first year of life - implications for age of vaccination. *South African Medical Journal* 1991; 79: 145-148.
434. **Abdool Karim SS**, Abdool Karim Q. Under-reporting in hepatitis B notifications. *South African Medical Journal* 1991; 79: 242-244.
435. **Abdool Karim SS**, Windsor IM, Gopal W. Low prevalence of Delta hepatitis virus infection among blacks in Natal. *South African Medical Journal* 1991; 80: 193-194.
436. Abdool Karim Q, **Abdool Karim SS**, Nkomokazi J. Sexual behaviour and knowledge of AIDS among black mothers: Implications for AIDS intervention programmes. *South African Medical Journal* 1991; 80: 340-343.
437. **Abdool Karim SS**, Abdool Karim Q, Chamane M. Impact of a measles immunisation campaign on measles admissions to a Natal hospital. *South African Medical Journal* 1991; 80: 579-581.
438. **Abdool Karim SS**, Andelman R. Impact of the political violence in Natal on emergency surgical services of a tertiary hospital. *South African Medical Journal* 1991; 80: 134-138.
439. **Abdool Karim SS**, Thejpal R, Coovadia HM. Household clustering and intra-household transmission patterns of hepatitis B virus infection in South Africa. *International Journal of Epidemiology* 1991; 20: 495-503.

1990:

440. Fouche A, Crewe RM, Windsor IM, **Abdool Karim SS**. Persistence of hepatitis B antigen in *Culex quinquefasciatus* (Diptera: Culicidae). *Journal of Medical Entomology* 1990; 27: 697-700.
441. Rutkove S, **Abdool Karim SS**, Loening WEK. Patterns of care in an overburdened tertiary hospital outpatients department. *South African Medical Journal* 1990; 77: 476-478.
442. Coovadia YM, **Abdool Karim SS**. A community-based seroprevalence survey of syphilis in black children. *Genitourinary Medicine* 1990; 66: 124.

1989:

443. **Abdool Karim SS**, Thejpal R, Singh B. High prevalence of hepatitis B virus infection in rural black adults in Mseleni, South Africa. *American Journal of Public Health* 1989; 79: 893-894.
444. Kiepiela P, Coovadia HM, Coward P, Woodhead R, **Abdool Karim SS**, Becker P. Age-related lymphocyte sub-population changes among healthy Africans from birth to adulthood. *Annals of Tropical Paediatrics* 1989; 9: 199-205.

1988:

445. **Abdool Karim SS**, Coovadia HM, Windsor IM, Thejpal R, van den Ende J, Fouche A. The prevalence and transmission of hepatitis B virus infection and urban, rural and institutionalized black children of Natal/KwaZulu, South Africa. *International Journal of Epidemiology* 1988; 17: 168-173.

1986:

446. Jinabhai CC, Coovadia HM, **Abdool Karim SS**. Socio-medical indicators of health in South Africa. *International Journal of Health Services* 1986; 16: 163-176.
447. Fouche A, **Abdool Karim SS**, Windsor IM, van den Ende J. Hepatitis B virus in a Culicine mosquito species in the Republic of South Africa. *South African Medical Journal* 1986; 70: 302.

11b. Books & Book Chapters and Reports

1. Abdool Karim Q, **Abdool Karim SS**, Baxter C (eds). The CAPRISA Clinical Trials: HIV

- Treatment and Prevention. 2017. Springer, Switzerland
2. Vermund, S.H., **Abdool Karim, S.** Governmental Support of Research. In: Robertson, D. and Williams, G.H. (eds). *Clinical and Translational Science: Principles of Human Research*. Second Edition, 2016. Elsevier Inc., London. pp.680-705
 3. **Abdool Karim SS**, Baxter C. Translating Pre-exposure Prophylaxis Evidence into Practice and Public Health Impact. In: Eaton LA, Kalichman SC (eds). *Biomedical Advance in HIV Prevention*. 2013. Springer, New York. pp 29-40.
 4. **Abdool Karim SS.** HIV Prevention. In: Volberding, Green, Lange & Gallant (eds). *Sande's HIV & AIDS Medicine* 2012
 5. **Abdool Karim SS** and Abdool Karim Q (eds). *HIV/AIDS in South Africa*. 2010 (second edition). Cambridge University Press, Cape Town South Africa
 6. **Abdool Karim SS**, Abdool Karim Q, Detels R. Acquired Immunodeficiency Syndrome. Chapter 9.13. In: Detels R, Beaglehole R, Lansang MA, Gulliford M. *Oxford Textbook of Public Health*, fifth edition. 2009. Oxford University Press, New York. Pp1193-1212
 7. Hankins C, Strathdee S, **Abdool Karim SS.** Chapter 49: HIV Transmission and its Prevention in Africa. Pg 565 – 576 In: *Global HIV/AIDS Medicine*. Edited by; Volberding PA, Sande MA, Lange J, Greene WC. Associate editor; Gallant J. Saunders Elsevier. Philadelphia, USA. 2008.
 8. Myer L, **Abdool Karim SS.** Chapter 12: Precision and validity in epidemiological studies: error, bias and confounding. In: Joubert G and Ehrlich R (eds). *Epidemiology: A research manual for South Africa*. 2nd Edition. Oxford University Press; Cape Town. 2007
 9. Joubert G, Ehrlich R (ed). Katzenellenbogen J, **Abdool Karim SS** (contributing ed). *EPIDEMIOLOGY A Research Manual for South Africa*, 2nd edition. Oxford University Press Southern Africa, Cape Town, South Africa. 2007.
 10. **Abdool Karim SS.** Voluntary counseling and testing: is it time to opt out? *Actualizaciones en sida* 2007; 15(55):37-40.
 11. **Abdool Karim SS.** The African Experience. In: Kenneth Mayer and HF Pizer (eds) *The AIDS Pandemic: Impact on science and society*. 2006. pp 351-373
 12. **Abdool Karim SS** and Abdool Karim Q (eds). *HIV/AIDS in South Africa*. 2005. Cambridge University Press, Cape Town South Africa
 13. Katzenellenbogen J, Joubert G, **Abdool Karim SS** (eds). *Epidemiology: A manual for South Africa*. Johannesburg: Oxford University Press, 1997.
 14. Metcalf CA, **Abdool Karim SS**, Yach D. Infectious disease hazards associated with travel to and from South Africa. Durban: Medical Research Council, 1994.
 15. Nell and Shapiro Consulting cc, **Abdool Karim SS**, Matjila MJ. Fighting AIDS: Evaluation of the National AIDS programme of the National Progressive Primary Health Care Network. Report submitted to the National AIDS Programme of the National Progressive Primary Health Care Network, 1993.
 16. Abdool Karim Q, **Abdool Karim SS.** Epidemiology of HIV infection in Natal/KwaZulu. In: *AIDS and your response*. Coventry (UK): Institute of World Concerns, 1993: 43-51.
 17. Soldan K, Abdool Karim Q, **Abdool Karim SS.** Home-based care for HIV/AIDS: Evaluation of the KwaZulu pilot programme. Report submitted to the KwaZulu Department of Health, 1993.
 18. **Abdool Karim SS**, Ziqubu-Page TT, Arendse R. Bridging the Gap: Potential for a health care partnership between African Traditional Healers and biomedical personnel in South Africa. Report submitted to the Medical Association of South Africa, 1992.
 19. Yach D, **Abdool Karim SS**, Ramphele M. Evaluation of the National Progressive Primary Health Care Network. Cape Town: PPHC Network 1989.
 20. **Abdool Karim SS** (ed). *Health and Human Rights: 1986 Conference Proceedings of the National Medical and Dental Association*. Durban: NAMDA, 1987.
 21. **Abdool Karim SS** (ed). *Primary Health Care*. Durban: NAMDA, 1987.
 22. Jinabhai CC, Coovadia HM, **Abdool Karim SS.** Socio-medical indicators for monitoring progress towards health for all in southern Africa. Second Carnegie inquiry into poverty and development in southern Africa (Paper 165). Cape Town: SALDRU, 1984.

11c. Patents

1. Patent 2003/0996. Application number: 12/357,099 (Publication date: 22 Mar 2011, Filing date: 21 Jan 2009, Priority date: 7 Jul 2000)
Nucleic acids encoding modified South African HIV-1 subtype C gag proteins
Process of selection of HIV-1 subtype C isolates, selected HIV-1 subtype C isolates, their genes and modifications and derivatives thereof

Inventors: Robert Edward Johnston, Salim Abdol Karim, Lynn Morris, Ronald Swanstrom, Carolyn Williamson

Countries: South Africa, India, USA, ARIPO, Germany, Italy, France, United Kingdom and Namibia

2. Patent: 2004/4205. Application number: PCT/IB02/04550 (Publication date: 20 Jan 2009, Filing date: 31 Oct 2002, Priority date: 31 Oct 2001)

HIV-1 subtype isolates, regulatory/accessory genes and modifications and derivatives thereof (Based on ZA20001/8978)

Inventors: Carolyn Williamson, Joanne Heidi van Harmelen, Clive Maurice Gray, William Bourn, Salim Abdool Karim

Countries: South Africa, USA, ARIPO, United Kingdom, France, Germany

3. Patent: EP 2 579 871 B1. Application number: 11726022.4 (Publication date: 26 August 2015 Bulletin 2015/35, Filing date: 07 June 2011)

Topical antiviral formulations for prevention of transmission of HSV-2

Inventors: Salim S. Abdool Karim, Quarraisha Abdool Karim, Ayesha Kharsany, Jim Rooney and Thomas Cichlar

Countries: South Africa and USA

4. Application number 1403613.1: Provisional Patent (PA159593/P) (filed 28 February 2014)

Novel Broadly Neutralizing Monoclonal Antibodies Against HIV-1

Inventors: Lynn Morris, Penny Moore, Salim Abdool Karim, John Mascola, Nicole Doria-Rose, Peter Kwong and Larry Shapiro

Countries: South Africa and USA

5. Patent: US 10,519,222 B2 / EP 3 110 844 B1 / WO2015/128846 A1. Application number PCT/IB2015/051465 (Publication date: 3 Sept 2015, Filing date: 27 Feb 2015, Priority date: 19 Dec 2014; Date of patent 31 Dec 2019)

Broadly neutralizing monoclonal antibodies against HIV-1 V1V2 env region

Inventors: Chaim Aryeh Schramm, Jason Gorman, John Mascola, Lawrence Stewart Shapiro, Lynn Morris, Nicole Amy Doria-Rosa, Penelope Linda Moore, Peter Dak Pin Kwong, Salim Safurdeen Abdool Karim

Countries: South Africa and USA

6. Pending Patent: CU17009 Application number 62/533,229 (Publication date: , Filing date: 17 July 2017, Priority date:)

Methods of assessing risk of and preventing infection by sexually transmitted disease including human immunodeficiency virus

Inventors: W. Ian Lipkin; Brent Williams; Mara Couto-Rodriguez; Salim Abdool Karim

Countries: South Africa and USA

11d. Abstracts and conference presentations

2022

2021

Harvard – MIT Health Sciences, online webinar, 22 Jan

- **Abdool Karim SS.** HST.S43 Spec Sub: Evolution of Epidemic

The Royal Society, Commonwealth Science, pre-recorded presentation, 26 Jan

- **Abdool Karim SS.** A tale of two pandemics: AIDS and Covid-19.

Africa Centres for Disease Control and Prevention, online webinar, 27 Jan

- **Abdool Karim SS.** African COVID-19 Vaccine Financing and Deployment Strategy

Western Cape Government, Leadership Conference, 29 Jan

- **Abdool Karim SS.** Leadership.

British High Commission, online webinar, 1 Feb

- **Abdool Karim SS.** Reflections on the second wave of Covid-19 in SA: Vaccinations and a forward look for 2021.

Institute of Global Health, University College London, Annual Meeting, Adolescent GCRF Funded Hub, online meeting, 4 Feb

- **Abdool Karim SS.** Covid-19: The good, the bad and the complicated.

World Health Organization, WHO Afro: Updates on the COVID-19 Resurgence and Variants online webinar, 11 Feb

- **Abdool Karim SS.** The Epidemiology of the 501Y.v2 variant of SARS-COV2 and the Impact on vaccine efficacy in South Africa.

Global Science TV episode, 17 Feb

- **Abdool Karim SS.** Herd Immunity.

Minerals Council, online webinar, 18 Feb

- **Abdool Karim SS.** COVID-19 vaccine options.

Commonwealth Science Conference, Building resilient societal systems, online webinar, 22 Feb

- **Abdool Karim SS.** A sustainable recovery from Covid-19.

VMRC4Africa CAPRISA-UCT Virtual PI meeting, online webinar, 24 Feb

- **Abdool Karim SS.** Vaginal microbiome and HIV prevention: Findings from the South African epidemic.

Commonwealth Science Conference, Live Q&A Panel Discussion, online webinar, 25 Feb

- **Abdool Karim SS.** A Sustainable Recovery from Covid-19.

Inaugural South African Clinician Scientists Conference Committee, online webinar, 26 Feb

- **Abdool Karim SS.** Lessons learnt on Covid-19 and other diseases.

Doherty Institute, University of Melbourne, online webinar, 3 Mar

- **Abdool Karim SS.** The South African vaccine strategy and the B1351 mutants.

African CDC Press Conference, online webinar, 4 Mar

- **Abdool Karim SS.** Update on Covid-19 in South Africa: Epidemiology, vaccines and variants.

The 5th Motsepe Foundation Gender Equality Wellness and Leadership Summit, The Impact of COVID-19 on Women's Health online webinar, 8 Mar

- **Abdool Karim SS.** Harnessing The role of Women in the Pandemic Recovery as Leaders in Various Spheres of Society.

Gairdner Consortium of Universities for Global Health, Gairdner Global Health Awardees Address online webinar, 13 Mar

- **Abdool Karim SS.** HIV prevention in women: Trials & Tribulations.

Global Closing of the 6th Partnership Forums, The Next Global Fund Strategy: Catalyzing Greater Impact in a Rapidly Evolving Environment, online webinar, 15 Mar

- **Abdool Karim SS.**

Sabin Vaccine Institute, Sabin's Pivoting in a Pandemic, recorded video, 16 Mar

- **Abdool Karim SS.**

Proactive Health Solutions, online webinar, 16 Mar

- **Abdool Karim SS.** SA COVID-19 Pandemic Response to Date.

Global Business Solutions Employment Conference, online webinar, 18 Mar

- **Abdool Karim SS.** An update on Covid-19, lessons learnt and the way forward for stakeholders.

UNAIDS Podcast Series, 29 Mar

- **Abdool Karim SS.** AIDS and COVID-19 vaccines.

Virtual Research Forum on Covid-19, Tufts University, online webinar, 30 Mar

- **Abdool Karim SS.** How is equitable access to the COVID-19 vaccine within priority groups being ensured?

Africa Vaccine Manufacturing for Health Security, Africa Centres for Disease Control and Prevention, online conference, 7 Apr

- **Abdool Karim SS.** SESSION 3 - Panellist preparatory call for Africa Vaccine Manufacturing.

Africa's vaccine manufacturing virtual conference, African Union & African CDC, online conference, 12 Apr

- **Abdool Karim SS.** Partnership to transfer technology to accelerate vaccine manufacturing in Africa.

Africa's vaccine manufacturing virtual conference, African Union & African CDC, online conference, 13 Apr

- **Abdool Karim SS.** Role of Universities and research institutions to support development of research hubs, online conference.

Rhodes University African Studies Centre and the University of Lagos (Nigeria)'s Institute of Africa and African Diaspora's Studies Colloquium, online conference, 23 Apr

- **Abdool Karim SS.** Covid-19 in Retrospect.

The NIHR Global Health Research Unit on Mucosal Pathogens Annual Meeting, online webinar, 7 May

- **Abdool Karim SS.** Covid-19 in South Africa: The Good, The Bad and The Complicated.

House Committee on Science, Space, and Technology, online webinar, 12 May

- **Abdool Karim SS.** Science Committee Hearing: COVID-19 Variants and Evolving Research Needs.

WHO Evidence for Policy Network, online webinar, 17 May

- **Abdool Karim SS.** COVID-19 Pandemic: New Waves & Variants.

The Munk Debate, online webinar, 17 May

- **Abdool Karim SS.** Be it resolved: We should be very worried about the variants.

Higher Health, Public Lecture on COVID-19 pandemic and the PSET sector, online public lecture, 18 May

- **Abdool Karim SS.** COVID-19 pandemic and the PSET sector: Towards Building Long Term, Sustainable Systems and Controls for Uninterrupted Teaching and Learning in the Face of Global Health Pandemics.

The Munk Debate, online webinar, 18 May

- **Abdool Karim SS.** Be it resolved: We should be very worried about the variants.

VuMedia, pre-recorded presentation, 18 May

- **Abdool Karim SS.** SARS-CoV-2 variants: Implications for public health & vaccines.

University of Cape Town's Investment Society, pre-recorded presentation, 18 May

- **Abdool Karim SS.** SARS-CoV-2 variants: Implications for public health & vaccines.

Internews, e-learning course for journalists, online webinar, 19 May

- **Abdool Karim SS.** Let's Talk Vaccines.

The UK Research & Innovation and the NRF 2021 Global Research Council (GRC) Annual Meeting, online webinar, 20 May

- **Abdool Karim SS.** Workshop on research investigations and their socio-economic contributions.

Université Laval, pre-recorded conference presentation, 25 May

- **Abdool Karim SS.** HIV prevention in women: Trials & Tribulations.

University of Cape Town, Investment Student Society, online webinar, 2 Jun

- **Abdool Karim SS.**

University of Cape Town, TB & Covid Conference: Free of TB and Covid through Innovation, online webinar, 6 Jun

- **Abdool Karim SS.** Covid-19: The good, the bad and the complicated.

Columbia University, online webinar, 7-8 Jun

- **Abdool Karim SS.** What can we learn from the HIV response about pandemic preparedness for SARS-CoV-2 and beyond?

2020

Bill & Melinda Gates Foundation, Vaginal Microbiome: Potential opportunities for intervention to optimize health Meeting, Durban, South Africa, 18 February

- **Abdool Karim SS.** HIV prevention in Africa: State of the field.

HVTN meeting, 21 February

- **Abdool Karim SS.** V1V2 Targeting CAP256-VRC26 Lineage Studies.

EPIC Course, Columbia University, 8 June

- **Abdool Karim SS.** Deciphering the source of the first cases in Wuhan: a seafood market and pangolins.
- **Abdool Karim SS.** How to botch the Covid-19 response: Experience of the UK and USA.

Aurum Board meeting, online webinar, 31 July

- **Abdool Karim SS.** Impact of COVID-19 in South Africa and the rest of Africa, and what strategies can be used to manage the pandemic and what are the research priorities

BIO Africa Digital Convention, online webinar, 24 August

- **Abdool Karim SS.** The Covid-19 Epidemic & Biotechnology

O'Neill Institute for National and Global Health Law Colloquium at Georgetown Law, online webinar, 2 September

- **Abdool Karim SS.** COVID-19 Heading into 2021: What Lies Ahead?

University of Free State, online webinar, 13 August 2020

- **Abdool Karim SS.** Health and modelling for the 'Post-COVID-19, Post-Crisis'

Consumer Goods Industry Leaders online webinar, 12 August

- **Abdool Karim SS.** Status update of the Covid-19 Pandemic

Foundation Huesped, Argentina, online webinar, 9 September

- **Abdool Karim SS.** COVID and HIV: The interaction of two pandemics

Isaac Newton Institute, online webinar, 11 September

- **Abdool Karim SS.** Intervention choices, what are the issues

International COVID-19 Webinar: current scenario, opportunities and challenges, online webinar, 23 September

- **Abdool Karim SS.** How South Africa is responding to pandemic crisis of COVID-19

CoE Directors meeting, online webinar, 26 August

- **Abdool Karim SS.** How the CoE on HIV Prevention has been contributing to the Covid-19 response

International COVID-19 Webinar: current scenario, opportunities and challenges, Aveiro University, Portugal, online webinar, 23 September

- **Abdool Karim SS.** How South Africa is responding to pandemic crisis of COVID-19

SAMA Covid webinar, 22 September

- **Abdool Karim SS.** The Covid-19 epidemic in South Africa: What next?

Harvard University Center for African Studies, online webinar, 30 September

- **Abdool Karim SS.** COVID-19 & Africa: Current State and Priorities

Harvard Worldwide Week, online webinar, 5 October

- **Abdool Karim SS.** How Africa, as a region, has handled the pandemic, Massachusetts Consortium on Pathogen Readiness (MassCPR) symposium on Global Perspectives on COVID-19

NRF-Swedish Noel Inspired Webinar Lecture, online webinar, 8 October

- **Abdool Karim SS.** The meaning of science in the age of covid-19

International Health Committee of the American Thoracic Society, online webinar, 23 October

- **Abdool Karim SS.** The Potential Impact of a COVID Vaccine

Gairdner Foundation lectures University of Ottawa National Program Lecture, 20 Oct – 23 Oct

- **Abdool Karim SS.** Lessons from HIV for the Covid-19 Response
- **Abdool Karim SS.** HIV Prevention in Women: Trials & Tribulations

23rd Southern African Internal Audit Conference, online webinar, 28 October 2020

- **Abdool Karim SS.** Consistent adaptive response vs planning in a time of crises

NICD symposium, online webinar, 4 November

- **Abdool Karim SS.** Lessons from HIV for covid-19 response

VMRC annual meeting, 12 November

- **Abdool Karim SS.** Vaginal microbiome and HIV prevention: Findings from the South African epidemic

Cartwright Lecture, Columbia University, online webinar, 18 November

- **Abdool Karim SS.** Covid-19 in South Africa: Medical, scientific and political challenges

South African Sugar Association annual conference

- **Abdool Karim SS.** COVID-19 strategic achievements and providing guidance on the way forward

MSD Virtual HIV Summit 2020 (Merck), 21 Nov

- **Abdool Karim SS.** HIV & COVID-19 - what we have learned so far

Council of the South African Council for Natural Scientific Professions (SACNASP), 25 Nov

- **Abdool Karim SS.** Data science in COVID: The Scientists Making the Decisions

UNESCO NBC webinar, 25 November

- **Abdool Karim SS.** Covid-19 vaccines: Access and equity

Cooperative Governance Meeting, 26 November

- **Abdool Karim SS.** Epidemiological disasters and the coping capacity: lessons out of COVID

KZN virtual conference, online webinar, 28 November

- **Abdool Karim SS.** CoVID-19 in South Africa – what lies ahead in 2021?

3rd Africa Galien Forum, 11 December

- **Abdool Karim SS.** Research in the face of COVID 19: Clinical trials in Africa

2019

Young Scientist Symposium on Infectious Diseases, 27 May 2019, Durban, South Africa

- **Abdool Karim SS.** HIV Prevention in Women in Africa: Challenges and Opportunities

South African AIDS Conference, 11 June 2019, Durban, South Africa

- **Abdool Karim SS.** HIV: No time for complacency (Plenary)

Epic Course, 26 June 2019, Columbia University, New York, New York

- **Abdool Karim SS.** Ending the HIV epidemic in the USA
- **Abdool Karim SS.** Sensitivity vs specificity and reliability vs validity

Royal Society lecture, 12 July 2019, London, UK

- **Abdool Karim SS.** HIV Prevention in Women in Africa: Challenges and Opportunities

KRISP Business Breakfast - Decoding the SA Indian Genome for Health Risk, 19 July 2019, Durban South Africa

- **Abdool Karim SS.** Diabetes: A scourge in South Africa

Phoenix Child Welfare AGM, 21 July 2018, Durban South Africa

- **Abdool Karim SS.** The HIV Epidemic in South Africa: Challenges & Prospects

2018

WHO Consultation, February 28th - March 1st, 2018, Geneva

- **Abdool Karim SS.** Reaching robust policy recommendation

37th Medicine Update Symposium, 15th April 2018

- **Abdool Karim SS.** The HIV Epidemic in South Africa: Challenges & Prospects

EECAAC, Moscow, Russia, 19-20 April 2018

- **Abdool Karim SS.** Specific HIV Prevention technologies for PWID
- **Abdool Karim SS.** Global achievements in HIV prevention

Fogarty at 50 Symposium, Washington D.C., 1 May 2018

- **Abdool Karim SS.** Multigenerational models of long-term capacity building: the trainees become the trainers

IAVI, New York, USA, 2 May 2018

- **Abdool Karim SS.** Preventing HIV in young women in Africa: challenges and prospects

Tackling Infections to Benefit Africa (TIBA) AGM, Durban, South Africa 29 May 2018

- **Abdool Karim SS.** A research journey to unravel why young women have the highest rates of HIV in S. Africa

Vaccine Research Center Seminar, NIH, Bethesda, Maryland, 12 June 2018

- **Abdool Karim SS.** CAPRISA-VRC collaborative passive immunisation studies with bnAb combinations

Population Council, Center for Biomedical Research, New York, USA, 13 June 2018

- **Abdool Karim SS.** Preventing HIV in young women in Africa: A decade of trials and tribulations

IAPAC Adherence Conference, Miami, USA, 8 June 2018

- **Abdool Karim SS.** Connecting the dots from 90-90-90 to HIV Epidemic Control: Milestones for the climb up Mt. Everest

BRICS Health Representatives Meeting, Durban, South Africa, 18 July 2018

- **Abdool Karim SS.** CAPRISA's contributions to Excellence in Research in South Africa
- **Abdool Karim SS.** HIV and TB: A focus on BRICS health priorities

Phoenix Child Welfare AGM, Durban, South Africa 21 July 2018

- **Abdool Karim SS.** *The HIV Epidemic in South Africa: Challenges & Prospects*

Pathology Research and Development (PathReD) Innovation Summit, Johannesburg, 2 August 2018

- **Abdool Karim SS.** Driving scientific research and innovation for social benefit: Examples from CAPRISA's HIV-TB research

AFREHealth Symposium, Durban, South Africa, 6 August 2018

- **Abdool Karim SS.** Research capacity building and partnerships

UKZN Research Flagships Launch, 5 September 2018

- **Abdool Karim SS.** Health in South Africa: Trends, Challenges & Opportunities

DoH KwaZulu-Natal Research Day, Durban, South Africa, 5 September 2018

- **Abdool Karim SS.** HIV in South Africa: An update with recent research findings

2017

USAID, 9 January 2017

- **Abdool Karim SS.** HIV prevention challenges in sub-Saharan Africa: HIV infection in young women in Africa

MIT course, Durban 19 January 2017

- **Abdool Karim SS.** HIV prevention: Prospects & Challenges

University of KwaZulu-Natal research Selectives, Durban, South Africa, 30 January 2017

- **Abdool Karim SS.** Study designs and levels of evidence
- **Abdool Karim SS.** Experimental studies

HIV Workshop for Specialists in all Disciplines Advanced Clinical Care Program, February 2017

- **Abdool Karim SS.** Epidemiology of HIV in South Africa

HPTN Meeting, Johannesburg, South Africa 28 February 2017

- **Abdool Karim SS.** CAP256-VRC26.25.LS mAb HIV prevention research plan

Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Washington, February 13–16, 2017

- McKinnon L, Liebenberg L, Yende N, Masson L, Kashuba A, Archary D, Abdool Karim Q, **Abdool Karim S**, Passmore J-A. Mucosal inflammation abrogates tenofovir-gel-mediated protection from HIV infection. [Abstract Number: 949]

International AIDS Conference, 23-26 July 2017, Paris, France

- Fisher K, Mabuka J, Baxter C, Cromarty R, Mansoor L, Abdool Karim Q, **Abdool Karim S**, Garrett N, Yende N, Morris L, Passmore J-A, Archary D. Antibody dependent cell-mediated phagocytic activity is increased in the genital tract mucosae of HIV-infected women with prior tenofovir gel exposure. (Abstract: WEPE)
- Klatt N, Birse K, Zevin A, Cheu R, Perner M, Romas L, Grobler A, Westmacott G, Xie I, Butler J, Mansoor L, McKinnon L, Passmore J-A, Abdool Karim Q, **Abdool Karim S**, Burgener A. Vaginal bacteria modify HIV pre-exposure prophylaxis efficacy in African women. (Abstract: MOPE)

- Mhlungu S, Yende-Zuma N, Ngcapu S, Mansoor L, **Abdool Karim S**, Abdool Karim Q, Passmore J, Liebenberg L. Sexually transmitted infections (STIs) increase levels of cytokine and cellular biomarkers of HIV risk. (Abstract: TUEP)
- Jewanraj J, Rositch A, Mhlungu S, Mtshali A, Leask K, Mansoor L, **Abdool Karim S**, Abdool Karim Q, Passmore J-A, Liebenberg L. Potential Immune Mechanism for the Relationship between HIV Risk and Multiple Concurrent HPV Infections. (Abstract: TUPE)
- Cicala C, Siro A, Schuetz A, Nawaz F, Arthos J, Williamson C, Paul R, Passmore J-A, Ananworanich J, Ansari A, **Abdool Karim S**, McKinnon L, Fauci A. HIV transmission and disease progression are linked to the frequency of $\alpha 4\beta 7^+$ CD4⁺ T cells. (Abstract: MOPE)

18th International Congress of Mucosal Immunology, 20 July 2017, Washington DC

- **Abdool Karim SS.** Vaginal microbiome in HIV

St Lukes School of Public Health, 23 August 2017, Tokyo, Japan

- **Abdool Karim SS.** The Global HIV epidemic: Successes, Challenges & Prospects

IFCC Worldlab Conference, 22 October 2017, Durban, South Africa

- **Abdool Karim SS.** HIV in women in Africa: new evidence from phylogenetic, genomic and protein research

KwaZulu-Natal Department of Health Research Day, 31 October 2017, Durban, South Africa

- **Abdool Karim SS.** CAPRISA 012 – SAMBA Trial - Phase I safety and PK trial of Subcutaneous Administration of Monoclonal Broadly-neutralizing Antibodies

Maternal Health Summit, 10 November 2017, Johannesburg, South Africa

- **Abdool Karim SS.** HIV and women: Challenges & Prospects

2016

National Institutes of Health, VRC meeting, Washington, D.C., 4 February 2016

- **S Abdool Karim.** Product Development Plan for CAP256-VRC26.25

CROI 2015, Boston, Massachusetts, 22-25 February 2016

- Singh R; Naranbhai V; Jamieson L; Garrett N; **Abdool Karim S**, Ndungu TP. BST-2, TRIM22, and RAD51 in Host Susceptibility to HIV-1 Infection and Virus Control.

5th Eastern Europe and Central Asia AIDS Conference, Russia, 23 March 2016

- **S. Abdool Karim.** Approaching the end of the epidemic: Review of advanced trends in HIV prevention
- **S. Abdool Karim.** Treatment as prevention: History and achievements

AVAC Press conference, Durban, 14 July 2016

- **S. Abdool Karim.** New HIV prevention options including PrEP what does it mean for South Africa?

AIDS 2016, Durban, South Africa, 19-22 July 2016

- **S.S. Abdool Karim.** Understanding high rates of HIV in young women in Africa: Implications of new epidemiological, phylogenetic, genomic and proteomic evidence.
- **S.S. Abdool Karim.** What have we learned from studies of topical agents: interpreting clinical results. THSY0802
- N. Naicker, A. Naidoo, L. Werner, N. Garrett, **S.S. Abdool Karim.** Safety and tolerability of tenofovir-containing antiretroviral therapy in women who acquired HIV in two tenofovir gel trials. THPEB058
- Y. Moosa, N. Garrett, C. Gray, V. Naranbhai, C. Williamson, **S. Abdool Karim.** HIV virological controllers in an African cohort. TUPEA013
- N. Garrett, E. Norman, V. Asari, N. Naicker, N. Majola, K. Leask, Q. Abdool Karim, **S. Abdool Karim.** Acceptability of early HIV treatment among South African women. WEAB0101
- T. de Oliveira, P. Khumalo, C. Cawood, R. Dellar, F. Tanser, G. Hunt, A. Grobler, A. Kharsany, L. Madurai, Q. Abdool Karim, **S. Abdool Karim.** HIV phylogenetic analysis sheds light on

transmission linkages in young women in high HIV burden districts in KwaZulu-Natal, South Africa. THAX0104

- B. Mabvakure, B. Lambson, K. Ramdayal, L. Masson, P. Moore, **S. Abdool Karim**, C. Scheepers, C. Williamson, D. Martin, J.-A. Passmore, G. Harkins, L. Morris. Analysis of HIV-1 subtype C envelope sequence diversity in the female genital tract from early infection reveals no evidence for compartmentalization. TUPEC219
- N. Ngcobo, L. Mansoor, S. Mkhize, C. Montague, M. Tshabalala, **S. Abdool Karim**, Q. Abdool Karim. Integration of HIV prevention and sexual reproductive health services using a quality improvement intervention: experiences from rural KwaZulu-Natal, South Africa. WEPEE572
- S. Ngcapu, A.M. Carias, L.J. Liebenberg, L. Werner, G.C. Cianci, M. McRaven, S. Sibeko, N.J. Garrett, J.-M. Kriek, L.R. McKinnon, **S. Abdool Karim**, Q. Abdool Karim, J.-A.S. Passmore, T.J. Hope. Effect of injectable hormonal contraceptives on vaginal epithelium thickness and genital HIV target cell density in women recently infected with HIV. WEAA0102
- C. Baxter, L. Mansoor, K. Mngadi, N. Ngcobo, N. Yende-Zuma, T. Gengiah, Q. Abdool Karim, **S. Abdool Karim**. Expanding the contraceptive method mix for women at high-risk of HIV: experiences from the CAPRISA 008 Tenofovir Gel Implementation trial. TUPEE556
- N. Ngandu, J. Carlson, D. Chopera, N. Ndabambi, S. Goodier, N. Garrett, N. Samsunder, Q. Abdool Karim, **S. Abdool Karim**, C. Williamson. Selection of HIV-1 variants with higher transmission potential by 1% tenofovir gel microbicide. TUPDA0101
- L. Liebenberg, L.R. McKinnon, K. Leask, A. Rositch, N. Garrett, N. Samsunder, A. Kharsany, A. Grobler, A. Singh, J.-A. Passmore, **S.S. Abdool Karim**, Q. Abdool Karim. The mechanisms and role of HPV in enhancing HIV transmission in women in South Africa
- L.E. Mansoor, Q. Abdool Karim, K.T. Mngadi, C. Montague, N. Yende-Zuma, H. Dawood, T.N. Gengiah, N. Samsunder, C. Baxter, J.L. Schwartz, G.F. Doncel, F. Ntombela, A. Grobler, **S.S. Abdool Karim**. Good adherence in trial of topical pre-exposure prophylaxis integrated into family planning services. FRAE0102

2015

Victor Daitz Foundation presentation, 18 February 2015

- **Abdool Karim SS**. CAPRISA: Research for impact on the global HIV epidemic

CROI 2015, Boston, Massachusetts, 24-26 February 2015

- **Abdool Karim SS**. Use of empiric TB treatment for people living with HIV HIV/TB Research Meeting

University of KwaZulu-Natal, Research Strategy Group Meeting, 7 May 2014

- **Abdool Karim SS**. Research productivity rewards: Thoughts on the journal article criterion

KZNDOH CCMT Symposium, 7 May 2015

- **Abdool Karim SS**. AIDS in South Africa: Prospects and challenges for KwaZulu-Natal

NIH-MRC IPPCR Course, Cape Town, South Africa, 11 May 2015

- **Abdool Karim SS**. Clinical and translational research in practice

FHI360 meeting, North Carolina, USA 18 May 2015

- **Abdool Karim SS**. HIV/AIDS in South Africa: Opportunities for research collaborations with CAPRISA

Ragon Institute Scientific Advisory Board Meeting, Boston, USA, 19 May 2015

- **Abdool Karim SS**. Clinical trial designs to expedite proof-of-concept and efficacy estimation

KwaZulu Natal Doctors Healthcare Coalition (KZNDHC) Healthcare Institute Conference, 6 June 2015

- **Abdool Karim SS**. The Global HIV epidemic: Progress, Prospects and challenges

SA AIDS Conference - Symposium: From Results to Roll-out – Accelerating Access of Biomedical Products after Clinical Trial Results, Durban, South Africa, -7-10 June 2015

- **Abdool Karim SS**. Advances in biomedical prevention research: Preparing for Success

Launch of the UNAIDS-Lancet Commission Report, London, UK, 25 June 2015

- **Abdool Karim SS.** Defeating AIDS: Advancing global health

HIV Center Strategic Advisory Committee Meeting, 2 July 2015

- **Abdool Karim SS.** The Global HIV Epidemic: Prospects and Challenges

8th IAS Conference on HIV Pathogenesis, Treatment & Prevention, Vancouver, Canada, 15 July 2015

- **Abdool Karim SS.** Clinical trials in young women Clinical Trial Literacy among Vulnerable Populations

Lifeline AGM, Kingspark Growthpoint Stadium, Durban, South Africa, 5 August 2015

- **Abdool Karim SS.** The HIV epidemic – an update.

PrEP meeting, Johannesburg, South Africa, 13 August 2015

- **Abdool Karim SS.** Biological plausibility for PREP use in women

Faculty Day, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa, 19 August 2015

- **Abdool Karim SS.** Partnering for research success: Lessons from CAPRISA

Institute for Human Virology Meeting, Boston, USA, 9 September 2015

- **Abdool Karim SS.** Advancing Global Health: Lessons from the response to the HIV epidemic

Gilead Sciences Lecture, California, USA, 23 September 2015

- **Abdool Karim SS.** Young women & HIV in South Africa: Risks, vulnerability and prevention strategies

Bernard Pimstone Lecture, University of Cape Town, Cape Town, South Africa, 1 October 2015

- **Abdool Karim SS.** Young women & HIV in South Africa: Risks, vulnerability and prevention strategies

2nd meeting of the Organising Committee of the 5th Eastern Europe and Central Asia HIV/AIDS Conference, Moscow, Russia, October 2016

- **Abdool Karim SS.** HIV prevention: Prospects and challenges

2014

Animal and Human Vaccine Development in South Africa: University of Pretoria, 30 January 2014

- **Abdool Karim SS.** Microbicides: State of the field & next challenges

CROI 2014, Boston, Massachusetts at the Hynes Convention Center, 3-6 March

- Garrett NJ, Werner L, Naicker N, Mthembu T, Naranbhai V, Sibeko S, Samsunder N, Williamson C, Abdool Karim Q, **Abdool Karim S.** Does Tenofovir Gel Alter HIV Disease Progression in CAPRISA 004 Trial Seroconvertors?
- Garrett NJ, Werner L, Misana K, McKinnon L, van Loggerenberg F, Ndung'u T, Gray C, Morris L, Williamson C, **Abdool Karim S.** Rapid Disease Progression in HIV-1 Subtype C Infected South African Women
- Redd A, Mullis C, Sheward D, Williamson C, Werner L, Garrett N, Porcella S, Abdool Karim Q, Quinn T, **Abdool Karim S.** TRAPS Study Team. Limited HIV-1 Superinfection in Seroconvertors from the CAPRISA 004 Microbicide Trial.

The John Ring La Montagne Memorial Lecture, NIAID, NIH - 13 March 2014

- **Abdool Karim SS.** Envisioning "The End of AIDS": Challenges and Prospects

Gilead Sciences, California, 14 March 2014

- **Abdool Karim SS.** Preventing HIV: CAPRISA's microbicide & vaccine research

HIV Congress 2014, Taj Lands End Hotel, Mumbai, India, March 2014

- **Abdool Karim SS.** New WHO recommendations and its impact on resource limited countries

16th ICID, Cape Town, 3 April 2014

- **Abdool Karim SS.** Antiretrovirals for HIV prevention: new hope and opportunity

Treatment as Prevention in Africa: Botswana April 30 – May 3, 2014

- **Abdool Karim SS.** Microbicides: State of the field & next challenges

Gates Foundation Meeting, New York, 3 June 2014

- **Abdool Karim SS.** Genital inflammation: a significant sub-clinical risk mechanism for HIV acquisition in young women in SA

BIA Spring meeting, 13th June 2014, SOAS, London

- **Abdool Karim SS.** Integrating HIV and TB treatment: Challenges and Opportunities

20th International AIDS Conference, 21-25 July, 2014 Melbourne, Australia

- **Abdool Karim SS.** State of the art: Epidemiology and access

SAMA Conference 2014: Healthcare in South Africa and the millennium development goals: yesterday, today & tomorrow 29-31 August 2014

- **Abdool Karim SS.** Health in South Africa: changes and challenges since 2009

16th Annual International Meeting of the Institute of Human Virology September 14, 2014

- **Abdool Karim SS.** The Global HIV Epidemic: Prospects and Challenges

PATH IX meeting, 19 September 2014, Sydney, Australia

- **Abdool Karim SS.** Antiretrovirals for HIV prevention

Southern African HIV Clinicians Society Conference 24 – 27 September 2014, Cape Town

- **Abdool Karim SS.** The HIV Epidemic: Progress & Challenges
- **Abdool Karim SS.** Is HIV incidence going down?

HIV Prevention Workshop, 24 October 2014, Hermanus, South Africa

- **Abdool Karim SS.** The HIV epidemic: Past, Present & Future...

HIV Research for Prevention (HIV R4P), 28-31 October, Cape Town, South Africa

- Wibmer CK, Sheward DJ, Bhiman JN, Ndabambi N, Elliot DH, Rouelle J, Smira A, **Abdool Karim SS**, Robinson JE, Morris L, Williamson C, Moore PL. Viral Escape Pathways from Broadly Neutralising Antibodies Targeting the HIV Envelope Cleavage Site Enhance MPER Mediated Neutralisation. [Oral presentation Abstract number: OA06.05]
- Kløverpris HN, Noorbhai A, Kuhn W, Yadon M, Ramsuran D, Nhamoyebonde S, Kasprovicz V, Walker B, Ndung'u T, Goulder P, **Abdool Karim S**, Mjösberg J, Leslie A. Innate Lymphoid Cells are Depleted in HIV Infection [Oral presentation Abstract number: OA04.02]
- Bhiman JN, Doria-Rose NA, Wibmer CK, Sheward DJ, Williamson C, **Abdool Karim SS**, Kwong PD, Mascola JR, Morris L, Moore PL. Maturation of Broadly Neutralizing V1V2 directed Antibodies in the Context of Autologous Viral Escape. [Oral presentation Abstract number: OA12.01]
- Richardson SI, Gray E, Mkhize N, Sheward D, Lambson B, Wibmer K, Masson L, Werner L, Garrett N, Passmore J-A, **Abdool Karim S**, Williamson C, Moore P, Morris L. The Sequence of the $\alpha 4\beta 7$ -binding Motif on Gp120 of Transmitted/Founder Viruses Contributes to the Dependence on the Integrin for HIV Infection. [Oral presentation Abstract number: OA21.02]
- Mkhize NN, Madiga M, Durgiah R, Gray ES, Moore PL, Sibeko S, **Abdool Karim S**, Morris L, CAPRISA Acute Infection Study Team. The Impact of Antiretroviral Treatment on HIV-1-Specific Broadly Neutralizing Antibody Responses. [Oral presentation Abstract number: OA30.03]
- Doria-Rose NA, Roark RS, Moore P, Ernandes MJ, Bhiman JN, Schramm CA, McKee K, O'Dell S, Louder M, **Abdool Karim SS**, Shapiro L, Morris, Mascola JR. Variable Dependence on Glycan Recognition within a Lineage of V1V2-directed HIV Neutralizing Antibodies. [Poster discussion Abstract number: PD05.02]

- Gengiah TN, Werner L, Abdool Karim Q, Salim S. **Abdool Karim SS**. Tenofovir Gel Use in Women at High Risk of HIV Infection: A Retrospective Analysis of the Sex Worker Sub-group within the CAPRISA 004 Cohort. [Poster Abstract number: P13.05]
- Scheepers C, Naicker D, Schramm C, Sheng Z, Ismail A, **Abdool Karim SS**, Lambson B. Strain Specific Anti-HIV Antibody Evolution during Acute Infection and Viral Escape. [Poster Abstract number: P34.08]
- Baxter C, Ngcapu S, Blackard JT, Powell EA, Penton PK, Abdool Karim Q, **Abdool Karim SS**. Impact of Tenofovir 1% Gel on Hepatitis B Virus Resistance in CAPRISA 004. [Poster Abstract number: P38.02]
- Archary D, Liebenberg LJ, Werner L, Tulsi S, Majola N, Naicker N, Dlamini S, Samsunder N, **Abdool Karim SS**, Passmore J-AS, Morris L, Garrett N. Softcup Compared to Cervicovaginal Lavage Sampling: Determining Total and HIVspecific IgGs in the Female Genital Tract – A Randomized Study. [Poster Abstract number: P40.03]
- Liebenberg LJ, Garrett N, Werner L, Majola N, Naicker N, Samsunder N, Dlamini S, Passmore J-AS, **Abdool Karim SS**, Archary D. A Randomized Study Comparing Softcup and Cervicovaginal Lavage Sampling to Measure Genital Cytokine Concentrations in HIV infected Women. [Poster Abstract number: P40.17]
- Arnold K, BurgenerA, Birse K, DunphyL, Shahabi K, Abou M, Kwatampora J, Nyanga B, Kimani J, Liebenberg L, Masson L, **Abdool Karim SS**, Passmore7 J-AS, Lauffenburger DA, Kaul R, McKinnon LR. Mucosal Proteomic Profiles Associated with Female Genital Tract Inflammation. [Poster Abstract number: P40.19]
- Ngcapu S, Meiring T, Masson L, Werner L, Liebenberg L, Garrett N, Mlisana K, Williamson C, Abdool Karim Q, **Abdool Karim S**, Passmore J-AS. Presence of Male Partner Semen Influences the Inflammatory and Innate Cytokine Environment in the Female Genital Tract. [Poster Abstract number: P40.21]

Institute of Infectious Disease & Molecular Medicine (IDM) Ten-Year Anniversary Symposium, 3 November 2014, Cape Town South Africa

- **Abdool Karim SS**. *The HIV Epidemic: Progress & Challenges*

Commonwealth Science Conference, 25-28 November 2014, Bangalore India

- **Abdool Karim SS**. HIV in young women in Africa: Imperatives for prevention science

African Society for Laboratory Medicine Conference, 30 November – 4 December 2014, Cape Town, South Africa

- **Abdool Karim SS**. Laboratory Science: Sanctuary of Scientific and Clinical Research Discovery

2013

FACTS Meeting, 4 February 2013

- **Abdool Karim SS**. How South African science helped the world respond to AIDS: South African scientific breakthroughs

Keystone, Colorado, 10-15 February 2013

- Chopera D, Cotton L, Zawaira A, Mann J, Ngandu N, Ntale R, Carlson J, Mlisana K, Woodman Z, Rosa D, Martin E, Miura T, Pereyra F, Walker B, Gray C, Martin D, Ndung'u T, Brockman M, **Abdool Karim S**, Brumme Z, Williamson C. Intersubtype differences in the effect of a rare p24 Gag mutation on HIV-1 replicative fitness

NHLS Research Summit, 21-22 February 2013

- **Abdool Karim SS**. Enabling research: enriching health through research

KZN specialist Network, 27 February 2013

- **Abdool Karim SS**. The search for an AIDS vaccine and cure: Prospects and Challenges

CROI 2013, Atlanta, USA, March 3-6, 2013

- Sobieszczyk ME, Werner L, Garrett N, Mlisana K, Feinstein A, Naicker N, Gray C, Passmore J-A, Williamson C, **Abdool Karim S** and the CAPRISA 002 Acute Infection Study Team. Prevalence and Predictors of Metabolic Abnormalities and Metabolic Syndrome in South African Women with Acute and Early HIV-1 Subtype C Infection.
- Chopera D, Mann J, Martin E, Ndabambi N, Naranbhai V, **Abdool-Karim S**, Brumme Z, Ndung'u T, Brockman M, Williamson C and the CAPRISA 004 study team. No impact of 1% Tenofovir Gel on HIV-1 Gag-Protease or Nef Function in Break-through Viruses from the CAPRISA 004 Trial

South African HIV Clinicians Society CME - 18 June

- **Abdool Karim SS**. 30 years since the discovery of HIV: remaining challenges and future science

6th SA AIDS Conference ICC Durban, South Africa 18 – 21 June 2013

- **Abdool Karim S**. Building on success: The role of South African science in the AIDS response [Plenary]
- **Abdool Karim S**. The clinical trials landscape against a South African backdrop. Symposium: Linking HIV prevention research in South Africa to the realities of women's lives
- Mngadi K, Maarschalk SN, Grobler A, Mansoor LE, Frohlich J, Madlala B, Ngcobo N, **Abdool Karim SS**, Abdool Karim Q. Adherence to the use of microbicides and partner disclosure.
- Shey M, Maharaj N, Liebenberg L, Archary D, Ngcapu S, Samsunder N, Garrett N, Abdool-Karim Q, Abdool-Karim S, Passmore J-A. Role of inflammatory cytokines and TLR ligands in modulating genital tract-derived dendritic cell activation
- Naicker N, Werner L, van Loggerenberg F, Mlisana K, Garrett N, Kharsany A, **Abdool Karim S**. Predictors of HIV Acquisition in High Risk Women in Durban, South Africa.
- Thebus R, Moore P, Gray E, Werner L, Bandawe G, Ngandu N, Mlisana K, **Abdool-Karim SS**, Morris L, Williamson C for the CAPRISA Acute Infection Study Team. Broadly cross-neutralizing antibodies are associated with changes in V1V2 variable loop length
- Tomita A, van Loggerenberg F, Werner L, Mpanza L, Mlisana K, Garrett N, **Abdool-Karim S**. Impact of Antiretroviral Therapy on Quality of Life among South African Women in the CAPRISA 002 Acute Infection study
- Archary D, Werner L, Yates N, **Abdool-Karim S**, Abdool-Karim Q, Passmore J-A, Morris L, Tomaras G. HIV-1 specific binding IgGs in the female genital tract correlate with systemic IgGs and sexually transmitted infections in the CAPRISA 004 Cohort.
- Shey M, Maharaj N, Liebenberg L, Archary D, Ngcapu S, Samsunder N, Garrett N, Abdool-Karim Q, **Abdool-Karim S**, Passmore J-A. Role of inflammatory cytokines and TLR ligands in modulating genital tract-derived dendritic cell activation
- Shey M, Maharaj N, Liebenberg L, Archary D, Ngcapu S, Samsunder N, Garrett N, Abdool-Karim Q, **Abdool-Karim S**, Passmore J-A. Cervical Tissue Explant Model to Study the Role of Inflammatory Cytokines and TLR Agonists on Dendritic Cell Migration and Activation

7th IAS Conference on HIV Pathogenesis and Treatment, 30 June– 3 July 2013

- Naidoo K, Abdool Karim Q, Bhushan A, Naidoo K, Yende-Zuma Y, Mchunu PK, Frohlich J, Karim F, Upfold M, Kocheleff P, **Abdool Karim SS**. High rates of unmasking tuberculosis in patients accessing HAART in rural South Africa: implications for HIV and TB treatment programs Abstract no. TUPDB0101
- Shey MS, Maharaj NR, Liebenberg LJ, Archary D, Ngcapu S, Samsunder N, Garrett N, Abdool-Karim Q, **Abdool-Karim S**, Passmore J-A. Role of inflammatory cytokines and TLR ligands in modulating genital tract-derived dendritic cell activation [Abstract TUPE228]
- Reddy K, Ooms M, Mlisana K, **Abdool Karim S**, Simon V, Ndung'u T, CAPRISA Acute Infection Team. Association of APOBEC3G genetic variants with HIV-1vif sequence variation and impact on HIV-1 pathogenesis [MOPDA0103]

Preparing for success: Social marketing and ARV-based prevention - September 2013 Think Tank

- **Abdool Karim S**. ARV-based prevention

AIDS Vaccine 2013: Progress, Partnership, and Preservation. Barcelona, 7-10 October 2013

- Bhiman JN, Doria-Rose N, Moore PL, Nonyane M, **Abdool Karim SS**, Kwong PD, Mascola JR, Morris L. Interplay between broadly cross-neutralizing V2 monoclonal antibodies and autologous viral evolution. [Oral abstract: OA05.03]
- Richardson SI, Mkhize N, **Abdool Karim SS**, Gray E, Morris L. Role of integrin $\alpha 4\beta 7$ in HIV transmission and pathogenesis. [Oral abstract: OA07.02]
- Doria-Rose NA, Moore P, Staupe R, Bhiman J, Ernandes M, Georgiev I, Bailer R, Louder M, O'Dell S, McKee K, Crooks E, Schmidt S, **Abdool Karim S**, Gorman J, Schramm C, Longo N, Pancera M, Rudicell R, Yang Y, Zhang Z, Zhu J, Binley J, Shapiro L, Kwong P, Morris L, Mascola J. A family of broad and highly potent V1V2-directed HIV-1 neutralizing antibodies with long CDRH3s from a South African seroconverter. [Abstract: P03.20]
- Schramm C, Doria-Rose NA, Gorman J, Moore PL, Staupe RP, Zhang Z, Yang Y, Bhiman J, Georgiev I, Longo NL, Pancera M, Mullikin JC, **Abdool Karim S**, Morris L, Kwong PD, Mascola JR, Shapiro L. Long CDR H3 of a broadly-neutralizing antibody is present at recombination. [Abstract: P03.38]
- Wimber CK, Bhiman JN, Gray ES, Tumba NL, **Abdool Karim SS**, Morris L, Moore PL. Escape from HIV-1 neutralising antibodies drives an increase in plasma neutralization breadth through recognition of multiple epitopes and immunotypes. [Abstract: P03.52]
- Chopera DR, Mann J, Mwimanzi P, Omarjee S, Kuang X, Ndabambi N, Goodier S, Martin E, Naranbhai V, **Abdool Karim SS**, Abdool Karim Q, Brumme Z, Ndung'u T, Williamson C, Brockman M. No evidence for selection of HIV-1 with enhanced Gag-Pro or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial. [Abstract: P05.19]
- Reddy K, Winkler C, Werner L, Mlisana K, **Abdool Karim SS**, Ndung'u T. APOBEC3G and -3F induced cytidine deamination and association with viral control in a population with high frequency of the APOBEC3G H186R variant. [Abstract: P0.13]
- Lambson B, Mitchell C, Gray E, **Abdool Karim SS**, Morris L. Copy number variation of the immunoglobulin heavy chain variable gene 1-69 in HIV-1 infected individuals. [Abstract: P06.14]
- Archary D, Seaton K, Yates NL, Werner L, Bergin PJ, Liebenberg LJ, Samsunder N, Garrett N, Abdool Karim Q, **Abdool Karim SS**, Liao H, Passmore J-A, Morris L, Tomaras GD. HIV-1 specific binding antibody titres in blood predict detection in the female genital tract in women who become infected in the CAPRISA 004 microbicide. [Abstract: P08.02]
- Mkhize NN, Garrett N, Archary D, Hermanus T, Majola N, Samsunder N, Williamson C, Shattock R, Passmore J-A, **Abdool Karim SS**, Morris L. Potent neutralizing antibodies can be recovered from genital tract using the non-invasive Softcup® technique. [Abstract: P08.03]
- Barnabas SL, Mkhize NN, Masson L, Werner L, Archary D, Mlisana K, Williamson C, Abdool Karim S, Morris L. Levels of HIV gp120-specific binding antibodies in the female genital tract are correlated with genital inflammation. [Abstract: P08.06]
- Ngcapu S, Masson L, Sibeko S, Shey M, Samsunder, **Abdool Karim SS**, Abdool Karim Q, Passmore J. Hormonal contraception use and HIV-1 risk in the context of prevention research: DMPA and NET-EN dampen immunity in the female genital tract. [Abstract: P08.17]

HASA Quality Improvement Summit Cape Town, 28-30 Oct 2013

- Ngcobo N, Mansoor LE, Mkhize S, Matlala R, Montague C, Tshabalala M, **Abdool Karim S**, Abdool Karim Q. Enhancing Access to Sexual Reproductive Health Services in a Public Sector Primary Care Clinic in Rural KwaZulu-Natal, using a Quality Improvement Intervention
- Mvandaba N, Mansoor LE, Tshabalala M, Mngadi K, **Abdool Karim SS**, Abdool-Karim Q. Increasing Cervical Cancer Screening in a Family Planning Clinic using a Quality Improvement Approach

HVTN Conference, Cape Town, South Africa, 25 October

- **Abdool Karim S**. The End of AIDS: Challenges & Prospects. Closing Plenary

Ragon-CAPRISA-HPP HIV Prevention Workshop, Drakensberg, KwaZulu-Natal, 12-14 November 2013

- **Abdool Karim S**. Microbicides: State of the field & next challenges
- **Abdool Karim S**. Recent developments in HIV prevention: Prospects & challenges for ending AIDS

2013 Biomedical HIV Prevention Forum, Abuja, Nigeria, 18th - 20th November, 2013

- **Abdool Karim S.** Antiretrovirals for HIV prevention: new hope and opportunity. Distinguished Scholar Award Lecture

2012

USAID Microbicide Research & Development Cooperating Agencies' Meeting, FHI 360 Conference Center, Washington, DC, February 7-8, 2012

- **Abdool Karim SS.** Microbicide research at CAPRISA

Howard Hughes Medical Institute, 22 February 2012

- **Abdool Karim SS.** New hope for HIV prevention...

Harvard Global Health Institute, 2 March 2012

- **Abdool Karim SS.** New hope for HIV prevention...

Harvard CFAR Symposium, Boston, 1 March 2012,

- **Abdool Karim SS.** State of the art: ART and Prevention: local and systemic PrEP and treatment for prevention
- **Abdool Karim SS.** Adherence, drug exposure & genital tract inflammation impact on HIV prevention: Insights from CAPRISA 004

CROI 2012, Seattle, USA, March 5-8, 2012

- **Abdool Karim Q, Abdool Karim SS.** Partnering for scientific innovation in HIV prevention and treatment. N'Galy-Mann Lecture. Invited Oral
- Johnson JA, Wei X, Morris L, **Abdool Karim SS**, Sibeko S, Abdool Karim Q, Kashuba ADM, Passmore J, Hunt G, Heneine W. Sensitive Tenofovir Resistance Screening of HIV-1 from the Genital Tract of Women with Breakthrough Infections in the CAPRISA 004 Tenofovir Gel Trial
- Naranbhai V, Altfield M, Abdool Karim Q, **Abdool Karim S**, Carr W, CAPRISA004 TRAPS Team. Natural Killer Cells Targeted Against Autologous in vitro HIV-infected Cells Correlate with HIV Protection in South African Women
- Fischer W, Hunt G, Sibeko S, Naranbhai V, Abdool Karim Q, **Abdool Karim S**, Morris L, Korber B. Tenofovir Resistance Mutation Frequencies Assessed by Deep Pyrosequencing of Plasma Virus from Breakthrough HIV Infections: CAPRISA 004 Microbicide Trial
- Mkhize N, Gray E, Moore P, Sibeko S, **Abdool Karim S**, Passmore J-A, Morris L. Broadly Neutralizing Plasma Immunoglobulin G Antibodies Transduce to the Female Genital Tract in HIV Infection
- Moore P, Gray E, Wibmer C, Bhiman J, Hermanus T, Madiga M, Nonyane M, **Abdool Karim S**, Williamson C, Morris L. Evolution of Broadly Neutralizing Antibodies during HIV-1 Infection

Microbicides 2012, Sydney, Australia, 15-18 April 2012

- **Abdool Karim SS.** CAPRISA 004 two years on: What were the lessons, what are the implications? Opening plenary
- **Abdool Karim SS.** Biological mechanisms and efficacy. In Symposium Making sense of the PrEP trial results.
- Baxter C, Yende-Zuma N, Tshabalala P, Mansoor L, Abdool Karim Q, **Abdool Karim SS.** 1% Tenofovir gel use in chronic hepatitis B virus carriers: Results from the CAPRISA 004 trial.
- Buthelezi TJ, Mlangeni MC, Samsunder N, Yende N, Kharsany ABM, Abdool Karim Q, **Abdool Karim SS.** Baseline prevalence of Human Papillomavirus Infection in Women participating in the CAPRISA 004 Tenofovir gel trial in KwaZulu-Natal, South Africa.

Alan Berkman Lecture Columbia University, New York, 25 April 2012

- **Abdool Karim SS.** New hope for HIV prevention...

6th International workshop on HIV treatment, pathogenesis and prevention research in resource-limited settings, Mombasa, Kenya, 8 May 2012

- **Abdool Karim SS.** Antiretrovirals for HIV prevention: Topical PrEP, Systemic PrEP and Treatment for Prevention

International Workshop on HLA and Immunogenetics. Liverpool, UK May 2012.

- Naranbhai V, de-Assis Rosa D, Qi Y, Altfield M, Werner L, Ndung'u T, **Abdool Karim S**,

Gram CM, Carrington M. KIR haplotype BB is associated with lower HIV-1 viral loads and higher CD4+ T-cell counts in the first two years after HIV-acquisition in South African women: early findings from the CAPRISA Acute Infection Team.

XIX International AIDS Conference, Washington DC, USA, 22-27 July 2012

- Bearnot B, Werner L, Kharsany ABM, **Abdool Karim S**, Frohlich JA, Abdool Karim Q. Impact of antiretroviral therapy initiation on HIV-positive status disclosure in rural South Africa
- MacQueen K, Albert L, Soccop S, van Loggerenberg F, Majola N, Kashuba A, **Abdool Karim S**, Abdool Karim Q.

AIDS Vaccine 2012, Boston, USA, September 9-12, 2012

- **Abdool Karim SS**. Current state of microbicides for HIV prevention
- Riou C, Mlisana K, Koup R, Roederer M, **Abdool Karim S**, de Bruyn G, Williamson C, Gray CM, Burgers WA, on behalf of the CAPRISA 002 Study Team. Increased differentiation coincides with decreased polyfunctionality for HIV but not CMV-specific CD8+ T cell responses.
- Ntale R, Chopera DR, Ngandu NK, Abrahams MR, Assis de Rosa D, Mlotshwa M, Werner L, Woodman Z, Mlisana K, **Abdool Karim S**, Gray CM, Williamson C, the CAPRISA 002 Study Team. Beneficial HLA-mediated viral polymorphisms on the transmitted virus additively influence disease progression in HIV-1 subtype C infection
- Madiga M, Mkhize NN, Moore PL, Gray ES, Sibeko S, **Abdool Karim S**, Morris L, for the CAPRISA Acute Infection Study Team. The impact of antiretroviral treatment on HIV-1-specific broadly neutralizing antibody responses.
- Tumba NL, Gray ES, Lambson BE, **Abdool-Karim SS**, Liao H-X, Haynes BF, Alam M, Morris L. Affinity maturation pathway of an anti-MPER neutralizing mAb - CAP206-CH12
- Burgers WA, Muller TL, Kiravu A, Naranbhai V, Sibeko S, Werner L, Abdool Karim Q and Abdool Karim SS. Infrequent, low magnitude HIV-specific T cell responses in HIV-uninfected participants in the 1% Tenofovir microbicide gel trial (CAPRISA004). AIDS Vaccine in Boston, September 2012

SANAC Plenary Meeting, 4 October 2012

- **Abdool Karim SS**. How South African science helped the world respond to AIDS: South African scientific breakthroughs

IDWeek 2012 (TM), San Diego, CA, October 17- 21, 2012

- Pellett Madan R, Abdool Karim et al. Activity in Female Genital Tract Secretions as a Biomarker of HIV Progression and Acquisition Risk

Mucosal Immunology Conference, Ubizane, South Africa, 14-16 November 2012

- **Abdool Karim SS**. CAPRISA 004 two years on: Key obstacles, lessons & priority research areas for a higher efficacy microbicide

SA HIV Clinicians Society Conference, Cape Town, 26-28 November 2012

- **Abdool Karim S** A history of HIV research in South Africa: What's next? (Plenary)

2011

Joint Civil Society and MTN CWG meeting, 7 October, Cape Town, South Africa

- **SS Abdool Karim**. What's happening with tenofovir gel? Access and product availability
- **SS Abdool Karim**. Setting the stage: year in review and looking ahead

IRMA and AVAC presentation, 27 September 2011, International teleconference

- **SS Abdool Karim**. Does Africa need a rectal microbicide?

Embury College, 7 September 2011, Durban, South Africa

- **SS Abdool Karim**. HIV and women in South Africa: New hope in antiretroviral microbicides to prevent HIV

Parliamentary Portfolio Committee Meeting, July, Durban, South Africa

- **SS Abdool Karim**. HIV and women in South Africa: New hope in antiretroviral microbicides

to prevent HIV

National Health Research Summit

- **SS Abdool Karim.** South African research in HIV/AIDS and TB: Strengths, weaknesses, opportunities and threats

6th International Workshop on HIV Transmission, 5-6 July 2011, Rome

- **SS Abdool Karim.** Tenofovir gel and HIV transmission: insights from the CAPRISA 004 trial

5th SA AIDS Conference, 8 June 2011, Durban, South Africa

- **SS Abdool Karim.** Future directions in ARV-based prevention: Research agendas, timely opportunities and data gaps
- **SS Abdool Karim.** HIV prevention: the latest biomedical tools
- **SS Abdool Karim.** What level of research evidence is needed for policy and practice?

Aaron Diamond AIDS Research Center, June 2011, New York

- **SS Abdool Karim.** Four key lessons from CAPRISA 004: Implications for future PrEP research

9th Conference on Research Advances in Clinical Research, ANRS, Paris, 5-6 May 2011

- **SS Abdool Karim.** Combination HIV prevention: New opportunities and technologies

Sub-Saharan Africa CFAR Conference, Kampala, 26 May 2011

- **SS Abdool Karim.** HIV and women in Africa: New hope in antiretroviral microbicides to prevent HIV

Keystone Symposia X8, 21 March 2011, Whistler, British Columbia

- **SS Abdool Karim.** Update on microbicide and pre-exposure prophylaxis trials

HIV Center, New York, 24 March 2011

- **SS Abdool Karim.** Microbicides: A new hope for HIV prevention

Merck HIV Chemoprevention Scientific Input Engagement Meeting, 14 March 2011

- **SS Abdool Karim.** Four key lessons from CAPRISA 004: Implications for future PrEP research

ARV-based prevention: a community and research forum on recent results and what happens next, 1 March 2011, Boston

- **SS Abdool Karim.** CAPRISA 004 trial update and follow-up steps

EMBO course, Stellenbosch University, 1 February 2011, Stellenbosch, South Africa

- **SS Abdool Karim.** Microbicides: A new hope for HIV prevention

MTN Meeting on next steps for ARV-based prevention, 17 January 2011, Johannesburg

- **SS Abdool Karim.** Tenofovir gel: Preparing for implementation in the health service: The CAPRISA 008 & 009 trials

2010

HIV Workshop, Durban, South Africa, 15 November 2010

- **SS Abdool Karim.** Topical antiretrovirals for HIV prevention

Microscopy Society of Southern Africa, November 2010

- Naicker T, Sibeko S, Kharsany ABM, Naranbhai V and **Abdool Karim SS** (2010). HIV-1 passage through the human cervico-vaginal mucosa. 40:13.

HIV Clinician's Society Meeting, Durban, South Africa, 15 September 2010

- **SS Abdool Karim.** Tenofovir gel for HIV and HSV-2 prevention: challenges to implementation

SANAC Workshop, Glenburn Lodge, 23 August 2010

- **SS Abdool Karim.** HIV Prevention Research in South Africa

WHO / UNAIDS Meeting on Next Steps for tenofovir gel, Johannesburg, August 2010

- **SS Abdool Karim.** CAPRISA 004 Effectiveness & safety of vaginal microbicide 1% tenofovir gel for prevention of HIV infection in women
- **SS Abdool Karim.** Impact of tenofovir gel on Herpes Simplex Virus Type-2 infection

SANAC Workshop, Glenburn Lodge, 23 August 2010

- **SS Abdool Karim.** HIV Prevention Research in South Africa

XVIII AIDS Conference Vienna, Austria, 20 July 2010

- **SS. Abdool Karim, Q Abdool Karim, JA Frohlich, A Grobler, ABM Kharsany, LE Mansoor, C Baxter, S Sibeko, KP Mlisana, L Mtongana, Z Omar, S Maarschalk, N Arulappan, M Mlotshwa, D Taylor** on behalf of the CAPRISA 004 Trial Group. Impact of 1% Tenofovir Gel on Resistance, Pregnancy and Hepatitis B
- **SS Abdool Karim.** Overview of the HIV epidemic in sub-Saharan Africa
- **ADM Kashuba, SS Abdool Karim, E Kraft, N White, S Sibeko, L Werner, L Mansoor, T Gengiah, S Sidhoo, V Naranbhai, Q Abdool Karim** on behalf of the CAPRISA 004 Team. Do systemic and genital tract tenofovir concentrations predict HIV seroconversion in the CAPRISA 004 tenofovir gel trial?
- **BG Williams, SS. Abdool Karim, EG, Q Abdool Karim.** Potential impact of tenofovir gel on the HIV epidemic in South Africa
- **SS Abdool Karim.** Current and planned HIV prevention trials: microbicides and PrEP

Microbicides 2010 Conference, Pittsburg, May 23, 2010

- **SS. Abdool Karim.** Does Africa need a rectal microbicide?
- **SS. Abdool Karim.** HIV Prevention Research: The Global Picture.
- **SS. Abdool Karim.** Current and planned HIV prevention trials: microbicides and PrEP
- **Gengiah T, Mansoor L, Naidoo A, Upfold M, Naidoo K, Maharaj B, Moodley B, Abdool Karim Q, Abdool Karim S** on behalf of the CAPRISA 004 Wisebag study team. The 'Wisebag': an innovative strategy for enhancing measurement of microbicide gel use in clinical trials. [Oral Abstract 57]
- **Sibeko S, Baxter C, Yende N, Mthongana L, Abdool Karim Q, Abdool Karim S,** on behalf of the CAPRISA 004 Team. Improving contraceptive uptake and reducing pregnancy rates in a microbicide trial. [Oral Abstract 5]
- **Mansoor L, Abdool Karim Q, Yende N, Abdool Karim SS** on behalf of the CAPRISA 004 study team. Measuring Adherence in the CAPRISA 004 Tenofovir Microbicide Gel Trial. [Poster Abstract 260]
- **Mtongana L, Omar Z, Miya N, Mansoor L, Yende N, Abdool Karim SS, Abdool Karim Q,** on behalf of the CAPRISA 004 Team. Does exclusion of study volunteers for renal, hepatic and bone related safety concerns impact the representativeness of the study population in a tenofovir trial: Experiences of the CAPRISA 004 trial? [Poster Abstract 280]
- **Kharsany A, Abdool Karim Q, Abdool Karim SS, Frohlich JA, Mlisana K, Grobler A, Yende N,** on behalf of the CAPRISA 004 Team. Urban – rural differences in baseline characteristics of CAPRISA 004 trial participants. [Poster Abstract 286]
- **Maarschalk S, Frohlich J, Ntombela F, Mlotshwa M, Abdool Karim SS, Abdool Karim Q,** on behalf of the CAPRISA 004 team. Structured tools for assessing literacy levels and comprehension assessment in the informed consent process: Experiences from a Microbicide trial in rural KwaZulu Natal, South Africa. [Poster Abstract 281]
- **Frohlich J, Maarschalk S, Ntombela F, Abdool Karim Q, Abdool Karim SS,** on behalf of the CAPRISA 004 Recruitment and Retention Team. Innovative strategies in a Phase IIb microbicide trial results in high retention: Experiences from CAPRISA 004. [Poster Abstract 285]

MMCI Annual Meeting, Crystal City Marriot, Arlington, VA, Friday, 19 March 2010

- **SS Abdool Karim.** Plans for communicating the results of CAPRISA 004

World Health Organisation, Geneva Switzerland, 17 February 2010

- **SS Abdool Karim.** The evolution of the HIV epidemic in South Africa.

Mini-symposium: HIV Epidemic in Africa: learning from cohorts, Durban, South Africa 10 March 2010

- **SS Abdool Karim.** Twenty years experience in establishing cohorts for HIV studies: Lessons learnt

2nd National Conference on HIV/AIDS Therapy: Current practice and future options Mumbai, India, 10 January 2010

- **SS Abdool Karim.** Research Agenda for Resource Limited Settings: Lessons Learnt & Directions for the Future

Council on Foreign Relations Global Health Meeting, Cape Town, 21 January 2010

- **SS Abdool Karim.** HIV prevention in South Africa: Is the NSP target of 50% reduction in HIV incidence feasible? A response...

2009

5th IAS Conference on Pathogenesis, Treatment and Prevention Cape Town, South Africa, 19-22 July 2009

- **Abdool Karim S.** Microbicide Trials: Current and Future Strategies
- M.C. Madiga, E. Gray, P. Moore, K. Mlisana, **S. Abdool Karim**, C. Williamson, L. Morris. Development of intra- and inter-subtype cross-neutralizing antibodies in HIV-1 subtype C infection (Abstract MOPEA003)
- K.B. Alexandre, B. Lambson, E. Gray, R. Chikwamba, K. Mlisana, **S. Abdool Karim**, J. McMahon, B. O'keefe, L. Morris. Entry inhibition of HIV-1 subtype C from blood and vaginal mucosa by the lectins griffithsin, cyanovirin-N and scytovirin: potential HIV microbicides (Abstract WEPDC206)
- Naidoo, K. Naidoo, **S. Abdool Karim**, N. Padayatchi, T. Gengiah, A. Singh, M. Khan, N. Yende, M. Murrman, G. Friedland. Impact of integrating TB and HIV care on adherence to anti-TB therapy and antiretroviral therapy, results from the Starting Tuberculosis and Anti-Retroviral Therapy - START study (Abstract WEPED189)

Harvard Initiative for Global Health (HIGH), 22 May 2009

- **Abdool Karim S.** Microbicides: A glimmer of hope for HIV prevention

MTN Annual Meeting, Arlington, Virginia, USA, 21 April 2009

- **Salim Abdool Karim**, Pamina Gorbach, Lisa Maslankowski, Irving Hoffman, Tom Moench, Al Profy, Barbra Richardson on behalf of the HPTN 035 Study Team. HPTN 035: Safety and Effectiveness of the Vaginal Microbicides BufferGel and 0.5% PRO 2000 Gel for the Prevention of HIV Infection in Women

Conference on Retroviruses and Opportunistic Infections Montreal, February 2009

- **Salim S Abdool Karim** on behalf of: Anne Coletti, Barbra Richardson, Gita Ramjee, Irving Hoffman, Michael Chirenje, Taha Taha, Muzala Kapina, Lisa Maslankowski, Estelle Piwowar, Benoit Mâsse, Sharon Hillier, Lydia Soto-Torres and the HPTN 035 Team. Safety and Effectiveness of Vaginal Microbicides BufferGel and PRO 2000 Gel for the Prevention of HIV Infection in Women. Results of the HPTN 035 Trial
- **Salim S. Abdool Karim** on behalf of : Kogieleum Naidoo, Anneke Grobler, Nesri Padayatchi, Andrew Gray, Jacqueline Pienaar, Tanuja Gengiah, Gonasagrie Nair, Sheila Bamber, Aarthi Singh, Munira Khan, Wafaa El-Sadr, Gerald Friedland and Quarraisha Abdool Karim. Addressing challenges in treating TB-HIV co-infected patients. The SAPiT Trial: Starting Antiretroviral therapy at three Points in TB

Highway Hospice Annual General Meeting, Durban South Africa 29 April 2009

- **Salim S. Abdool Karim.** HIV/AIDS and TB in South Africa

Harvard Center for AIDS Research Conference Series, Boston, USA, 22 May 2009

- **Salim S. Abdool Karim.** Challenges in treating TB and HIV
- **Salim S. Abdool Karim.** Challenges in treating HIV-TB co-infection

2008

AIDS Vaccine Initiative (IAVI) Opening of the new AIDS Vaccine Design and Development Laboratory, Brooklyn Army Terminal, New York, 12 November 2008

- **Abdool Karim S.** AIDS pandemic and HIV prevention strategies

UNAIDS Workshop – The future of UNAIDS, Durban, South Africa, 17th November 2008

- **Abdool Karim S.** AIDS Research: Contributions to controlling HIV: Role of UNAIDS in Research

World Health Organization/University of Nanjing Symposium, Scientific, regulatory and public health aspects of microbicide research and development, Nanjing, China, 3-6 November 2008

- **Abdool Karim S.** Research design: Why undertake clinical trials
- **Abdool Karim S.** Microbicide regulation in South Africa
- **Abdool Karim S.** Microbicides and the community

Bio2Biz, Johannesburg, South Africa, 15th September 2008

- **Abdool Karim S.** Clinical development and testing of Tenofovir microbicide gel: A South African biotech initiative

AIDS 2008 Vaccine Meeting, Cape Town, South Africa, 13-15 October 2008

- **Abdool Karim S.** Antiretroviral Prophylaxis: Point of convergence in the scientific agendas for pre- and post-exposure prophylaxis, microbicides & perinatal HIV prevention
- Treurnicht FK, Mlotshwa M, Mlisana K, Woodman Z, Abrahams M-R, Bredell W, Bandawe G, Martin D, **Abdool Karim SS**, Gray C, Williamson C and the CAPRISA 002 Acute Infection Study Team. HIV-1 subtype C superinfection associated with a shift in CTL responses and transient increase in viral load.
- Bandawe G, Martin D, Treurnicht F, Mlisana K, **Abdool Karim S**, Williamson C and the CAPRISA Acute Infection Study team. Positive selection in HIV-1 subtype C gp41 in acute and chronic infection.
- Mlotshwa M, Riou C, van Loggerenberg F, Mlisana K, Williamson C, **Abdool Karim S** and Gray CM and the CAPRISA 002 study team. Rapid evolution of HIV specific T cell responses within the first six months of subtype C infection
- Moore PL, Ranchobe N, Lambson BE, Gray ES, Abrahams M-R, Mlisana K, **Abdool Karim SS**, Williamson C, Morris L, the CAPRISA Acute Infection Study Team and CHAVI. Analysis of Neutralization Escape Suggests Limited Neutralizing Antibody Specificities in Early HIV-1 Subtype C infection.
- Riou C, Burgers WA, Mlotshwa M, de Assis Rosa D, Mlisana K, Koup R, Roederer M, **Abdool Karim SS**, Williamson C, Gray CM and the CAPRISA 002 Study Team. Less Differentiated and more long-lived CD8+ T memory cells during early subtype C HIV-1 infection Correlates with Lower Viral Set Point.
- Lambson BE, Moore PL, Abrahams M-R, Mlisana K, **Abdool Karim SS**, Williamson C and Morris L. Generation of multiple HIV-1 subtype C envelope single-genome amplification (SGA) products from cervico-vaginal lavage samples from the CAPRISA Acute Infection cohort
- Roberts L, Passmore J, Bebell L, Iriogbe I, Williamson C, Mlisana K, Van Loggerenberg F, Abdool Karim Q, **Abdool Karim S**. Elevated inflammatory cytokines in the female genital tract during acute HIV-1 infection correlate with enhanced CD4 and T-cell decline and higher viral load at set point

Center for HIV/AIDS Vaccine Immunology (CHAVI) Clinical Site Meeting, Cape Town, South Africa, 11-12 October 2008

- **Abdool Karim S.** Identifying acute HIV infection: Interim results from CHAVI 001

AIDSXVII Conference, Mexico City, 3-8 August 2008

- **Abdool Karim S.** S including: ART containing vaginal microbicides in the clinical pipeline: status of the studies
- Mlisana K; Feinstein A; Sobieszczek M; Werner L; Williamson C; van Loggerenberg F and **Abdool Karim S.** Clinical features of Acute Subtype C HIV-1 Infection associated with disease progression in South African Women
- Abdool Karim Q, Meyer-Weitz A, Mboyi L, Carrara H, Mahlase G, Frohlich JA, **Abdool Karim**

SS. The influence of AIDS stigma and discrimination and social cohesion on HIV testing and willingness to disclose HIV in rural KwaZulu-Natal, South Africa

- Sobieszczyk M; Mlisana K; Feinstein A; Werner L; Auld S; Williamson C; van Loggerenberg F and **Abdool Karim S.** Metabolic Abnormalities in South African Women Acutely Infected with HIV-1 Subtype C.

Keystone Workshop, Fairmont Banff Springs, Canada, 27 March-01 April 2008

- Burgers WA, Williamson C, Mlisana K, **Abdool Karim S**, Roederer M, Koup R, Gray C and the CAPRISA 002 study team. Function and phenotype of T cell responses in acute HIV-1 subtype C infection
- Mlotshwa M, Riou C, Khoury G, van Loggerenberg F, Mlisana K, Williamson C, **Abdool Karim S** and Gray CM and the CAPRISA 002 study team. IL-2+ CD4+ T cell responses, but not INF-g+ CD8+ T cell responses, predict HIV-1 disease progression in subtype C acutely infected subjects.

3rd International Conference on HIV Treatment Adherence, Jersey City, New Jersey, 17-18 March 2008

- van Loggerenberg F, Murrman M, Naidoo K, **Abdool Karim SS** and Grant A, for the CAPRISA 058 study team. CAPRISA 058: Development of an enhanced adherence support programme (E-ASP) for Highly Active Antiretroviral Therapy (HAART) in Durban, South Africa

Microbides 2008 Conference, New Delhi, India, 25 February 2008

- **Abdool Karim S.** Opportunities & Challenges of Microbicide Research in Africa
- Frohlich JA, Ntombela F, Abdool Karim Q, **Abdool Karim SS** on behalf of the CAPRISA 004 team. Multi-dimensional Approach to Community Preparedness –Experiences. From Rural KwaZulu-Natal, South Africa.
- Kharsany ABM, Frohlich JA, Mlisana KP, **Abdool Karim SS**, Abdool Karim Q on behalf of the CAPRISA 050/051 team . High HIV incidence rates in young women in urban and rural KwaZulu-Natal: Experiences in preparation for the CAPRISA 004 Phase IIb Tenofovir Gel Trial
- Maarschalk SN, Kharsany ABM, Frohlich J, Mlotshwa M, Mbambo S, Ndimande C, Phungula B, Manyoni N, Ngwenya P, Zwane P, Luthuli L, Mkhize Z, Ngobeni P, Abdool Karim Q, **Abdool Karim SS** on behalf of the CAPRISA 004 team. A structured tool for assessing Literacy Levels and Linguistic Preferences in preparation for the informed consent process: Experiences from the CAPRISA 004 Phase IIb Tenofovir Gel Trial
- Baxter C, Frohlich JA, Kharsany ABM, Sibeko S, Maarschalk S, Arulappan N, **Abdool Karim SS**, Abdool Karim Q on behalf of the CAPRISA 004 Team. Contraceptive provision and choices among women participating in the CAPRISA 004 Phase IIb Tenofovir Gel Trial in urban and rural KwaZulu-Natal, South Africa
- Mansoor LE, Abdool Karim Q, Madlala B, MacQueen K, Mlotshwa M, van Loggerenberg F, **Abdool Karim SS** on behalf of the CAPRISA 004 team. Development of Materials and Tools for the Adherence Support Program in CAPRISA 004 Phase IIb Tenofovir Gel Trial

CROI 2008, Boston, United States, 3-7 February 2008

- Chopera DR, Woodman Z, Mlotshwa M, Martin DP, Seighe C, Assis de Rosa D, Mlisana K, **Abdool Karim S**, Gray CM, Williamson C. Transmission of HIV-1 CTL escape variants provides HLA-mismatched recipients with a survival advantage
- Williamson C, Abrahams M, Treurnicht F, Seighe C, Wood N, Passmore J, Bebell L, Mlisana K, Hahn B, **Abdool Karim S.** The Majority HIV-1 Subtype C Infections are a Result a Single HIV-1 Variant Transmission, with Multiple Variant Transmission Associated with Increased Inflammatory Cytokines in Genital Secretions
- Moore PL, Gray ES, Choge IA, Ranchobe N, Mlisana K, **Abdool Karim SS**, Williamson C, Morris L, the CAPRISA 002 study and the CHAVI Consortium. The C3-V4 Region Is A Major Target Of Autologous Neutralizing Antibodies In HIV-1 Subtype C Infection

2007

IOM Committee on Methodological Challenges in HIV Prevention Trials, Washington, United States, 6-7 February 2007

- **Abdool Karim S.** HIV incidence estimation for prevention trials
- **Abdool Karim S.** Phase IIb trial to assess the safety & effectiveness of the vaginal microbicide

1% Tenofovir gel for the prevention of HIV infection in women in South Africa

UN Country Representatives HIV/AIDS Workshop for Southern Africa, Johannesburg, South Africa, 19-21 March 2007

- **Abdool Karim S.** Why is HIV hyper-endemic in South Africa?

HIV Infection and the Central Nervous System: Developed and Resource-Limited Settings, Venice - San Servolo, Italy, 14-16 April 2007

- **Abdool Karim S.** Evolving challenges in treatment implementation in resource poor countries

Biomedical Research Ethics Forum, Durban, South Africa , 11 April 2007

- **Abdool Karim S.** Ethics challenges in testing new interventions for HIV prevention and reproductive health

Centers for Disease Control and Prevention, Atlanta, United States, 1 May 2007

- **Abdool Karim S.** HIV incidence estimation for prevention trials

Royal Society of South Africa, Pietermaritzburg, South Africa, 9 May 2007

- **Abdool Karim S.** HIV/AIDS in South Africa

3rd South African AIDS Conference, Durban, South Africa, 5-8 June 2007

- **Abdool Karim S.** Progress in developing technologies for HIV prevention: HIV vaccines and microbicides
- **Abdool Karim S.** Research design 101: An update on current HIV prevention studies in South Africa
- **Abdool Karim S.** TB and HIV treatment - evolving challenges
- van Loggerenberg F, Mlisana K, Williamson C, Auld SC, Morris L, Gray C, Abdool Karim Q, Grobler A, Barnabas N, Iriogbe I, **Abdool Karim SS**, for the CAPRISA 002 Acute Infection Study Team. HIV incidence rates and challenges in establishing a cohort at high risk of HIV infection in KwaZulu-Natal, South Africa: Experiences of the CAPRISA Acute Infection Study
- Choge I, Gray ES, Moore PL, Mlisana K, **Abdool Karim SS**, Williamson C, Morris L and the CAPRISA 002 study team. Generation of functional HIV-1 subtype C V1/V2 chimeras for use in pseudovirus neutralization assays
- Ranchobe N, Choge IA, Bandawe G, Abrahams M, Gray ES, Woodman Z, Mlisana K, **Abdool Karim SS**, Williamson C, Morris L, Moore PL and the CAPRISA 002 study team. Cloning functional HIV-1 subtype C envelope genes from single viral RNA genomes for the investigation of neutralization escape in HIV-1 subtype C infected individuals
- Leseke N, Gray ES, Moore PL, Decker JM, Mlisana K, Shaw GM, **Abdool Karim SS**, Williamson C, Morris L and the CAPRISA 002 study team. CD4i and Anti-MPER Antibody Responses in Subtype C Acute HIV-1 Infection
- Moore PL, Gray ES, Choge IA, Decker JM, Bibollet-Ruche F, Li H, Leseke N, Treurnicht F, Mlisana K, Shaw GM, **Abdool Karim SS**, Williamson C and Morris L and the CAPRISA 002 study team. Neutralizing antibody responses in acute HIV-1 subtype C infection
- Maarschalk S, Abdool Karim Q; Alsie P; Frohlich J; Werner L; **Abdool Karim S.** Impact of ARVs on positive HIV status disclosure and Anti-Retroviral treatment outcomes in patients in a rural AIDS treatment project in KwaZulu-Natal
- Wood N, Bandawe, G, Mlisana K, **Abdool Karim S**, Williamson C, Seoighe C. Re-evaluating the evidence for a reduced length of the HIV-1 envelope variable loops in acute infection
- Mlotshwa M, Khoury G, van Loggerenberg F, Mlisana K, Williamson C, **Abdool Karim S**, Gray CM and the CAPRISA 002 study team. HIV specific T cell responses at the acute stage of HIV-1 subtype C infection
- Chopera DR, Woodman Z, Mlotshwa M, Hide W, Gray C, Mlisana K, **Abdool Karim S**, Williamson C. Characterisation of CTL escape mutations in gag and nef in early HIV-1 infection.
- Treurnicht FK, Wood N, Woodman ZL, Mlisana K, **Abdool Karim SS**, Seoighe C, Williamson C and the CAPRISA 002 Study Team. Genetic signatures in full-length genomes from acute infection HIV-1 subtype C from KwaZulu Natal, South Africa
- Woodman Z, Nofemele A, Grobler J, Morris L, **Abdool Karim S**, Williamson C. Investigation of the role of HIV-1 Env viral entry efficiency on transmission and disease progression in individuals infected with more than one strain of HIV-1

AIDS Vaccine conference, in Seattle, Washington, USA, 20-23 August 2007

- Moore PL, Choge IA, Gray ES, Ranchobe N, Mlisana K, **Abdool Karim SS**, Williamson C and Morris L and the CAPRISA 002 study team. Role of Anti-V1V2 Antibodies in Autologous Neutralization of Acute HIV-1 Subtype C viruses.

IAVI Board Meeting Southern Africa, 19-22 June 2007

- **Abdool Karim SS**. Overview of clinical trials of HIV/AIDS prevention in Southern Africa

Royal Society of Tropical Medicine & Hygiene Conference, London, UK, 13 September 2007

- **Abdool Karim SS**. Trials and tribulations of TB - HIV co-infection

MTN VOICE study, Community Working Group. 20 October 2007

- **Abdool Karim SS**. What is Pre-Exposure Prophylaxis? (PrEP)

HIV Advisory Board Meeting, Royal Windsor Hotel, Brussels, 27-21 October 2006

- **Abdool Karim SS**. Incidence and prevalence of HIV/AIDS

2006

AIDS Vaccine 2006, Amsterdam, 29 August – 1 September 2006

- Burke D, **Abdool Karim SS**, Russel N, Wecker M, Allen M, Tomaras G, Ferarri G, Gray C, Gilbert P, Chulay J. Safety and Immunogenicity of an Alphavirus Replicon HIV Gag Vaccine (AVX101) in Healthy HIV-uninfected Adults

International AIDS Conference, Toronto, Canada, 12– 17 August 2006

- **Abdool Karim SS**. Integrating TB and HIV programs and services: the dilemma. WHO Workshop
- Burke D, **Abdool Karim SS**, Russel N, Wecker N, Allen M, Ferarri G, Gray C, Gilbert P and Chulay J. Safety and Immunogenicity of an Alphavirus Replicon HIV Gag Vaccine (AVX101) in Healthy HIV-uninfected Adults
- Mlisana K, Williamson C, van Loggerenberg F, Iriogbe I, Auld S, Grobler A, Morris L, Gray C, **Abdool Karim SS** for the CAPRISA 002 Acute Infection Study Team. CAPRISA 002 Acute Infection Study: early clinical and laboratory parameters including CD4+ cell counts and viral load measurements in acute HIV-1 subtype C infection. [abstract number CDA0047]
- Bebell L, Passmore J, Williamson C, Mlisana K, Iriogbe I, **Abdool Karim S**. Clinical Correlations of Inflammatory Cytokines in the Female Genital Tract during Acute HIV-1 Infection. [Abstract number: MOAX0102]
- Mashego M, Abdool Karim Q, Sayana S, Carrara H, Frohlich J, Sobieszczek M, Mlotswa M, Mbambo S, **Abdool Karim SS**. Use of a Clinical Evaluation Tool to identify early and acute HIV infection in a cohort of HIV negative women in rural South Africa. [Abstract number: CDBO140]
- Kharsany ABM, Carrara H, Ncama BP, **Abdool Karim SS**, Abdool Karim Q. Feasibility of Establishing Cohorts for Phase IIB/III HIV Prevention Trials in Sexually Transmitted Diseases (STD) Primary Care Clinics in Durban, South Africa. [Abstract number: TUPE0449]
- Wiseman RC, Padayatchi N, Carrara H, Naidoo , Singh A, Nair G, Khan M, **Abdool Karim SS**. Response to ARV therapy among patients with CD4 counts below 50 cells/mm3 in a resource-constrained setting in South Africa
- Carrara H, Abdool Karim Q, Frohlich J, Mashego M, Mlotswa M, Mbambo S, **Abdool Karim SS**. Comparing HIV incidence rates derived from modeling cross-sectional HIV prevalence data to that obtained from longitudinal studies of HIV negative persons – implications for sample size and accrual in HIV prevention efficacy trials [Abstract number: CDCO354]
- Kharsany ABM, Cele Z, Coetzee K, Carrara H, Ncama BP, **Abdool Karim SS**, Abdool Karim Q. Use of a stepwise pooling algorithm for the detection of HIV RNA for screening for Acute HIV-1 infection in a STI clinic Population in Durban, South Africa. [Abstract number: MOPE0132]
- Mlotshwa M, Khoury G, van Loggerenberg F, Mlisana K, Williamson C, **Abdool Karim S**, Gray C. Breadth and Magnitude of HIV-specific T cell recognition at the acute stage of subtype C infection does not correlate with viraemia
- Mlisana K, Auld S, Iriogbe I, Sobieszczek M, Grobler A, Williamson C, **Abdool Karim SS**, and the CAPRISA Acute HIV Infection Study Team

- Bandawe GP, Treunricht F, Woodman Z, Mlisana K, Morris L, Loggerenberg F, **Abdool Karim SS**, Williamson C for the CAPRISA 002 Acute Infection Study Team. Genetic characteristics of GP160 in acute HIV-1 subtype C infection that may impact disease progression

8th Brazilian Congress of Collective Health and 11th World Congress of Public Health- Public Health in a Globalized World: Breaking down /Political, Social and Economic Barriers in Rio de Janeiro, Brazil, 21-25 August 2006

- **Abdool Karim SS**. AIDS in Africa: impacts on health and demographic patterns. (Invited speaker)

PACT conference, Cape Town, South Africa, 3 October 2006

- **Abdool Karim SS**. The State of the HIV epidemic in South Africa. (Invited keynote speaker)

SARETI, Senegal, 11-12 October 2006

- **Abdool Karim SS**. HIV counseling and testing: demands and dilemmas for opting out. (Invited speaker)

Bio2Biz, Durban, South Africa, September 2006

- **Abdool Karim SS**. Microbicides and their role in HIV prevention. (Invited speaker)

Congressional Briefing: Capitol Hill, Washington, USA, 18 July 2006

- **Abdool Karim SS**. Microbicide Clinical Trials: Needs and Challenges. (Invited speaker)

HIV Prevention Workshop, St George's Hotel Cape Town, South Africa, 22 April 2006

- **Abdool Karim SS**. Microbicides & their role in the prevention agenda. (Invited speaker)

Office of AIDS Research Advisory Council (OARAC) Meeting, Durban South Africa, 6 April 2006

- **Abdool Karim SS**. Microbicide Clinical Trials: Current Status and Challenges. (Invited speaker)

GlaxoSmithKline HIV Advisory Board Meeting , Royal Windsor Hotel, Brussels, 25 October 2006

- **Abdool Karim SS**. HIV epidemiology relevant to HIV vaccine design & trials. (Invited speaker)

IAVI 2006 Global Team Meeting, 18 September 2006

- **Abdool Karim SS**. Engaging Innovative Developing Countries' Research Engine. (Invited speaker)

SIDA 2006, Buenos Aires, 8th September 2006

- **Abdool Karim SS**. Voluntary counseling and testing: is it time to opt out? (Invited keynote speaker)
- **Abdool Karim SS**. Microbicides for the Prevention of HIV. (Invited keynote speaker)

2005

European & Developing Countries Clinical Trials Partnership (EDCTP) Conference, 3 October 2005

- **Abdool Karim SS**. Global progress on the development of HIV vaccines and microbicides. (Invited keynote address)

2nd South African AIDS Conference Durban, South Africa 9 June 2005

- **Abdool Karim SS**. New Generation Microbicides. Invited Plenary
- Carrara H, Mashego M, Mlotswa M, Mbambo S, Frohlich J, **Abdool Karim SS**, Abdool Karim Q. Coital frequency, condom use and HIV incidence rates in a cohort of young women in rural KwaZulu Natal: the need for additional HIV prevention strategies.
- van Loggerenberg F, Mlisana K, Grobler A, **Abdool Karim SS**. Self-reported anal sex: Perceptions of risk and preferences for practise in a cohort of female sex workers.
- Barkhan D, Paximadis M, Mathebula T, Mohube P, Makgotho P, Mashiloane M, Cutler E, Magooa P, Puren A, van Loggerenberg F, Mlisana K, Williamson C, **Abdool Karim S**, Gray

CM. Associations between Class I HLA types and disease status in individuals from southern Africa infected with HIV-1 subtype C

- Iriogbe I, Dube T, Grobler A, Cheune J, Khan M, Burst J, Edward D, Nadioo K, **Abdool Karim SS**. The role of a Non-governmental organization (NGO) in an HIV-1 endemic region.

3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, 24-25 July 2005

- **Abdool Karim SS**. Impact of antiretroviral therapy on HIV prevention. (Invited plenary address)
- Williamson C, Grobler J, Seoighe C, Ramjee G, Morris L, **Abdool Karim SS**. Lower rates of adaptive evolution in HIV-1 dual infections compared to single infections

Presidents Emergency Plan for AIDS Relief (PEPFAR) Planning Meeting, Pretoria, South Africa, 4 May 2005

- **Abdool Karim SS**. PEPFAR-funded CAPRISA AIDS Treatment (CAT) Programme

2004

National Institutes of Health, Washington, USA, 26 March 2004

- **Abdool Karim SS**. AIDS Research in South Africa: Trials and Tribulations (Invited talk)

2nd International Workshop on Acute HIV-1 Infection, Bethesda, Washington, USA, 3-4 May 2004

- **Abdool Karim SS**. Acute HIV infection in high prevalence settings: Opportunities and constraints (Invited talk)

Clinical Conference, Nelson R Mandela School of Medicine, Durban, South Africa, 12 May 2004

- **Abdool Karim SS**. Impact of HAART on HIV prevention and mortality – implications for the ART rollout programme (Invited talk)

Aurum Health Research - VTN visit, Orkney, South Africa, 18 May 2004

- **Abdool Karim SS**. The role of HIV vaccines in fighting the HIV epidemic (Invited talk)

XV International AIDS Conference, Bangkok, Thailand, 11-16 July 2004

- Kharsany, ABM, Frohlich J, Mashego M, Makhaye GM, **Abdool Karim SS**. Epidemiology of STDs among rural women in Vulindlela, South Africa: Challenges for HIV prevention
- Churchyard GJ, Charalambous S, Smit J, Sefuthi C, Calver A, Pemba AD, Corbett EL, Fielding K, Chiasson R, **Abdool Karim SS**. The clinical spectrum of mycobacterial disease occurring early in antiretroviral therapy among gold miners in South Africa.
- Frohlich J, Makhaye GM, Kharsany, ABM, **Abdool Karim SS**, Abdool Karim Q. Temporal trends in HIV infection in rural South Africa: Implications for HIV prevention research.
- Harrison AD, Cleland J, Gouws E, Frohlich J, **Abdool Karim SS**. Sexual networking and partner choice: contextual determinants of high risk partnerships among rural South African youth.

AIDS Vaccine 2004, Lausanne, Switzerland, 30th August – 1st September 2004.

- Morafo V, Singh B, Khoury G, Masemola A, Mashishi T, Paximadis M, Barkhan D, Puren A, Williamson C, **Abdool Karim S**, Gray C. Immunological reactivities of subtype B-derived CTL epitopes in subtype C HIV-1 infected individuals.

School of Development Studies Conference, Durban, South Africa, 21-22 October 2004

- **Abdool Karim SS**. Biomedical Perspectives on HIV/AIDS

HIV Pathogenesis Programme, Durban, South Africa, 1-2 October 2004

- **Abdool Karim S**. Addressing the challenges of rolling out AIDS treatment in South Africa

IASO 1st Regional Congress Sun City, 28-31 October 2004

- **Abdool Karim SS**. The evolving HIV epidemic in South Africa

2003

8th World STI/AIDS Congress Uruguay, 4 December 2003

- **Abdool Karim SS.** Microbicides for HIV and STI prevention. Plenary address

International ethical guidelines for research involving human subjects, Santiago, Chile, 15-17 October 2003

- **Abdool Karim S.** Global inequities: implications for developing country research

International Academic Workshop on emerging Diseases, China, 26 October 2003

- **Abdool Karim SS.** CAPRISA: an overview of a South African CIPRA

FDA Antiviral Advisory Committee (AVAC), 20 August 2003

- **Abdool Karim SS.** HIV/AIDS and STIs in Women: the urgent need for an efficacious microbicide

23rd Medicine Update, Durban, South Africa, 17 August 2003

- **Abdool Karim S,** Vinodh Gathiram Memorial Lecture: HIV – an evolving epidemic in KwaZulu-Natal

Conference on Retrovirus and Opportunistic Infections, Boston, USA< 10-14 February 2003

- Jack C, Friedland G, Lalloo U, El-Sadr W, Cassol S, Murrman M, Abdool Karim Q, **Abdool Karim S.** Integration of Antiretroviral Therapy into an existing tuberculosis directly observed therapy program in a resource constrained setting (START study) [Abstract # 783]

SA AIDS Conference, Durban, South Africa, 3-6 August 2003

- Abdool Karim Q, Jack C, Friedland G, Lalloo U, El-Sadr W, **Abdool Karim SS** on behalf of the START team. Integrating TB and AIDS care – a feasible option for resource constrained settings?
- Frohlich J, Abdool Karim Q, **Abdool Karim SS.** Missed opportunities for treating STI's at a rural primary health care setting in South Africa.
- Frohlich J, Abdool Karim Q, Gouws E, **Abdool Karim SS.** Community willingness to participate in HIV prevention research – experiences from rural KwaZulu Natal
- Kharsany A, Abdool Karim Q, Olowolagaba A, Connolly C, Biam K, **Abdool Karim SS.** Tuberculosis treatment adherence and outcomes within a public health facility in Central Durban.
- Makhaye G, Abdool Karim Q, **Abdool Karim SS.** HIV Seroprevalence and incidence rates in pregnant women attending antenatal clinics in Vulindlela
- Mashego M, Frohlich J, Makhaye G, Abdool Karim Q, **Abdool Karim SS.** Community Health Workers – key informants in establishing AIDS-related mortality.
- Mlisana KP, van Loggerenberg F, Mkhize M, Morris L, Gray C, Ramjee G, **Abdool Karim S.** Clinical investigations and natural history of HIV-1 subtype C infection in a female sex worker cohort

2002:

The 25th Biennial Congress of the South African Paediatric Association and the South African Association of Paediatric Surgeons, Wild Coast Sun, South Africa, October 2002

- **Abdool Karim SS. HIV/AIDS in South Africa (Plenary Address)**

Annual Congress of the Dermatological Society of South Africa, Durban, South Africa, April 2002

- **Abdool Karim SS.** Opening Address

Microbicides 2002, Antwerp, Belgium, 12-15 May 2002

- Morrow K, Rosen R, Richter L, Forbes A, Emans A, Day J, Profy A, **Abdool Karim SS,** Mayer K. The acceptability of an investigational vaginal microbicide agent, PRO2000 gel. (Abstract C-181).
- Day J, Morrow K, Rosen R, **Abdool Karim SS,** Emans A, Maslankowski L, Mayer K and the HPTN 020 Protocol Team. How to find out what men think? Lessons learned from a microbicide clinical trial. (Abstract C-248).

2001:

2nd Biannual Molecular & Cell Biology Symposium, Pretoria, South Africa, November 2001

- **Abdool Karim SS.** Epidemiology of HIV/AIDS in South Africa (Invited address)

Allergy Society of South Africa (ALLSA) Congress, Durban, South Africa, October 2001

- **Abdool Karim SS.** The challenge of AIDS (Opening address)

2nd All Africa Anaesthesia Congress: SASA 2001, Durban, South Africa, September 2001

- **Abdool Karim SS.** The epidemiology of HIV/AIDS in South Africa. (Invited address)

AIDS Vaccine 2001, Philadelphia, USA, 5-8 September 2001

- Mashishi T, Hunt G, Loubser S, Nyoka S, Hide W, Williamson C, Ferrari G, Puren A, Ramjee G, **Abdool Karim SS**, Cao H, Sheppard H, Gray C. Immune recognition of conserved regions within Nef from HIV-1 subtype C infected individuals from southern Africa. (Abstract no: 32)
- Grobler J, Rademeyer C, Morris L, Gray CM, Ramjee G, **Abdool Karim SS**, Williamson C. Evidence of dual infection with two distinct subtype C viral populations in a female sex worker from KwaZulu-Natal, South Africa. (Abstract no: 93)
- Coetzer M, Cilliers T, Papathanasopoulos MA, Ramjee G, **Abdool Karim SS**, Williamson C, Morris L. Analysis of coreceptor usage among sequential HIV-1 subtype C isolates from acutely infected sex workers in South Africa. (Abstract no: 110)
- Papathanasopoulos MA, Morris L, **Abdool Karim SS**, Williamson C, Ehrenberg PK, McCutchan F. Construction and biological characterization of an infectious HIV-1 subtype C molecular clone. (Abstract no: 269).
- Bures R, Morris L, Williamson C, Ramjee G, Deers M, Fiscus SA, **Abdool Karim SS**, Montefiori DC. Antibody-mediated neutralization of subtype C HIV-1. (Abstract no: S1).

Keystone Symposium: AIDS Vaccines in the New Millennium, March 2001

- **Abdool Karim SS.** Perspectives from the Developing World on AIDS Vaccine Trials. (Invited Address)
- Williamson C, Malaza AL, Puren AJ, Morris L, Ramjee G, **Abdool Karim SS**, Gray CM. Investigation of host factors associated resistance to HIV-1 infection in multiply exposed, persistently seronegative sex workers from KwaZulu-Natal, South Africa. (Abstract no: 135)

2000:

2nd National Conference of People Living with HIV/AIDS, Durban, South Africa, March 2000

- **Abdool Karim SS.** Opening Plenary Address

XIII International AIDS Conference, Durban, South Africa, 9 – 14 July 2000

- Puren AJ, Ramjee G, **Abdool Karim SS**, Gray CM. HLA associations with HIV-1 seronegative sex workers from KwaZulu-Natal, South Africa. (Abstract No: MoOrA228).
- Van Harmelen J, Carr JK, Williamson C, Morris L, **Abdool Karim SS**, Kim B, McCutchan FE. Analysis of the first full-length genome sequences of South African HIV-1 subtype C isolates. (Abstract No: MoPpA1004).
- Papathanasopoulos M, Cilliers T, van Harmelen J, **Abdool Karim SS**, Ramjee G, Williamson C, Morris L. Cloning and characterization of HIV-1 subtype C envelope proteins. (Abstract No: MoPeA2018).
- Gouws E, Williams B, **Abdool Karim SS**, Abdool Karim Q, Lurie M, Harrison A, Colvin M, Sitas F, Ramjee G. Patterns of infection: using age prevalence and incidence data to understand the epidemic of HIV in South Africa. (Abstract No: MoPeC2467).
- Lurie M, Williams B, Sturm AW, Garnett G, Zuma K, Gittlesohn J, **Abdool Karim SS**. Migration and the spread of HIV in Southern Africa: prevalence and risk factors among migrants and their partners, and non-migrants and their partners. (Abstract No: MoPpD1049).
- Hughes G, Hoyo C, Puoane T, Stein Z, **Abdool Karim SS**. Rural South African women and their risk for undetected sexually transmitted diseases and HIV infection. (Abstract No: MoPeD2779).
- Williamson C, Swanstrom R, Morris L, Thomas R, Ping L-H, Pascual A, Johnston RE, **Abdool Karim SS**. Selection of a representative HIV-1 subtype C isolate for use in the development of candidate vaccines for Southern Africa. (Abstract No: TuOrA415).

- Malaza AL, Morris L, Ramjee G, Nyoka S, Gray CM, **Abdool Karim SS**, Williamson C. Studies on multiply exposed but persistently HIV seronegative sex workers from KwaZulu/Natal, South Africa. (Abstract No: TuPpA1228).
- Mashishi T, Hunt G, Bredell H, Morris L, Ramjee G, **Abdool Karim SS**, Gray C. Conservation of South African HIV-1 subtype C Nef sequences at different stages of disease progression: implications for vaccine strategies. (Abstract No: WeOrA598).
- Connolly C, Ramjee G, Sturm W, **Abdool Karim SS**. Incidence of sexually transmitted infections among HIV positive sexworkers in KwaZulu/Natal, South Africa. (Abstract No: WePpC1387).
- Rustonjee R, **Abdool Karim SS**, Kharsany A. A randomized control trial of azitromycin versus doxycycline/ciprofloxacin in the treatment of sexually transmitted chlamydia trachomatis and concomitant neisseria gonorrhoea infections. (Abstract No: WePeC4334).
- Hughes G, Hoyo C, Stein Z, **Abdool Karim SS**. The effect of oscillating male migration on rural South African women's health: implications for sexually transmitted diseases and HIV/AIDS. (Abstract No: WeOrD518).
- Lurie M, Williams B, Sturm AW, Garnett G, Mkaya-Mwamburi D, **Abdool Karim SS**. HIV discordance among migrant and non-migrant couples in South Africa. (Abstract No: WeOrD519).
- Gouws E, Abdool Karim Q, Frohlich J, **Abdool Karim SS**. Preparing for Phase III HIV Vaccine trials: Experiences from rural South Africa. (Abstract No: ThOrD678).

1999:

University of Natal Clinical Conference - 1999.

- **Abdool Karim SS**. HIV/AIDS in South Africa. (Keynote Address)

AIDS vaccine evaluation group meeting, Washington, USA, November 1999

Abdool Karim SS. HIV/AIDS in South Africa: HIV vaccine research opportunities (Invited Address)

13th Meeting of the International Society of Sexually Transmitted Disease Research, Denver, Colorado, USA, July 1999

- Harrison A, **Abdool Karim SS**, Floyd K, Lombard C, Lurie M, Ntuli N, Wilkinson D. Syndrome packets and health worker training improve quality of sexually transmitted disease case management in rural South Africa: results of a randomised controlled trial.
- Lurie M, **Abdool Karim SS**, Sturm AW. Migration and the spread of HIV/STD in South Africa: Preliminary data on the prevalence of HIV/STD among male migrants and their partners, and non migrant couples.
- Lurie M, **Abdool Karim SS**, Sturm AW. HIV and STD discordance among migrant and non-migrant couples in South Africa.

1998:

16th Epidemiological Society of Southern Africa Conference, Midrand, South Africa, October 1998.

- **Abdool Karim SS**. HIV in South Africa: From description to intervention. (Keynote address)
- Wilkinson D, Gouws E, Sach M, **Abdool Karim SS**. Does removing user fees encourage attendance for curative services at the expense of preventive services?
- Harrison A, Wilkinson D, Lurie M, **Abdool Karim SS**. Improving quality of sexually transmitted disease (STD) case management: Results of a clinic-randomized intervention trial.
- Harrison A, Jackson E, Ntuli N, Wilkinson D, Lurie M, **Abdool Karim SS**. Gender, risk perception and protective practices in prevention of sexually transmitted diseases: Impact of rural community health education programme.

4th Reproductive Health Research Priorities Conference, August 1998.

- Harrison A, Wilkinson D, Lurie M, **Abdool Karim SS**. Toward better reproductive health services: Results of a randomized intervention trial to improve quality of sexually transmitted disease case management.
- Harrison A, Jackson E, Ntuli N, Wilkinson D, Lurie M, **Abdool Karim SS**. Gender, risk perception and protective practices in prevention of sexually transmitted diseases: Impact of rural community health education programme.

12th World AIDS Conference, Geneva, June-July 1998.

- Panelist: NIAID Satellite symposium on the Rakai Control of STDs for AIDS Prevention Study.
- **Abdool Karim SS.** Should less developed countries be involved in vaccine development. Global action for an AIDS Vaccine Symposium.
- Ramjee G, **Abdool Karim SS.** Acceptability of a vaginal microbicide among sex workers in KwaZulu-Natal, South Africa.
- Ramjee G, **Abdool Karim SS.** Prevalence of sexually transmitted infections including HIV among sex workers in KwaZulu-Natal midlands, South Africa.
- Morar NS, Ramjee G, Wilkinson D, **Abdool Karim SS.** Intravaginal substance use and douching practices among sex workers in South Africa: implications for microbicide use.
- Morar NS, Ramjee G, **Abdool Karim SS.** Safe sex practices among sex workers at risk of HIV infection.

1997:

HIV and the Lung Guidelines Meeting, CHEST: Southern Africa '97 Conference, Windhoek, Namibia, August 1997.

- **Abdool Karim SS.** HIV and the Lung. (Opening Address)

3rd Reproductive Health Priorities Conference, Wilderness, South Africa, August 1997.

- **Abdool Karim SS.** Reproductive Health Research Priorities for South Africa. (Keynote Address)

18th African Health Sciences Congress, Cape Town, South Africa, April 1997.

- Harrison A, Wilkinson D, Lurie M, **Abdool Karim SS.** "Mystery patient" evaluation of quality of care in syndromic management of STDs.
- Wilkinson D, Sach ME, **Abdool Karim SS.** In search of equity: impact of the policy of free care for children under six and for pregnant women attending rural mobile clinic services in Hlabisa.
- Connolly AM, Wilkinson D, **Abdool Karim SS.** Management of STDs in private general practice in a rural health district.
- Lurie M, Harrison A, Wilkinson D, **Abdool Karim SS.** Migration patterns in northern KwaZulu-Natal and their implications for the spread, treatment and prevention of HIV and other STDs.
- Ramjee G, **Abdool Karim SS.**, Morar NS, Gwamanda Z, Xulu G, Ximba T, Gouws E. Acceptability of a vaginal microbicide among sex workers in KwaZulu-Natal, South Africa.
- Wilkinson D, Connolly A, Harrison A, Lurie M, **Abdool Karim SS.** STD syndromes in rural South Africa: results of health facility surveillance.
- Morar NS, Ramjee G, Gwamanda Z, **Abdool Karim SS.** Safe sex practices among sex workers at risk of HIV infection.
- Morar NS, Ramjee G, **Abdool Karim SS.** Vaginal insertion and douching practices among sex workers at truck stops in KwaZulu-Natal.

Joint Congress of the Infectious Diseases and Sexually Transmitted Diseases Society in Southern Africa, Cape Town, South Africa, September 1997

- Connolly AM, Wilkinson D, Harrison A, Lurie M, **Abdool Karim SS.** Management of sexually transmitted diseases in the private health sector in a rural district.
- Harrison A, Wilkinson D, Lurie M, **Abdool Karim SS.** Rural adolescents seeking care for STDs: Results from surveillance in primary care facilities.
- Harrison A, Wilkinson D, Lurie M, **Abdool Karim SS.** Methods for measuring quality of care: Baseline results from an intervention study to improve syndromic management of STDs.
- Lurie M, Harrison A, Wilkinson D, **Abdool Karim SS.** Health seeking behaviours for STDs in rural South Africa.
- Lurie M, Harrison A, Wilkinson D, **Abdool Karim SS.** Migration and HIV/STD in rural South Africa: Implications for future study and interventions.
- Wilkinson D, **Abdool Karim SS.**, Harrison A, Lurie M, Colvin M, Connolly C. Unrecognised sexually transmitted diseases among women in rural South Africa - the Hidden Epidemic.

1996:

XIV International Scientific Meeting of the International Epidemiological Association, Nagoya, Japan, August 1996.

- **Abdool Karim SS**, Abdool Karim Q. Migration, migrant labour and HIV infection in South Africa.
- Dilraj A, Ramjee G, **Abdool Karim SS**. Timely reporting and accurate diagnosis of measles in schoolchildren for control of outbreaks.

Pan African Federation for Mother and Child Health (PAFMACH) Conference, South Africa, September 1996.

- Ramjee G, **Abdool Karim SS**, Morar N, Bechan S. Acceptability of a vaginal microbicide for the prevention of HIV and STD transmission among commercial sex workers.

2nd International working conference on Health Informatics in Africa (Helina '96), Johannesburg, South Africa

- **Abdool Karim SS**, Abdool Karim Q, Dilraj A, Rustomjee R. Epidemiological Surveillance in South Africa: Strengths, weaknesses and lessons for the future.
- Dilraj A, Ramjee G, **Abdool Karim SS**. Effectiveness of the school reporting system of communicable diseases for the control of measles.

1994:

The 1994 Annual Conference of the National Occupational Safety Association, Durban, South Africa

- **Abdool Karim SS**. HIV/AIDS: Time to act now. (Keynote address).

1993:

12th Epidemiological Conference, Durban, South Africa, 18-20 August 1993

- Dilraj A, **Abdool Karim SS**. Gender differences in measles deaths.
- Ziqubu-Page T, **Abdool Karim SS**, Pillai G, Cassimjee MH, Morar N. Reducing drug costs.

Natal/KwaZulu Hospital Infection Control Society Annual Conference, Durban, South Africa, 1993.

- **Abdool Karim SS**. Epidemiology in Local Authority Health Care Services.

South African Institute of Public Health Annual Conference, Durban, South Africa, 1993.

- **Abdool Karim SS**. Epidemiology in Local Authority Health Care Services.

International Epidemiological Association Conference in Sydney, Australia, 1993.

- **Abdool Karim SS**, Abdool Karim Q, Dilraj A, Chamane M. Evaluation of a mass measles campaign in South Africa.
- Abdool Karim Q, **Abdool Karim SS**, Singh B, Ngzongo S, Short R. HIV infection in rural South Africa: Findings of an anonymous population-based seroprevalence survey.

1992:

(VIII Jornada de Saude) The Mozambican National Institute for Health Conference, Maputo, Mozambique.

- **Abdool Karim SS**, Abdool Karim Q. HIV infection in rural Natal/KwaZulu.

1991:

10th Annual Conference of the Epidemiological Society of Southern Africa, Cape Town, South Africa.

- **Abdool Karim SS**, Abdool Karim Q, Chamane M. Impact of a mass Measles immunisation campaign on measles admissions to a tertiary hospital.

1990:

9th Annual Conference of the Epidemiological Society of Southern Africa, East London, South Africa.

- **Abdool Karim SS.** Impact of political violence in Natal on emergency surgical services of a tertiary hospital.

The National Emergency Services Group Conference, Port Elizabeth, South Africa.

- **Abdool Karim SS.** Impact of the political violence in Natal on emergency surgical services of a tertiary hospital.
- **Abdool Karim SS.** Health care of refugees - The Durban experience.

1989:

7th Annual Conference of the Epidemiological Society of Southern Africa.

- **Abdool Karim SS, Thejpal R, Coovadia HM, van den Ende J, Windsor IM.** Household clustering and intra-household transmission patterns of Hepatitis B virus infection in South Africa.

1988:

Physicians for Human Rights seminar, New York Academy of Sciences.

- **Abdool Karim SS.** Health and Human Rights in South Africa.

"Ten Years after Alma Ata" Conference, National Council for International Health, Washington, USA.

- **Abdool Karim SS.** Primary Health Care in South Africa.

1987:

Joint New York Academy of Sciences, America's Watch and the Columbia University Center for the Study of Medicine and Society conference, New York, USA.

- **Abdool Karim SS.** Health and Human Rights in South Africa.

115th Annual Meeting of the American Public Health Association, New Orleans, USA.

- **Abdool Karim SS.** Health and politics in the current South African scene
- **Abdool Karim SS.** Public Health in South Africa.

1986:

Seventh Biennial Congress of the South African Paediatric Association, Cape Town, South Africa.

- **Abdool Karim SS, Coovadia YM, Windsor IM.** The prevalence and transmission of hepatitis B virus infection in urban, rural and institutionalised South African Black Children.
- **Abdool Karim SS, Thejpal R, Coovadia HM, van den Ende J, Windsor IM.** Familial Clustering of Hepatitis B virus infection in black families from Umlazi, Durban.